WO2018225851A1 - N-置換アミノ酸を含むペプチドの合成方法 - Google Patents
N-置換アミノ酸を含むペプチドの合成方法 Download PDFInfo
- Publication number
- WO2018225851A1 WO2018225851A1 PCT/JP2018/021998 JP2018021998W WO2018225851A1 WO 2018225851 A1 WO2018225851 A1 WO 2018225851A1 JP 2018021998 W JP2018021998 W JP 2018021998W WO 2018225851 A1 WO2018225851 A1 WO 2018225851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fmoc
- amino acid
- peptide
- group
- skeleton
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 298
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 223
- 238000000034 method Methods 0.000 title claims abstract description 87
- 230000002194 synthesizing effect Effects 0.000 title description 8
- 125000006239 protecting group Chemical group 0.000 claims abstract description 223
- -1 N-substituted amino Chemical group 0.000 claims abstract description 180
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 claims abstract description 43
- 239000007790 solid phase Substances 0.000 claims abstract description 21
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 156
- 239000002253 acid Substances 0.000 claims description 109
- 239000002904 solvent Substances 0.000 claims description 90
- 125000003277 amino group Chemical group 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 72
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 52
- 125000000524 functional group Chemical group 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 41
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 40
- 125000000539 amino acid group Chemical class 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 239000007791 liquid phase Substances 0.000 claims description 16
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 150000001721 carbon Chemical group 0.000 claims description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 10
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 150000001735 carboxylic acids Chemical class 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002092 orthoester group Chemical group 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 279
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 232
- 235000001014 amino acid Nutrition 0.000 description 208
- 150000001875 compounds Chemical class 0.000 description 204
- 239000000243 solution Substances 0.000 description 195
- 239000011347 resin Substances 0.000 description 168
- 229920005989 resin Polymers 0.000 description 168
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 142
- 238000010511 deprotection reaction Methods 0.000 description 120
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 95
- 125000001309 chloro group Chemical group Cl* 0.000 description 95
- 239000000047 product Substances 0.000 description 92
- 230000014759 maintenance of location Effects 0.000 description 90
- 238000004458 analytical method Methods 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 65
- 230000015572 biosynthetic process Effects 0.000 description 63
- 238000003786 synthesis reaction Methods 0.000 description 61
- 239000000203 mixture Substances 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 55
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 50
- DWTYPCUOWWOADE-UHFFFAOYSA-M hydron;tetramethylazanium;sulfate Chemical compound C[N+](C)(C)C.OS([O-])(=O)=O DWTYPCUOWWOADE-UHFFFAOYSA-M 0.000 description 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 48
- 238000007363 ring formation reaction Methods 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 41
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 39
- 229910052757 nitrogen Inorganic materials 0.000 description 39
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 238000010647 peptide synthesis reaction Methods 0.000 description 37
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 36
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 33
- 125000001424 substituent group Chemical group 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 229910052938 sodium sulfate Inorganic materials 0.000 description 26
- 235000011152 sodium sulphate Nutrition 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 238000011068 loading method Methods 0.000 description 25
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 108010069514 Cyclic Peptides Proteins 0.000 description 23
- 102000001189 Cyclic Peptides Human genes 0.000 description 23
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 23
- 239000010410 layer Substances 0.000 description 23
- 238000003797 solvolysis reaction Methods 0.000 description 23
- 238000001514 detection method Methods 0.000 description 22
- 230000007062 hydrolysis Effects 0.000 description 22
- 238000006460 hydrolysis reaction Methods 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 125000003710 aryl alkyl group Chemical group 0.000 description 18
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 150000001923 cyclic compounds Chemical class 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 15
- 125000005843 halogen group Chemical group 0.000 description 15
- 230000009257 reactivity Effects 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 108010088535 Pep-1 peptide Proteins 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 description 14
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 238000005520 cutting process Methods 0.000 description 13
- 125000004430 oxygen atom Chemical group O* 0.000 description 13
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 12
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 235000006408 oxalic acid Nutrition 0.000 description 12
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 11
- 229940125782 compound 2 Drugs 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 11
- 238000007086 side reaction Methods 0.000 description 11
- JARBLLDDSTVWSM-IJAHGLKVSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-trityloxybutanoic acid Chemical compound O([C@H](C)[C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 JARBLLDDSTVWSM-IJAHGLKVSA-N 0.000 description 10
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229910052723 transition metal Inorganic materials 0.000 description 10
- 150000003624 transition metals Chemical class 0.000 description 10
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 8
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 8
- 108010002156 Depsipeptides Proteins 0.000 description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
- KPFBUSLHFFWMAI-HYRPPVSQSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-formyl-3-methoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=C(C=O)C[C@H]2[C@@H]2CC[C@](OC(C)=O)(C(C)=O)[C@]21C KPFBUSLHFFWMAI-HYRPPVSQSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- 239000011976 maleic acid Substances 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 8
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- JWVLJHMKVOZWMC-LHEWISCISA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@H](N(C)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 JWVLJHMKVOZWMC-LHEWISCISA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 0 C*C1(CC2)[C@@]22[C@]1CCC2 Chemical compound C*C1(CC2)[C@@]22[C@]1CCC2 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- DTVJLZWXYPPOHJ-QHCPKHFHSA-N (2s)-3-(4-chlorophenyl)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid Chemical compound C([C@H](N(C)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)C1=CC=C(Cl)C=C1 DTVJLZWXYPPOHJ-QHCPKHFHSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 6
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 6
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FZBMNXOJLBTQHV-ZDUSSCGKSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C)ON1C(=O)CCC1=O FZBMNXOJLBTQHV-ZDUSSCGKSA-N 0.000 description 5
- ZLZOTVKOIDTAHM-DEOSSOPVSA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[3-fluoro-4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@H](C(=O)O)CC1=CC(=C(C=C1)OC(C)(C)C)F ZLZOTVKOIDTAHM-DEOSSOPVSA-N 0.000 description 5
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 5
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 5
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 5
- 238000005903 acid hydrolysis reaction Methods 0.000 description 5
- 235000019647 acidic taste Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229940127113 compound 57 Drugs 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000004437 phosphorous atom Chemical group 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 5
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 5
- 125000005500 uronium group Chemical group 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 4
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 4
- GOUUPUICWUFXPM-XIKOKIGWSA-N (2s,4r)-1-(9h-fluoren-9-ylmethoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 GOUUPUICWUFXPM-XIKOKIGWSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 4
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- SEGJNMCIMOLEDM-UHFFFAOYSA-N n-methyloctan-1-amine Chemical compound CCCCCCCCNC SEGJNMCIMOLEDM-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 3
- HAKKTZOUPCDMCN-UHFFFAOYSA-N 4-tert-butylpiperidine Chemical compound CC(C)(C)C1CCNCC1 HAKKTZOUPCDMCN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000005336 allyloxy group Chemical group 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 150000001718 carbodiimides Chemical group 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- OAWXZFGKDDFTGS-UHFFFAOYSA-N pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCN1C(O)=O OAWXZFGKDDFTGS-UHFFFAOYSA-N 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 2
- AYOFKFOWDYLJCP-BGERDNNASA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(oxan-2-yloxy)propanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@H](C(=O)O)COC1OCCCC1 AYOFKFOWDYLJCP-BGERDNNASA-N 0.000 description 2
- NWUDNVNGHPHPLF-HMTLIYDFSA-N (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(oxan-2-yloxy)propanoic acid Chemical compound C1=2C=3C=CC=CC=3C(COC(=O)N([C@@H](COC3CCCCO3)C(=O)O)C)C1=CC=CC=2 NWUDNVNGHPHPLF-HMTLIYDFSA-N 0.000 description 2
- BSOWHWUPGMSWJV-XVWGVMGSSA-N (2S,3R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(oxan-2-yloxy)butanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@H](C(=O)O)[C@@H](C)OC1OCCCC1 BSOWHWUPGMSWJV-XVWGVMGSSA-N 0.000 description 2
- SWZCTMTWRHEBIN-JOCHJYFZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-JOCHJYFZSA-N 0.000 description 2
- JAUKCFULLJFBFN-RUZDIDTESA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-RUZDIDTESA-N 0.000 description 2
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 description 2
- YMEGJWTUWMVZPD-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(C(F)(F)F)C=C1 YMEGJWTUWMVZPD-QFIPXVFZSA-N 0.000 description 2
- JZTKZVJMSCONAK-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CO)C(O)=O)C3=CC=CC=C3C2=C1 JZTKZVJMSCONAK-INIZCTEOSA-N 0.000 description 2
- UCARTONYOJORBQ-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-trityloxypropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UCARTONYOJORBQ-UMSFTDKQSA-N 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 2
- KJLKPACOHZKRFM-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfonylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCS(=O)(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 KJLKPACOHZKRFM-SFHVURJKSA-N 0.000 description 2
- ZVWHTEOKMWNXGP-KRWDZBQOSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N([C@@H](CO)C(O)=O)C)C3=CC=CC=C3C2=C1 ZVWHTEOKMWNXGP-KRWDZBQOSA-N 0.000 description 2
- GBROUWPNYVBLFO-QHCPKHFHSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-phenylpropanoic acid Chemical compound C([C@H](N(C)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(O)=O)C1=CC=CC=C1 GBROUWPNYVBLFO-QHCPKHFHSA-N 0.000 description 2
- BUJQSIPFDWLNDC-FQEVSTJZSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 BUJQSIPFDWLNDC-FQEVSTJZSA-N 0.000 description 2
- JOFHWKQIQLPZTC-LBPRGKRZSA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 JOFHWKQIQLPZTC-LBPRGKRZSA-N 0.000 description 2
- UOZAKKJRIKXQPY-QFIPXVFZSA-N (2s)-3-(3-chlorophenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC(Cl)=C1 UOZAKKJRIKXQPY-QFIPXVFZSA-N 0.000 description 2
- CQPNKLNINBUUOM-QFIPXVFZSA-N (2s)-3-(4-chlorophenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(Cl)C=C1 CQPNKLNINBUUOM-QFIPXVFZSA-N 0.000 description 2
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 2
- IMJNOISBRBWGIF-DEOSSOPVSA-N (3S)-4-(4-tert-butylpiperidin-1-yl)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@@H](CC(=O)O)C(=O)N1CCC(CC1)C(C)(C)C IMJNOISBRBWGIF-DEOSSOPVSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- VUTZFAOGDXUYEJ-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methylbenzene Chemical compound C1=CC(C)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 VUTZFAOGDXUYEJ-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 2
- VSSPPCXYCLZPJC-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(propyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)CCC)C3=CC=CC=C3C2=C1 VSSPPCXYCLZPJC-UHFFFAOYSA-N 0.000 description 2
- BDCFWIDZNLCTMF-UHFFFAOYSA-N 2-phenylpropan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1 BDCFWIDZNLCTMF-UHFFFAOYSA-N 0.000 description 2
- DPARCFUCRMHCEG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-5-oxo-1,3-oxazolidine-3-carboxylic acid Chemical compound ClC1=CC=C(CC2N(COC2=O)C(=O)O)C=C1 DPARCFUCRMHCEG-UHFFFAOYSA-N 0.000 description 2
- TZCYLJGNWDVJRA-UHFFFAOYSA-N 6-chloro-1-hydroxybenzotriazole Chemical compound C1=C(Cl)C=C2N(O)N=NC2=C1 TZCYLJGNWDVJRA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- TUEIURIZJQRMQE-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)phenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1B(O)O TUEIURIZJQRMQE-UHFFFAOYSA-N 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001409 amidines Chemical group 0.000 description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000012351 deprotecting agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 108010037248 lantibiotic Pep5 Proteins 0.000 description 2
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- OJZNYUDKNVNEMV-UHFFFAOYSA-M trimethylstannanylium;hydroxide Chemical compound C[Sn](C)(C)O OJZNYUDKNVNEMV-UHFFFAOYSA-M 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- AGJAUFUNZWHLKE-UHFFFAOYSA-N (2E,4E)-N-isobutyl-2,4-tetradecadienamide Natural products CCCCCCCCCC=CC=CC(=O)NCC(C)C AGJAUFUNZWHLKE-UHFFFAOYSA-N 0.000 description 1
- GIVDJEWGBRSZQH-SSEXGKCCSA-N (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-(2-phenylpropan-2-yloxy)phenyl]propanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@@H](C(=O)O)CC1=CC=C(C=C1)OC(C)(C)C1=CC=CC=C1 GIVDJEWGBRSZQH-SSEXGKCCSA-N 0.000 description 1
- FETKOPZLVOJHTL-LJAQVGFWSA-N (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[3-fluoro-4-(2-phenylpropan-2-yloxy)phenyl]propanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@H](C(=O)O)CC1=CC(=C(C=C1)OC(C)(C)C1=CC=CC=C1)F FETKOPZLVOJHTL-LJAQVGFWSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- FBNFRRNBFASDKS-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-prop-2-enoxybutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 FBNFRRNBFASDKS-IBGZPJMESA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- YCXXXPZNQXXRIG-IBGZPJMESA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 YCXXXPZNQXXRIG-IBGZPJMESA-N 0.000 description 1
- QQCAMJPAJDEDCG-RGMNGODLSA-N (2s)-3-(1h-imidazol-5-yl)-2-(methylamino)propanoic acid;hydrochloride Chemical compound Cl.CN[C@H](C(O)=O)CC1=CNC=N1 QQCAMJPAJDEDCG-RGMNGODLSA-N 0.000 description 1
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical group CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- OYULCCKKLJPNPU-DIFFPNOSSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxybutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](O)C)C(O)=O)C3=CC=CC=C3C2=C1 OYULCCKKLJPNPU-DIFFPNOSSA-N 0.000 description 1
- CGNQPFAECJFQNV-NRNQBQMASA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxybutanoic acid;hydrate Chemical compound O.C1=CC=C2C(COC(=O)N[C@@H]([C@H](O)C)C(O)=O)C3=CC=CC=C3C2=C1 CGNQPFAECJFQNV-NRNQBQMASA-N 0.000 description 1
- SVMHNLJBTQAABX-VWLOTQADSA-N (3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[methyl(octyl)amino]-4-oxobutanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)N[C@@H](CC(=O)O)C(=O)N(CCCCCCCC)C SVMHNLJBTQAABX-VWLOTQADSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- NXRGKFVQYZGDIY-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1.CC1=CC=CC(C)=N1 NXRGKFVQYZGDIY-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JAUKCFULLJFBFN-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1CC(C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 1
- VIIAUOZUUGXERI-ZETCQYMHSA-N 3-fluoro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1 VIIAUOZUUGXERI-ZETCQYMHSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 1
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NZRAJPJYXNMXBK-QFIPXVFZSA-N C1=CC=CC=2C3=CC=CC=C3C(C12)COC(=O)N[C@@H](C)CC1=CC(=C(C=C1)OC(C)(C)C1=CC=CC=C1)F Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C12)COC(=O)N[C@@H](C)CC1=CC(=C(C=C1)OC(C)(C)C1=CC=CC=C1)F NZRAJPJYXNMXBK-QFIPXVFZSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- DFXYSKFTDPNZFK-UHFFFAOYSA-N CC(C)(c1ccccc1)OC(C=C=C)=O Chemical compound CC(C)(c1ccccc1)OC(C=C=C)=O DFXYSKFTDPNZFK-UHFFFAOYSA-N 0.000 description 1
- RWNJOBPALOENHX-UHFFFAOYSA-N CCC(C(C)(C)CC(c1c2cccc1)=CC2=C)=O Chemical compound CCC(C(C)(C)CC(c1c2cccc1)=CC2=C)=O RWNJOBPALOENHX-UHFFFAOYSA-N 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 238000010485 C−C bond formation reaction Methods 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- JLJQLIYYDJOMJC-UHFFFAOYSA-N OC1[U]CCCC1 Chemical compound OC1[U]CCCC1 JLJQLIYYDJOMJC-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- RKTBAMPZUATMIO-MXZHIVQLSA-N [[(e)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N\OC(N(C)C)=[N+](C)C RKTBAMPZUATMIO-MXZHIVQLSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000005108 alkenylthio group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005130 alkyl carbonyl thio group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 125000006319 alkynyl amino group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 125000005134 alkynylsulfinyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- 125000005109 alkynylthio group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 108010034028 arodyn Proteins 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- YHNUDLCUIKMNSN-UHFFFAOYSA-N bis(1,2,4-triazol-1-yl)methanone Chemical compound C1=NC=NN1C(=O)N1C=NC=N1 YHNUDLCUIKMNSN-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 125000000707 boryl group Chemical group B* 0.000 description 1
- SBGUYEPUJPATFD-UHFFFAOYSA-N bromo(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(Br)N1CCCC1 SBGUYEPUJPATFD-UHFFFAOYSA-N 0.000 description 1
- GQKVINJBYYRJRF-UHFFFAOYSA-N bromo-tris(dimethylamino)phosphanium Chemical compound CN(C)[P+](Br)(N(C)C)N(C)C GQKVINJBYYRJRF-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005145 cycloalkylaminosulfonyl group Chemical group 0.000 description 1
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- LCFXLZAXGXOXAP-QPJJXVBHSA-N ethyl (2e)-2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N\O)\C#N LCFXLZAXGXOXAP-QPJJXVBHSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- CQXDYHPBXDZWBA-UHFFFAOYSA-N tert-butyl 2,2,2-trichloroethanimidate Chemical compound CC(C)(C)OC(=N)C(Cl)(Cl)Cl CQXDYHPBXDZWBA-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel method for synthesizing a peptide that can be synthesized with high purity and high synthesis efficiency in the synthesis of a peptide containing an N-substituted amino acid.
- Non-Patent Document 1 Peptides are high-value chemical species that have been marketed in the past as pharmaceuticals.
- Non-Patent Document 1 cyclic peptides and N-methylated (or N-alkylated) non-natural peptides have improved membrane permeability due to improved fat solubility and improved metabolic stability due to acquired resistance to hydrolases. It is expected (Non-Patent Document 2).
- Non-Patent Document 2 Recently, a study on a cyclic peptide that is a drug-like (preferably drug-like: preferably exhibits both membrane permeability and metabolic stability), which is a key for transfer into cells or oral preparations, has progressed. (Non-Patent Documents 3 and 4).
- Patent Document 1 a patent document that clarifies the conditions required for a drug-like cyclic peptide has been published (Patent Document 1), and its importance in drug discovery and its recognition are increasing.
- the Fmoc method and the Boc method are widely known, and many of these findings were obtained from the development of natural peptide synthesis methods. Since the Fmoc group is stable to acids, when the N-terminal amino group is protected with the Fmoc group, the deprotection reaction is performed with a base such as DBU or piperidine. Therefore, as a protecting group for the peptide side chain functional group, for example, an acid deprotectable group is used, and the peptide chain is elongated by selectively deprotecting the N-terminal amino group.
- the Fmoc method can be deprotected with an acid as low as trifluoroacetic acid (TFA), such as t-butyl (tBu) group or trityl (Trt) group as the protecting group of the amino acid side chain.
- TFA trifluoroacetic acid
- tBu t-butyl
- Trt trityl
- a peptide can be cleaved from the resin and the protecting group of the side chain functional group can be deprotected under mild conditions as compared with the Boc method.
- N-alkylated peptide synthesis has the following problems in the deprotection step of the protecting group in the group.
- TFA is generally used for the step of cleaving from the resin and deprotection of the protecting group of the side chain functional group.
- the cleaving reaction from the resin and the deprotection reaction of the side chain functional group are simultaneously performed using a 90% aqueous TFA solution.
- N-methylated peptide particularly in the case of a sequence in which N-methyl amino acids are continuous, it is known that a side reaction in which acid hydrolysis proceeds via oxazolonium and the peptide chain is cleaved.
- Non-patent Documents 7 and 8 In addition, in the case of peptides in which amino acids having a ⁇ -hydroxy group such as serine and threonine are included in the sequence, not only acid hydrolysis but also N ⁇ O acyl shift reaction is a side effect in these steps using TFA. It is known that it may proceed as a reaction and become a depsipeptide (Non-patent Documents 7 and 8).
- Non-patent Document 9 discloses a method for improving by using a lower concentration of TFA or minimizing the reaction time in order to avoid decomposition.
- the cleaving reaction from the resin proceeds at a satisfactory rate, while the deprotection reaction of the side chain proceeds. Or progress may be extremely slow.
- Non-Patent Document a problem of low reactivity in the elongation process is also known.
- the N-terminus of the newly formed amide bond is an N-methyl amino acid
- the subsequent amide formation reaction (elongation reaction) with the amino acid may not proceed sufficiently due to the bulkiness of the secondary amine (Non-Patent Document). 2, 5).
- Non-Patent Document 9 Recently, efforts have been made to improve condensation efficiency by increasing the reaction temperature by irradiating microwaves.
- the present inventors paid attention to a cyclic peptide containing an N-alkylated amino acid which can be a drug-like peptide, and studied a method for parallel synthesis of peptide compounds having such characteristics.
- a cyclic peptide containing an N-alkylated amino acid which can be a drug-like peptide
- the problems found in the compounds described in the above-mentioned known literatures become prominent with conventional synthesis methods using TFA.
- the inventors have found that the cyclic peptide cannot be isolated.
- TFA Even if the concentration of TFA is low, TFA is contained in a large excess with respect to the target product. Therefore, if the reaction is stopped by neutralizing these, the amount of base added will also be excessive. Therefore, a large excess of salt remains with the target peptide, which adds complexity to the purification process. Furthermore, although TFA itself is a solvent that effectively dissolves the peptide, reducing the concentration of the TFA solution leads to a decrease in the solubility of the peptide. Regarding the solubility, not only in consideration of industrialization, but in parallel synthesis in which many different peptide compounds are treated at once, it is necessary to select a solvent having high solubility for a group of peptides.
- the present inventors have reduced the steric size of the protecting group of Fmoc-amino acid having a functional group with a protecting group on the side chain, which has not been actively pursued so far.
- Thr protector since it has a secondary alcohol branched at the ⁇ -position as a side chain functional group, the Thr protector has a relatively low condensation efficiency due to its bulk.
- acetyl (Ac) group, tBu group, Trt group, benzyl (Bn) group, t-butyldimethylsilyl (TBS) group and the like are generally used in peptide synthesis ( Albert Isidro-Llobet, et al. Amino Acid-Protecting Groups. Chem. Rev., 2009, 109, 2455. Due to its bulkiness, the condensation efficiency decreases. Even in the case of a tBu group that can be deprotected with an acid, a high concentration of TFA conditions is required for the deprotection, so that the above-described problems during deprotection become apparent.
- Other protecting groups are not protective groups that can be easily removed using an acid.
- a protecting group that is a sterically small protecting group that does not reduce the condensation efficiency and that can be easily deprotected by an acid that can avoid the above-mentioned problems of acid hydrolysis and N ⁇ O-acyl shift. is there.
- the present invention has been found to become prominent during parallel synthesis of peptides containing N-substituted amino acids, and it has been found that acid hydrolysis of peptides in the deprotection step using TFA and N ⁇ It is an object of the present invention to find a novel reaction process that can reduce problems of side reactions such as O-acyl shift and TFA esterification of a hydroxy group and that guarantees peptide solubility.
- an appropriate protecting group for the side chain functional group from the viewpoint of reducing the bulk of the protecting group for the purpose of improving the low reactivity during elongation, and from the viewpoint that it can be deprotected under the deprotection conditions according to the present invention. It is an object of the present invention to provide a method for obtaining a peptide containing an N-substituted amino acid with high purity and high synthesis efficiency by using a suitable protecting group in (1).
- the present inventors used a conventional peptide synthesis method using TFA to synthesize compounds described in known literature.
- the generally practiced improvement methods such as the method of lowering the concentration of TFA or the method of lowering the reaction temperature could not be sufficiently solved.
- TFA used in conventional peptide synthesis was not used at all, and the target was successfully obtained with high selectivity.
- TFA is not used in the cleaving step from the solid phase, and weaker acids such as 2,2,2-trifluoroethanol (TFE) and hexafluoro-2-propanol (HFIP). Use acid.
- TFE 2,2,2-trifluoroethanol
- HFIP hexafluoro-2-propanol
- a protecting group of a side chain functional group that is not deprotected in the cleaving step is used.
- the rate of side reactions such as hydrolysis of amide bonds is sufficiently small even by concentration after the reaction.
- the side reaction rate is low even for peptides containing highly N-substituted amino acids or cyclized peptides that are more susceptible to side reactions. For this reason, the target compound can be obtained as a main product.
- the side reaction such as hydrolysis
- the side reaction rate is sufficiently slow even after performing (3) high solubility even for non-natural peptides with high liposolubility, and (4) cleaving while retaining the protecting group of the side chain functional group
- a reagent that satisfies the condition By using a reagent that satisfies such conditions, it is possible to synthesize a peptide containing a large number of N-substituted amino acids, particularly a drug-like peptide containing a large number of N-alkyl groups. Reagents satisfying such conditions can be used not only for parallel synthesis but also for industrial synthesis of specific peptides.
- a peptide synthesis method capable of deprotecting a side chain protecting group so as to suppress hydrolysis and N ⁇ O-acyl shift and promote a deprotection reaction that is a target main reaction.
- a strong acid such as TFA
- the stage in which the protecting group is eliminated as a cationic species is also important. It may become.
- the deprotection with the weak acid is promoted by using a solvent having ionization ability as a solvent for promoting the step of removing the protecting group as a cationic species.
- the side chain functional group of an amino acid having a side chain with a low degree of ionization under neutral conditions such as Ser and Thr
- hydroxyl groups that are side chain functional groups of amino acids other alkyl alcohol groups having hydroxy groups in the side chain
- phenol groups that are side chain functional groups of amino acids such as Tyr
- side chain functions of amino acids such as His.
- side chain carboxylic acid that is the side chain functional group of amino acids such as Asp and Glu
- carboxylic acid of the main chain of the peptide or amino acid the weak acid conditions when cutting out from the resin Has found a protecting group that is not deprotected and can be deprotected under the above weak acid conditions.
- an amino acid such as ⁇ -hydroxy- ⁇ -amino acid (for example, Thr, Ser, and derivatives thereof), which has a low reactivity during the extension reaction, has a protecting group
- the above weak acid condition The present invention has found a protecting group that can be deprotected with a low molecular weight and can improve the low reactivity during the extension reaction.
- the present invention is as follows. [1] The following steps: 1) an amino acid having at least one of the following functional groups i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one of the following i) and ii) (Fmoc-protected amino acid analog), or Preparing a peptide (Fmoc-protected peptide) containing the Fmoc-protected amino acid and / or the Fmoc-protected amino acid analog; i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) free or active esterified at least one carboxylic acid group, 2) A step of supporting the Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide prepared in step 1) on a solid phase, 3) a step of deprotecting a protecting group having an Fmoc skeleton of an Fm
- a method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog [2] A protecting group in which at least one side chain of the amino acid or amino acid analog constituting the peptide obtained in the step 4) is not deprotected under basic conditions and is deprotected with a first acid. And further comprising the step of deprotecting the protecting group with the first acid before or after the step 5), and using the second acid in the step 5) Is a manufacturing method according to [1], The manufacturing method in which both the first acid and the second acid are weaker than TFA, and the acidity of the first acid is higher than the acidity of the second acid.
- Step 4) of [1] or Step 3) of [3] A step of deprotecting a protecting group having the Fmoc backbone of a newly added Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide with a base to expose an amino group, and a new Fmoc-protected amino acid, Fmoc-protected amino acid analog Adding a body or Fmoc-protected peptide to form an amide bond, The production method according to any one of [1] to [6], wherein these steps are repeated once or a plurality of times.
- the produced peptide contains an amino acid residue or amino acid analog residue having one reaction point on the C-terminal side, and an amino acid residue, amino acid analog residue or carvone having another reaction point
- the production method according to any one of [1] to [7], comprising an acid analog on the N-terminal side.
- the production method according to [9] wherein the amino acid residue, amino acid analog residue or carboxylic acid analog having the other reactive site is at the N-terminus, and the bond is an amide bond.
- the production method according to [13], wherein the fluoroalcohol is TFE or HFIP.
- the protecting group of the side chain is a protecting group that is deprotected in the range of pH 1 to pH 7, or is a protecting group that is deprotected at 10% or less of TFA, [2] to [14] The manufacturing method in any one.
- the side chain protecting group is selected from the following a) to d): a) When the protecting group of the side chain is a protecting group of the hydroxyl group of the side chain of Ser, Thr, Hyp, and derivatives thereof, the MOM skeleton group, Bn skeleton, Dpm skeleton, Trt represented by the following general formula Any protecting group selected from a skeleton, a silyl skeleton and a Boc skeleton; b) When the protecting group for the side chain is a protecting group for the hydroxyl group of the side chain of Tyr or a derivative thereof, the MOM skeleton, the Bn skeleton, the Dpm skeleton, the Trt skeleton, the silyl skeleton, the Boc skeleton represented by the following general formula: any protecting group selected from the tBu skeleton; c) when the protecting group for the side chain is a protecting group for the imidazole ring of the side
- R2 is H.
- R1 to R5 are each independently H, alkyl, aryl, or halogen, and R6 and R7 are alkyl
- R1, R2, R4, and R5 are each independently H, alkyl, aryl, or halogen
- R3 is methoxy
- R6 and R7 are H
- R1 and R3 are methoxy
- R2, R4, and R5 are each independently H, alkyl, aryl, or halogen
- R6 and R7 are H, or R1, R4, and R5 are Each independently H, alkyl, aryl, or halogen
- R 2 and R 3 together form —O—CH 2 —O—.
- R1 to R15 are each independently H, alkyl, aryl, alkoxy, or halogen
- R1, R2, and R4 to R15 are each independently H, alkyl, aryl, alkoxy, or halogen
- R3 is methyl or methoxy
- R1 is Cl and R2 to R15 are each independently H, alkyl, aryl, alkoxy, or halogen
- R1 to R4 and R7 to R15 are each independently H, alkyl, aryl , Alkoxy, or halogen
- R5 and R6 together form -O-.
- ⁇ Protecting group having a silyl skeleton> (Where R1 to R3 are each independently alkyl or aryl. ) ⁇ Protecting group having Boc skeleton> (Where R1 to R9 are each independently H, alkyl, or aryl. ) ⁇ Protecting group having tBu skeleton> (Where R1 to R9 are each independently H, alkyl, or aryl. ) ⁇ Protecting group having phenyl-EDOTn skeleton> (Where R1 to R3 are each independently H or methoxy).
- a peptide containing an N-substituted amino acid can be obtained with high synthesis efficiency and high purity.
- FIG. 1 is a diagram showing a basic synthesis route of a cyclic peptide containing N-methylamino acid in the sequence.
- FIG. 2 shows the target peptide (compound 131), the target hydrolyzate (TM + H 2 O), and the target product under the deprotection conditions of a 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIPS). It is a figure which shows the result analyzed by LCMS which shows the detection of the solvolysis body (TM + HFIP) by HFIP.
- FIG. 1 is a diagram showing a basic synthesis route of a cyclic peptide containing N-methylamino acid in the sequence.
- FIG. 2 shows the target peptide (compound 131), the target hydrolyzate (TM + H 2 O), and the target product under the deprotection conditions of a 0.1 M tetramethylammonium hydrogen sulfate / HFIP solution (2% TIP
- FIG. 3 shows the target peptide (compound 131), the target hydrolyzate (TM + H 2 O), and the target product under the deprotection conditions of 0.05M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS). It is a figure which shows the result analyzed by LCMS which shows the detection of the solvolysis body (TM + HFIP) by HFIP.
- FIG. 4 is an LCMS showing detection of the target peptide (compound 133) and the N ⁇ O-acyl shifter of the target substance under the deprotection conditions of 0.05M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS). It is a figure which shows the result of having analyzed.
- FIG. 5 shows the addition of the target peptide (compound 131), the target hydrolyzate (TM + H 2 O), and the target product with HFIP under the deprotection conditions of 0.05 M oxalic acid / HFIP solution (2% TIPS). It is a figure which shows the result analyzed by LCMS which shows the detection of a solvent decomposition product (TM + HFIP).
- FIG. 6 shows the addition of the target peptide (compound 131), the target hydrolyzate (TM + H 2 O), and the target product with HFIP under the deprotection conditions of 0.05 M maleic acid / HFIP solution (2% TIPS).
- FIG. 7 shows the result of LCMS analysis showing detection of the target peptide (compound 133) and the N ⁇ O-acyl shifter of the target compound under the deprotection condition of 0.05 M oxalic acid / HFIP solution (2% TIPS).
- FIG. 8 shows the result of LCMS analysis showing detection of the target peptide (compound 133) and the N ⁇ O-acyl shifter of the target substance under the deprotection condition of 0.05 M maleic acid / HFIP solution (2% TIPS).
- FIG. 9 shows that the target peptide (Compound 137) and the solvolysis product of the target compound by HFIP (which has any amide bond) under the deprotection condition of 0.05M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS). It is a figure which shows the result analyzed by LCMS which shows the detection of the thing which received solvolysis by HFIP.
- FIG. 9 shows that the target peptide (Compound 137) and the solvolysis product of the target compound by HFIP (which has any amide bond) under the deprotection condition of 0.05M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS).
- FIG. 10 shows the target peptide (compound 137) and the solvolyzed product of TFE of the target compound under the deprotection conditions of 0.05M tetramethylammonium hydrogensulfate / TFE (2% TIPS) It is a figure which shows the result analyzed by LCMS which shows the detection of the thing which received solvolysis by TFE).
- FIG. 11 shows the target peptide (compound 135) when the reaction was stopped by adding 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) to the deprotection conditions and adding base (DIPEA) to the solution. It is a figure which shows the result analyzed by LCMS which shows the detection of).
- FIG. 11 shows the target peptide (compound 135) when the reaction was stopped by adding 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) to the deprotection conditions and adding base (DIPEA) to
- FIG. 12 shows the target peptide (compound 133) when the reaction was stopped by adding 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) under deprotection conditions and adding base (DIPEA) to the solution. It is a figure which shows the result analyzed by LCMS which shows the detection of).
- FIG. 13 shows the results of LCMS analysis showing the detection of the target peptide (Compound 112) and the target peptide with Thr omitted (Compound 113) when Fmoc-Thr (Trt) -OH is added.
- FIG. 14 is a diagram showing the results of LCMS analysis showing detection of the target peptide (compound 114) when Fmoc-Thr (THP) —OH is added. No Thr was eliminated from the target peptide (Compound 114) (Compound 113).
- FIG. 15 shows the detection of the target peptide (Compound 115) and the target peptide (Metric 116) from which MeSer was lost when synthesis was performed using Fmoc-MeSer (DMT) -OH ⁇ 0.75DIPEA. It is a figure which shows the result analyzed by LCMS.
- FIG. 16 shows detection of the target peptide (Compound 115) and the target peptide from which MeSer is lost (Compound 116) in the case of synthesis using Fmoc-MeSer (THP) -OH (Compound 6). It is a figure which shows the result analyzed by LCMS.
- FIG. 17 shows the results of LCMS analysis showing detection of the target peptide (compound 131) and the target hydrolyzate (TM + H 2 O) under 5% TFA / DCE (5% TIPS) deprotection conditions.
- FIG. 18 shows that the target peptide (compound 133), the N ⁇ O-acyl shift product of the target product, and one hydroxyl group of the target product are TFA esterified under 5% TFA / DCE (5% TIPS) deprotection conditions. It is a figure which shows the result of having analyzed by LCMS which shows the detection of the compound which TFA esterified two hydroxyl groups of the target compound and the target object.
- FIG. 19 shows the target peptide (compound 133), the N ⁇ O-acyl shift product of the target product, and one hydroxyl group of the target product under the deprotection condition of 5% TFA / DCE (5% TIPS) (0 degree).
- FIG. 20 shows the target peptide (compound 133), the N ⁇ O-acyl shift product of the target product, and one hydroxyl group of the target product under the deprotection conditions of 5% TFA / DCE (5% TIPS) (25 degrees). It is a figure which shows the result of having analyzed by LCMS which shows the detection of the compound which TFA esterified, and the compound in which two hydroxyl groups of the target object were TFA esterified.
- FIG. 21 is a diagram showing a synthesis method including an extension reaction in a liquid phase.
- the present invention relates to a method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog comprising the following steps. 1) an amino acid having at least one of the following functional groups i) and ii) (Fmoc-protected amino acid), an amino acid analog having at least one of the following i) and ii) (Fmoc-protected amino acid analog), or Preparing a peptide (Fmoc-protected peptide) containing the Fmoc-protected amino acid and / or the Fmoc-protected amino acid analog; i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) free or active esterified at least one carboxylic acid group, 2) A step of supporting the Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide prepared
- the present invention relates to a method for producing a peptide comprising at least one N-substituted amino acid or N-substituted amino acid analog comprising the following steps. 1) Amino acid having at least one functional group of i) and ii) below (Fmoc-protected amino acid), Amino acid analog having at least one functional group of i) and ii) below (Fmoc-protected amino acid analog) Or a step of preparing a peptide (Fmoc-protected peptide) containing either or both of the Fmoc-protected amino acid and the Fmoc-protected amino acid analog; i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) free or active esterified at least one carboxylic acid group, 2) a step of deprotecting the protecting group having the Fmoc skeleton of the Fmoc-protected amino acid, Fmo
- the “peptide” in the present invention is not particularly limited as long as it is a peptide formed by amide bond or ester bond of amino acids and / or amino acid analogs, but preferably 5 to 30 residues, more preferably 7 to 15 residues. More preferably a peptide having 9 to 13 residues.
- the peptide synthesized in the present invention includes at least one or more N-substituted amino acids or amino acid analogs (also referred to as N-substituted amino acids), preferably two or more, Preferably it contains 3 or more, more preferably 5 or more N-substituted amino acids. These N-substituted amino acids may be present continuously or discontinuously in the peptide.
- the peptide in the present invention may be a linear peptide or a cyclic peptide, and is preferably a cyclic peptide.
- the “cyclic peptide” in the present invention can be obtained by synthesizing a linear peptide according to the method of the present invention and then cyclizing. Cyclization includes cyclization by carbon-nitrogen bond such as amide bond, cyclization by carbon-oxygen bond such as ester bond and ether bond, cyclization by carbon-sulfur bond such as thioether bond, carbon-carbon bond Any form such as cyclization by cyclization or cyclization by heterocyclic ring construction may be used. Although not particularly limited, cyclization via a covalent bond such as an amide bond or a carbon-carbon bond is preferred, and cyclization via an amide bond between a side-chain carboxylic acid group and an N-terminal main chain amino group is particularly preferred. . The position of the carboxylic acid group, amino group, or the like used for cyclization may be on the main chain or on the side chain, and is not particularly limited as long as it is in a cyclizable position.
- N-substituted amino acid in the present invention means an amino acid or an amino acid analog in which the main chain amino group is N-substituted among the “amino acid” or “amino acid analog” described later, and N-methyl Preferred are N-alkylated amino acids or amino acid analogs such as Specifically, as the N-substituted amino acid, the main chain amino group of the amino acid or amino acid analog is an NHR group, and R is an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, hetero group.
- Examples thereof include an aryl group, an aralkyl group, or a cycloalkyl group, and those in which a carbon atom bonded to an N atom and a carbon atom from the ⁇ -position form a ring, such as proline.
- the substituent of each group that may be substituted is not particularly limited, and examples thereof include a halogen group, an ether group, and a hydroxyl group.
- such an N-substituted amino acid is preferably an alkyl group, an aralkyl group, a cycloalkyl group or the like.
- amino acids in the present invention are ⁇ , ⁇ , and ⁇ amino acids, and natural amino acids (in this application, natural amino acids refer to 20 types of amino acids contained in proteins. Specifically, Gly, Ala, Ser, It is not limited to Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, and Pro). Good.
- an ⁇ -amino acid it may be an L-type amino acid, a D-type amino acid, or an ⁇ , ⁇ -dialkyl amino acid.
- the selection of the amino acid side chain is not particularly limited, and examples thereof include a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, and a cycloalkyl group.
- the amino acid side chain may be given a substituent, and is freely selected from arbitrary functional groups including, for example, an N atom, an O atom, an S atom, a B atom, an Si atom, and a P atom.
- the number of substituents is not particularly limited, and may be one, or two or more.
- the “amino acid analog” preferably means ⁇ -hydroxycarboxylic acid.
- the side chain of ⁇ -hydroxycarboxylic acid is not particularly limited as in the case of amino acids, and examples thereof include a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, and a cycloalkyl group.
- the steric structure of the ⁇ -hydroxycarboxylic acid may correspond to the L form or D form of the amino acid.
- a side chain is not specifically limited, For example, it can select freely from arbitrary functional groups containing N atom, O atom, S atom, B atom, Si atom, and P atom.
- the number of substituents is not particularly limited, and may be one, or two or more.
- it may have an S atom and further have a functional group such as an amino group or a halogen group.
- any steric configuration is allowed as in the case of ⁇ -amino acids, and the selection of the side chain is not particularly limited and is the same as in the case of ⁇ -amino acids.
- amino acid and amino acid analog constituting the peptide synthesized in the present invention include all the corresponding isotopes.
- the isotopes of “amino acids” and “amino acid analogs” are those in which at least one atom is replaced with an atom having the same atomic number (number of protons) and a different mass number (sum of protons and neutrons). is there.
- isotopes contained in the “amino acid” and “amino acid analog” constituting the peptide compound of the present invention include, for example, hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, chlorine Specifically, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl may be mentioned. .
- the amino acid or amino acid analog may have one or two or more substituents.
- substituents include substituents derived from O atoms, N atoms, S atoms, B atoms, P atoms, Si atoms, and halogen atoms.
- halogen-derived substituent examples include fluoro (—F), chloro (—Cl), bromo (—Br), iodo (—I) and the like.
- Examples of the substituent derived from the O atom include hydroxyl (—OH), oxy (—OR), carbonyl (—C ⁇ O—R), carboxyl (—CO 2 H), oxycarbonyl (—C ⁇ O—OR), Carbonyloxy (—O—C ⁇ O—R), thiocarbonyl (—C ⁇ O—SR), carbonylthio group (—S—C ⁇ O—R), aminocarbonyl (—C ⁇ O—NHR), carbonyl Amino (—NH—C ⁇ O—R), oxycarbonylamino (—NH—C ⁇ O—OR), sulfonylamino (—NH—SO 2 —R), aminosulfonyl (—SO 2 —NHR), sulfa Examples include moylamino (—NH—SO 2 —NHR), thiocarboxyl (—C ( ⁇ O) —SH), and carboxylcarbonyl (—C ( ⁇ O) —CO 2 H).
- oxy examples include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy and the like.
- carbonyl examples include formyl (—C ⁇ O—H), alkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aralkylcarbonyl and the like. .
- Examples of oxycarbonyl include alkyloxycarbonyl, cycloalkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl and the like.
- (-C O-OR)
- carbonyloxy examples include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy and the like.
- thiocarbonyl examples include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, aralkylthiocarbonyl and the like.
- carbonylthio examples include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio and the like. .
- aminocarbonyl examples include alkylaminocarbonyl, cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl and the like.
- compounds in which the H atom bonded to the N atom in —C ⁇ O—NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl are exemplified.
- Examples of carbonylamino include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino and the like. .
- compounds in which the H atom bonded to the N atom in —NH—C ⁇ O—R is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl or aralkyl.
- Examples of oxycarbonylamino include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aralkyloxy And carbonylamino.
- alkoxycarbonylamino cycloalkoxycarbonylamino
- alkenyloxycarbonylamino alkynyloxycarbonylamino
- aryloxycarbonylamino heteroaryloxycarbonylamino
- aralkyloxy And carbonylamino aralkyloxy And carbonylamino.
- sulfonylamino examples include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino and the like.
- alkylsulfonylamino examples include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino and the like.
- H atom bonded to the N atom in —NH—SO 2 —R is further substituted with alkyl, cycloalkyl,
- aminosulfonyl examples include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl and the like.
- compounds in which the H atom bonded to the N atom in —SO 2 —NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl are exemplified.
- sulfamoylamino examples include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenylsulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, hetero Arylsulfamoylamino, aralkylsulfamoylamino and the like can be mentioned.
- the two H atoms bonded to the N atom in —NH—SO 2 —NHR are substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl. They may be substituted, and these two substituents may form a ring.
- substituent derived from the S atom examples include thiol (—SH), thio (—S—R), sulfinyl (—S ⁇ O—R), sulfonyl (—S (O) 2 —R), sulfo (—SO 3 H).
- thio examples are selected from alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio and the like.
- sulfinyl examples include alkylsulfinyl, cycloalkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl and the like.
- sulfonyl examples include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl and the like.
- substituent derived from the N atom examples include azide (—N 3 , also referred to as “azido group”), cyano (—CN), primary amino (—NH 2 ), secondary amino (—NH—R), tertiary Amino (—NR (R ′)), amidino (—C ( ⁇ NH) —NH 2 ), substituted amidino (—C ( ⁇ NR) —NR′R ′′), guanidino (—NH—C ( ⁇ NH) —NH 2 ), substituted guanidino (—NR—C ( ⁇ NR ′ ′′) — NR′R ′′), and aminocarbonylamino (—NR—CO—NR′R ′′).
- secondary amino examples include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino and the like.
- tertiary amino are independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl and the like, for example, alkyl (aralkyl) amino And an amino group having two arbitrary substituents, and these two arbitrary substituents may form a ring.
- substituted amidinos are the three substituents R, R ′, and R ′′ on the N atom are alkyl, cycloalkyl, alkenyl, alkynyl, aryl , Heteroaryl, and groups independently selected from aralkyl, for example, alkyl (aralkyl) (aryl) amidino and the like.
- substituted guanidino examples include R, R ′, R ′′, and R ′ ′′ where alkyl, cycloalkyl, alkenyl, alkynyl , Aryl, heteroaryl, and aralkyl groups independently selected from each other, or a group in which these form a ring.
- aminocarbonylamino examples include those in which R, R ′, and R ′′ are hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl. Examples thereof include a group independently selected from the above, or a group that forms a ring.
- substituent derived from the B atom examples include boryl (—BR (R ′)) and dioxyboryl (—B (OR) (OR ′)). These two substituents R and R ′ are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl and the like, or they may form a ring .
- the amino acid or amino acid analog of the present invention includes various substitutions including O atom, N atom, S atom, B atom, P atom, Si atom and halogen atom which are usually used in low molecular weight compounds. You may have 1 or 2 or more groups. These substituents may be further substituted with another substituent.
- amino acid and amino acid analog constituting the peptide synthesized in the present invention may also be referred to as “amino acid residue” and “amino acid analog residue”, respectively.
- “Fmoc-protected amino acid” and “Fmoc-protected amino acid analog” are amino acids and amino acid analogs each having at least one of the following functional groups i) and ii): i) a main chain amino group protected by at least one protecting group having an Fmoc skeleton; ii) at least one carboxylic acid group which is free or active esterified.
- the “protecting group having an Fmoc skeleton” in the present invention means a group in which an arbitrary substituent is introduced at an arbitrary position of the constituent skeleton of the Fmoc group or Fmoc group.
- Specific examples of the protecting group having an Fmoc skeleton include, for example, 9-fluorenylmethyloxycarbonyl (Fmoc) group, 2,7-di-tert-butyl-Fmoc (Fmoc *) group, 2-fluoro-Fmoc ( Fmoc (2F)) group, 2-monoisooctyl-Fmoc (mio-Fmoc) group, 2,7-diisooctyl-Fmoc (dio-Fmoc) group and the like.
- a protecting group having an Fmoc skeleton in place of the protecting group having an Fmoc skeleton, a protecting group that can be deprotected with a basic condition or a nucleophilic species exhibiting basicity (for example, piperidine or hydrazine) can also be used.
- a basic condition or a nucleophilic species exhibiting basicity for example, piperidine or hydrazine
- protecting groups include 2- (4-nitrophenylsulfonyl) ethoxycarbonyl (Nsc) group, (1,1-dioxobenzo [b] thiophen-2-yl) methyloxycarbonyl (Bsmoc) Group, (1,1-dioxonaphtho [1,2-b] thiophen-2-yl) methyloxycarbonyl ( ⁇ -Nsmoc) group, 1- (4,4-dimethyl-2,6-dioxocyclohexyl-1 -Ylidene) -3-methylbutyl (ivDde) group, tetrachlorophthaloyl (TCP) group, 2- [phenyl (methyl) sulfonio] ethyloxycarbonyltetrafluoroborate (Pms) group, ethanesulfonylethoxycarbonyl (Esc) group, And 2- (4-sulfophenylsulfony
- a protecting group capable of deprotection other than acid or base can be used.
- a protecting group include, for example, a benzyloxycarbonyl (Z) group that can be deprotected by hydrogenation in the presence of a transition metal catalyst such as palladium, a combination of a palladium catalyst and a scavenger (for example, tetrakis (Triphenylphosphine) palladium (0) (in combination with Pd (PPh 3 ) 4 ) and phenylsilane)
- a transition metal catalyst such as palladium
- a combination of a palladium catalyst and a scavenger for example, tetrakis (Triphenylphosphine) palladium (0) (in combination with Pd (PPh 3 ) 4 ) and phenylsilane
- oc alkylthiol or arylthiol in combination with base
- oNBS, Ns 2,4-dinitrobenzen
- the amino group of the main chain is protected by the Fmoc group, and the functional group of the side chain is protected by a basic non-cleavable protecting group such as piperidine or DBU, if necessary, and
- a basic non-cleavable protecting group such as piperidine or DBU, if necessary
- An Fmoc-protected amino acid or an Fmoc-protected amino acid analog in which the main chain carboxylic acid group is not protected can be preferably used.
- An Fmoc-protected amino acid or an Fmoc-protected amino acid analog having an amino group protected with a protecting group having an Fmoc skeleton and a carboxylic acid group having no protecting group can also be preferably used.
- the functional group is preferably protected with a protective group.
- a protecting group a well-known protecting group that can be deprotected under any conditions can be used.
- a protecting group a protecting group that is not cleaved under basic conditions and is deprotected under a condition that becomes a weaker acid than TFA is preferable.
- the acidic and deprotectable protecting group include protecting groups that can be deprotected in the range of pH 1 to pH 7, preferably in the range of pH 2 to pH 6.
- a protecting group that can be deprotected at 10% or less of TFA, or a protecting group having the structure described below can be used.
- a well-known protecting group can be used as the protecting group for the side chain.
- those described in the following documents i) and ii) that satisfy the above conditions among the protecting groups can be employed as the side chain protecting group.
- the method of the present invention can be used for peptide synthesis by parallel synthesis.
- a protecting group is not necessarily required for the side chain of the amino acid, but when a protecting group is required for the side chain, the protecting group to be used should be quickly deprotected under the deprotection conditions of the present invention. Is preferred.
- the side chain protecting groups are preferably 50% deprotected within 24 hours, particularly preferably 90% deprotected within 4 hours.
- a protecting group satisfying such conditions a protecting group having a Trt skeleton, a THP skeleton, a THF skeleton, or a TBS skeleton described later is preferable.
- At least one hydrogen atom is substituted on the protecting group side atom directly bonded to the functional group (from the protecting group of the Trt skeleton).
- protecting groups which are also sterically low in volume. Of these, a protecting group in which a substituent other than hydrogen forms a ring is more preferable, and THP and THF are particularly preferable.
- the method of the present invention can also be used for industrial peptide synthesis.
- it is not always necessary to have a protecting group on the side chain of the amino acid, as in the parallel synthesis, but when it has a protecting group on the side chain, it preferably has the same protecting group as in the parallel synthesis.
- TFA generally used at the time of deprotection A strong acid such as may be used.
- a bulky protecting group can be used.
- a condition for forming a weaker acid than TFA is preferably a weak acid having a pKa value of 0 to 9 in water, a positive ionization ability Y OTs value and a pKa of 5 to 14 in water.
- the conditions which use the weak acid solution contained in the solvent which are are mentioned.
- a weak acid having a pKa value in water of 0 to 9 a weak acid having a pKa in water of 1 to 5 is more preferable.
- the concentration of the weak acid to be dissolved in the solvent may be arbitrary as long as the condition for making the acid weaker than TFA is satisfied.
- fluoroalcohols are a generic name for a carbon atom constituting an alcohol in which a fluorine atom is bonded to a carbon atom other than the carbon atom to which the hydroxyl group is bonded.
- the fluoroalcohol includes those having a hydroxyl group bonded to an aromatic ring, such as 2,3,4,5,6-pentafluorophenol.
- TFE 2,2,2-trifluoroethanol
- HFIP hexafluoro-2-propanol
- the weak acid solution further contains another organic solvent (for example, dichloromethane, 1,2-dichloroethane, etc.) or a cation scavenger (for example, triisopropylsilane). Etc. can also be added.
- another organic solvent for example, dichloromethane, 1,2-dichloroethane, etc.
- a cation scavenger for example, triisopropylsilane.
- the Fmoc-protected amino acid or the Fmoc-protected amino acid analog has a protecting group in its side chain
- the following can be preferably mentioned as the side-chain protecting group.
- the side chain protecting group is a hydroxyl protecting group of Ser, Thr, Hyp, and derivatives thereof
- the MOM skeleton, the Bn skeleton, the Dpm skeleton, the Trt skeleton, the silyl skeleton represented by the following general formula, or A protecting group having a Boc skeleton is preferred.
- substituent Me and Et on the skeleton those substituted with other alkyl groups, benzyl groups, aryl groups, and the like can also be used.
- Other alkyl groups may be used in place of the substituent Me.
- an alkyl group, an aryl group, a halogen group or the like may be substituted on the benzene ring.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- crosslinked via two carbon atoms, etc. may be used.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- crosslinked through the oxygen atom can also be used.
- THP and Trt are particularly preferable.
- the side chain protecting group is particularly preferably THP or Trt, and when the amino acid residue is Thr, the side chain protecting group is particularly preferably THP.
- the side chain protecting group is a protecting group of an amino acid having a hydroxyl group substituted with an aryl group such as Tyr, D-Tyr, Tyr (3-F), for example, the MOM skeleton represented by the following general formula: , A protecting group having a Bn skeleton, a Dpm skeleton, a Trt skeleton, a silyl skeleton, a Boc skeleton, or a tBu skeleton is preferable.
- substituent Me and Et on the skeleton those substituted with other alkyl groups, benzyl groups, aryl groups, and the like can also be used.
- Other alkyl groups may be used in place of the substituent Me.
- an alkyl group, an aryl group, a halogen group or the like may be substituted on the benzene ring.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- crosslinked via two carbon atoms, etc. may be used.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- crosslinked through the oxygen atom can also be used.
- An alkyl group or aryl group other than H may be substituted.
- the side chain protecting group is particularly preferably tBu, Trt, Clt, or THP, and when the amino acid residue is Tyr (3-F)
- the chain protecting group is particularly preferably tBu or Pis.
- the side chain protecting group is a protecting group of an amino acid having imidazole in the side chain, such as His or MeHis, for example, a protecting group having a MOM skeleton, a Bn skeleton, or a Trt skeleton represented by the following general formula is used. It is preferable.
- Me and Et on the skeleton those substituted with other alkyl groups, benzyl groups, aryl groups, and the like can also be used.
- Other alkyl groups may be used in place of the substituent Me.
- an alkyl group, an aryl group, a halogen group or the like may be substituted on the benzene ring.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- Trt is particularly preferable.
- the side chain protecting group is particularly preferably Trt.
- a protecting group for the carboxylic acid group of the main chain when used as a “free or active esterified carboxylic acid group”, as a protecting group for the carboxylic acid group of the side chain of Asp, Glu, and derivatives thereof, when the carboxylic acid group of the side chain of Asp, Glu, and a derivative thereof is used as a “free or active esterified carboxylic acid group”, as a protecting group for the carboxylic acid group of the main chain, for example, the following general formula And a protecting group having a MOM skeleton, a Bn skeleton, a Dpm skeleton, a Trt skeleton, a tBu skeleton, or a phenyl-EDOTn skeleton represented by the formula: Further, a protective group having an ortho ester skeleton in which three alkoxy groups are bonded to a carbon atom derived from a carboxylic acid group can also be used as a protective group for carboxylic acid.
- substituent on the skeleton those substituted with another alkyl group, benzyl group, aryl group or the like can also be used.
- Other alkyl groups may be used in place of the substituent Me. Further, an alkyl group, an aryl group, a halogen group or the like may be substituted on the benzene ring.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- An alkyl group, aryl group, alkoxy group, halogen group or the like may be substituted on the aromatic ring.
- crosslinked through the oxygen atom can also be used.
- Other alkyl groups, aryl groups and the like may be substituted.
- a dicyclopropylmethyl group can also be used.
- Fmoc-protected peptide means a peptide containing either or both of the “Fmoc-protected amino acid” and the “Fmoc-protected amino acid analog”.
- examples of such peptides include dipeptides and oligopeptides having two or more molecules including one or both of the above-mentioned Fmoc-protected amino acids and Fmoc-protected amino acid analogs.
- a Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide (sometimes referred to as Fmoc-protected amino acid) can be supported on a solid phase using a resin.
- the group (resin binding group) used for bonding with the Fmoc-protected amino acid or the like of the resin used is not particularly limited as long as the peptide can be cleaved with an acid. There are no particular limitations on the loading amount and loading ratio of the Fmoc-protected amino acid.
- trityl chloride resin (Trt resin), 2-chlorotrityl chloride resin (Clt resin), 4-methyltrityl chloride resin (Mtt resin), 4-methoxytrityl chloride resin (Mmt)
- the resin is a resin bond determined as “H ( ⁇ 5% TFA in DCM)” as acid sensitivity described in the solid-phase synthesis handbook (issued by Merck Co., Ltd., issued on May 1, 2002). It preferably has a group and can be appropriately selected according to the functional group on the amino acid side to be used.
- a carboxylic acid main chain carboxylic acid or a side chain carboxylic acid represented by Asp or Glu
- a hydroxy group (phenol group represented by Tyr) on an aromatic ring is used as a functional group on the amino acid side.
- Trt resin trityl chloride resin
- Clt resin 2-chlorotrityl chloride resin
- the resin is trityl chloride resin (Trt resin), 2-chlorotrityl chloride resin (Clt resin).
- Mtt resin 4-methyltrityl chloride resin
- the type of polymer constituting the resin is not particularly limited. In the case of a resin composed of polystyrene, either 100-200 mesh or 200-400 mesh may be used. Further, the crosslinking rate is not particularly limited, but those having 1% DVB (divinylbenzene) crosslinking are preferable.
- An amino acid, Fmoc-protected amino acid analog, or Fmoc-protected peptide is supported on the resin.
- the free carboxylic acid may be a main chain carboxylic acid of an amino acid or an amino acid analog, or a side chain carboxylic acid (Asp or the like).
- a free OH group or free SH group of the main chain or side chain of the amino acid located at the C-terminus of the Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide is used as the solid phase. It can also be used for loading.
- the protecting group having the Fmoc skeleton of the Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide carried on the solid phase is deprotected with a base to expose the amino group.
- a deprotecting agent generally used in peptide synthesis can be used (for example, Amino Acid-Protecting Groups (Chem. Rev. 2009, 109, 2455-2504)).
- a deprotecting agent for example, a secondary amine, a base having an amidine skeleton, or a base having a guanidine skeleton is preferable.
- Specific examples of the secondary amine include piperidine, morpholine, pyrrolidine and piperazine.
- Specific examples of the base having an amidine skeleton include 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) and 1,5-diazabicyclo [4.3.0] -5-nonene. (DBN).
- Specific examples of the base having a guanidine skeleton include 1,1,3,3-tetramethylguanidine.
- the exposed amino group and the newly added Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide free or active esterified carboxylic acid group are condensed to form a peptide bond.
- the condensing agent for condensing the amino group and the carboxylic acid group is not particularly limited as long as it can form an amide bond, and condensing agents generally used in peptide synthesis are preferable (for example, Peptide Coupling Reagents, More than a Letter Soup (Chem. Rev. 2011, 111, 6557-6602)).
- Specific examples of such a condensing agent include condensing agents having a carbodiimide skeleton.
- a condensing agent having a carbodiimide skeleton can be used in a condensation reaction in combination with a hydroxy compound capable of forming an active ester.
- Examples of the condensing agent having a carbodiimide skeleton include N, N′-dicyclohexylcarbodiimide (DCC), N, N′-diisopropylcarbodiimide (DIC), and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (See, for example, WATANABEATAChemical catalog, Amino acids and chiral building blocks to new medicine).
- hydroxy compounds that can form active esters include 1-hydroxy-1H-benzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), ethyl 2-cyano-2- (hydroxyimino) acetate ( oxyma), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBt or HODhbt), N-hydroxy-5-norbornene-2,3-dicarboximide (HONB), 2,3,4,5,6-pentafluorophenol (HOPfp), N-hydroxysuccinimide (HOSu), 6-chloro-1-hydroxy-1H-benzotriazole (Cl-HOBt) (for example, WATANABE® Chemical Catalog, Amino acids and chiral building blocks to new medi see cine).
- HOBt 1-hydroxy-1H-benzotriazole
- HOAt 1-hydroxy-7-azabenzotriazole
- salts having these skeletons for example, K-oxyma which is a potassium salt of oxyma can also be used.
- K-oxyma which is a potassium salt of oxyma
- HOBt, HOAt, oxyma, and HOOBt are particularly preferable.
- O- (1H-benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (HBTU)
- HATU phosphonium condensing agent / uronium condensing agent -(7-aza-1H-benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU)
- HATU and DIPEA a combination of HATU and DIPEA, or a combination of COMU and DIPEA.
- N, N′-carbonyldiimidazole (CDI), 1,1′-carbonyl-di- (1,2,4-triazole) (CDT), 4- (4,6-dimethoxy-1,3, Condensing agents such as 5-triazin-2-yl) -4-methylmorpholinium chloride (DMT-MM) and propylphosphonic anhydride (T3P) can also be used.
- the production method of the present invention comprises a step of deprotecting a protecting group having an Fmoc skeleton of a newly added Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide with a base to expose an amino group, and a new Fmoc
- the method further includes the step of adding a protected amino acid, an Fmoc protected amino acid analog or an Fmoc protected peptide to form an amide bond. These steps may be repeated once or multiple times.
- a desired peptide sequence can be obtained by repeating deprotection of a protecting group having an Fmoc skeleton and a condensation reaction with the next new Fmoc-protected amino acid, Fmoc-protected amino acid analog or Fmoc-protected peptide. It is.
- the target peptide is obtained and then cut out from the solid phase (cutout step). Moreover, it is also possible to perform peptide structural transformation or cyclization before the excision step.
- the side chain functional group protected by the protecting group may or may not be deprotected, and only some of the several protecting groups are deprotected. May be.
- the cleaving step is preferably performed while the side chain functional group is protected.
- the reaction condition of the cutting step of the present invention is preferably a condition that becomes a weak acid, particularly preferably a condition that becomes a weak acid rather than TFA.
- a weak acid is preferably an acid having a pKa value in water higher than that of TFA. More specifically, the pKa value is preferably in the range of 0 to 15, and the pKa value in water is more preferably in the range of 6 to 15.
- the acid that is weaker than TFA used in this step include TFE and HFIP. Two or more weak acids may be combined in any ratio such as TFE / acetic acid. Moreover, you may mix arbitrary solvents, such as DCM, DCE, and water, in arbitrary ratios.
- a combination of TFE and DCM is particularly preferable.
- Other organic solvents, reagents (eg, DIPEA, etc.), cation scavengers (eg, triisopropylsilane, etc.) and the like may be added to the solution used for cutting.
- the weak acid used for cleaving is preferably weaker than the acid used in the deprotection reaction.
- two types of acids having different acidities that become weaker acids than TFA are prepared in advance, and acids that become weaker acids are used for cutting.
- the weak acid used for the cleaving is not particularly limited as long as it is weaker than TFA.
- the deprotection step of the side chain protecting group of the present invention it is possible to selectively perform a desired deprotection reaction by reducing side reactions such as hydrolysis and N ⁇ O-acyl shift.
- the deprotection of the side chain protecting group is preferably carried out under the condition that the acid becomes weaker than TFA.
- the reaction can be carried out at any temperature, preferably at 0 to 40 ° C.
- a base such as ammonia or a primary to tertiary amine can be used.
- basic heterocyclic compounds for example, pyridine, imidazole, and analogs thereof
- pyridine imidazole, and analogs thereof
- these steps can be performed either before or after the excision step.
- the peptide produced by the production method of the present invention comprises an amino acid residue or amino acid analog residue having one reactive site in the side chain on the C-terminal side, and an amino acid residue or amino acid having another reactive site It can be a peptide comprising an analog residue or a carboxylic acid analog on the N-terminal side.
- Such peptides include, for example, an amino acid residue or amino acid analog residue having one reactive site on the C-terminal side chain, and an amino acid residue or amino acid analog having another reactive site on the N-terminal side. It can be produced by selecting a raw material Fmoc-protected amino acid, Fmoc-protected amino acid analog and Fmoc-protected peptide so that a body residue or a carboxylic acid analog is included.
- This peptide can be cyclized by combining one reactive site with another reactive site.
- the production method of the present invention may include such a cyclization step. Specifically, the cyclization step can be performed based on the description in WO2013 / 100132.
- a residue obtained by concentrating the reaction solution (cutting solution) obtained in the cleaving step under reduced pressure may be used for the cyclization step, and the cleaving solution is used as it is for the cyclization step. May be.
- the “carboxylic acid analog” is a compound having an amino group and a carboxyl group at the same time and having 3 or more atoms between them, various carboxylic acid derivatives having no amino group, and two residues. Peptides formed from ⁇ 4 residues and amino acids whose main chain amino group is chemically modified with an amide bond with a carboxylic acid are included. Further, the “carboxylic acid analog” may have a boric acid or boric acid ester moiety that can be used for cyclization. The “carboxylic acid analog” may be a carboxylic acid having a double bond site or a triple bond site, or a carboxylic acid having a ketone or a halide.
- a portion other than the functional group that defines these compounds may be substituted, and for example, selected from an alkyl group, an aralkyl group, an aryl group, a cycloalkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, and the like. (Free substituents).
- the cyclization step includes, but is not limited to, cyclization of the two reaction points by, for example, an amide bond, a disulfide bond, an ether bond, a thioether bond, an ester bond, a thioester bond, or a carbon-carbon bond. Not.
- Cyclization by amide bond formation can be performed by, for example, reacting the N-terminal amino acid residue, the N-terminal amino acid analog residue, or the N-terminal carboxylic acid analog (an amino group in the main chain or an amino group present in the side chain). ) And a reactive site of an amino acid residue or amino acid analog having one carboxylic acid in the side chain to form an amide bond.
- the condensing agent those similar to those used in the above-described peptide bond can be used.
- the side chain carboxylic acid and the N-terminal main chain amino group, or the side chain amino group and the C-terminal main chain carboxylic acid Can be condensed.
- the protecting group of the carboxylic acid on the C-terminal side and the protecting group of the carboxylic acid on the side chain used for cyclization, or the protecting group of the amino group on the main chain on the N-terminal side and the amino group of the side chain used for cyclization The protecting group is preferably selected in consideration of its orthogonality. Preferred protecting groups in this series of peptide synthesis are as described above.
- Cyclization by carbon-carbon bond formation may be performed by, for example, reacting an N-terminal amino acid residue, an N-terminal amino acid analog residue, or an N-terminal carboxylic acid analog with an amino acid residue having one reactive site in the side chain. Cyclization by forming a carbon-carbon bond with the reactive site of a group or amino acid analog. Specifically, for example, an alkenyl group is selected as a reaction point of an N-terminal amino acid residue, an N-terminal amino acid analog residue, or an N-terminal carboxylic acid analog, and the amino acid has one reactive point in the side chain.
- a cyclization reaction can be carried out by a carbon-carbon bond reaction catalyzed by a transition metal by selecting an alkenyl group as a reaction point of the residue or amino acid analog residue.
- the transition metal used as the catalyst include ruthenium, molybdenum, titanium, and tungsten.
- the cyclization reaction can be performed by a metathesis reaction.
- reaction point of an N-terminal amino acid residue, an N-terminal amino acid analog residue or an N-terminal carboxylic acid analog, and an amino acid residue or amino acid analog residue having one reactive point in the side chain A cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst, employing a combination of aryl halide and boronic acid or a boronic acid analog as a reaction point.
- a transition metal as a catalyst
- palladium, nickel, and iron are mentioned as a transition metal used as a catalyst.
- the cyclization reaction can be performed by the Suzuki reaction.
- reaction point of an N-terminal amino acid residue, an N-terminal amino acid analog residue or an N-terminal carboxylic acid analog, and an amino acid residue or amino acid analog residue having one reactive point in the side chain As a reaction point, a combination of an alkenyl group and an aryl halide or alkenyl halide can be adopted, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst. At this time, palladium and nickel are mentioned as a transition metal used as a catalyst. For example, when palladium is used, the cyclization reaction can be performed by a Heck-type chemical reaction.
- the reaction point of an N-terminal amino acid residue, an N-terminal amino acid analog residue or an N-terminal carboxylic acid analog, and an amino acid residue or amino acid analog residue having one reactive point in the side chain As a reaction point, a combination of an acetylene group and an aryl halide or alkenyl halide is selected, and a cyclization reaction can be carried out by a carbon-carbon bond reaction using a transition metal as a catalyst.
- the transition metal used as a catalyst includes palladium, copper, gold, and iron.
- the cyclization reaction can be performed by the Sonogashira reaction.
- the obtained product can be purified as necessary.
- a general purification method for peptides such as a reverse phase column or a molecular sieve column can be used. It can also be purified by crystallization or solidification using an appropriate solvent. It is also possible to concentrate under reduced pressure before purification.
- all prior art documents cited in the present specification are incorporated herein by reference.
- reaction solvent used for peptide synthesis and solid phase synthesis was for peptide synthesis (purchased from Watanabe Chemical, Wako Pure Chemical).
- DCM, DMF, NMP, 2% DBU in DMF, 20% piperidine in DMF, and the like were used.
- a dehydrated solvent, a super-dehydrated solvent, and an anhydrous solvent purchased from Kanto Chemical, Wako Pure Chemical, etc.
- Example 1 Basic Synthesis Route of Cyclic Peptide Containing N-Methyl Amino Acid in Sequence
- the synthesis of cyclic peptide containing N-methyl amino acid in the sequence employs the solid phase synthesis by Fmoc method, and the following five steps are shown in FIG. The synthesis route was as described.
- Step of cleaving the peptide from 2-chlorotrityl resin Step of condensing the carboxylic acid (white circle unit) of the side chain of Asp of the excised peptide with the amino group at the N-terminus (triangular unit) of the peptide chain and cyclizing with an amide bond
- Fmoc-amino acid used for peptide synthesis by peptide synthesizer In the peptide synthesis described in this Example, the following Fmoc-amino acid was used for synthesis by peptide synthesizer (step A).
- Fmoc-Ser (THP) -OH Compound 1
- Fmoc-Thr THP) -OH
- Compound 2 Fmoc-MeSer (THP) -OH
- Compound 6 Fmoc-MeHis (Trt) -OH (Compound 7)
- Fmoc-D-Tyr (THP) -OH Compound 8
- Fmoc-D-Tyr Pis) -OH (Compound 11)
- Fmoc-Tyr (3-F, tBu) -OH Compound 13
- Fmoc -MePhe (4-Cl) -OH Compound 16
- Fmoc-Tyr 3-F, Pis) -OH (compound 22).
- Example 1-1 (2S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3-((tetrahydro-2H-pyran-2-yl) oxy) propanoic acid (Compound 1, Fmoc-Ser Synthesis of (THP) -OH) (S) -2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3-hydroxypropanoic acid (Fmoc-Ser-OH, purchased from Watanabe Chemical, 1.0 g, 3.06 mmol) and p -Toluenesulfonic acid pyridinium (PPTS, 0.038 g, 0.153 mmol) was added with toluene (10 mL), and the water contained by azeotropy was removed by distilling off toluene under reduced pressure.
- PPTS p -Toluenesulfonic acid
- Example 1-2 (2S, 3R) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3-((tetrahydro-2H-pyran-2-yl) oxy) butanoic acid (Compound 2, Fmoc -Thr (THP) -OH) (2S, 3R) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3-hydroxybutanoic acid monohydrate (Fmoc-Thr-OH monohydrate, Tokyo Kasei) Purchased from 5.0 g, 13.9 mmol) and a mixture of pyridinium p-toluenesulfonate (PPTS, 0.175 g, 0.70 mmol) with toluene (50 mL) and azeotroped by distilling off toluene under reduced pressure Removed moisture.
- PPTS pyridinium p-toluen
- the obtained solid was dried with a pump under reduced pressure at 25 ° C. for 2 hours to obtain a sodium salt of Fmoc-Thr (THP) —OH (2.80 g, 6.26 mmol).
- a sodium salt of Fmoc-Thr (THP) —OH (2.80 g, 6.26 mmol).
- ethyl acetate (50 mL) and 0.05 M aqueous phosphoric acid solution (140 mL) at pH 2.1 were added, and the mixture was stirred at 25 ° C. for 5 minutes. The organic and aqueous layers were separated.
- Example 1-3 (2S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) (methyl) amino) -3-((tetrahydro-2H-pyran-2-yl) oxy) propanoic acid (Compound 6, Fmoc-MeSer (THP) -OH) (S) -2-((((9H-fluoren-9-yl) methoxy) carbonyl) (methyl) amino) -3-hydroxypropanoic acid (Fmoc-MeSer-OH) was synthesized by a method described in the literature ( Literature: International publication number WO 2013/100132 A1).
- Example 1-4 (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) (methyl) amino) -3- (1-trityl-1H-imidazol-4-yl) propanoic acid (Compound 7, Fmoc -MeHis (Trt) -OH)
- (S) -3- (1H-imidazol-4-yl) -2- (methylamino) propanoic acid hydrochloride 75 g, 364.71 mmol) in dichloromethane (1000 mL) and dichlorodimethylsilane.
- 1,4-dioxane 1000 mL
- potassium carbonate 84 g, 603.39 mmol
- water 1000 mL
- (2,5-dioxopyrrolidin-1-yl) carbonate 9H-fluoren-9-yl) methyl (Fmoc-OSu, 102 g, 302.38 mmol) was added, and the mixture was stirred at 0 ° C. for 2 hours.
- the obtained reaction solution was washed with diethyl ether (2000 mL), and then the pH of the solution was adjusted to 6 to 7 using acetic acid.
- Example 1-5 (2R) -2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-((tetrahydro-2H-pyran-2-yl) oxy) phenyl) propanoic acid (compound 8.
- Fmoc-D-Tyr (THP) -OH) (R) -2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-hydroxyphenyl) propanoic acid (Fmoc-D-Tyr-OH, purchased from Watanabe Chemical, 500 mg, 1.24 mmol) and a catalytic amount of pyridinium paratoluenesulfonate (PPTS, 15.6 mg, 0.062 mmol), and toluene (5.0 mL) was added. Removed.
- PPTS pyridinium paratoluenesulfonate
- the organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and further dried under reduced pressure with a pump to obtain 596 mg of residue.
- the obtained residue 300 mg was dissolved in tetrahydrofuran (THF) (2.5 mL), 1.0 M phosphoric acid aqueous solution (pH 8.0, 2.5 mL) was added, and the mixture was stirred at 50 ° C. for 3 hours.
- Ethyl acetate (3 mL) was added to the reaction solution, the organic layer and the aqueous layer were separated, and the aqueous layer was extracted with ethyl acetate (3 mL). All the obtained organic layers were mixed and washed twice with saturated brine (3 mL).
- T-Butyl methyl ether (TBME) (4.6 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 13 mL) were added to the white solid, and the mixture was stirred at 25 degrees for 5 minutes. After separating the organic layer, the aqueous layer was extracted with t-butyl methyl ether (TBME) (4.6 mL). The obtained organic layers were collected and washed twice with saturated brine (4.6 mL). The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- TBME t-butyl methyl ether
- Example 1-6 Synthesis of 2,2,2-trichloroacetimidic acid 2-phenylpropan-2-yl (compound 9)
- 2-Phenylpropan-2-ol purchasedd from Wako, 2.0 g, 14.7 mmol
- diethyl ether (Et 2 O) 4.8 mL
- 1.9 M NaHMDS in tetrahydrofuran (THF) 850 ⁇ L, 1.62 mmol
- THF tetrahydrofuran
- the reaction solution was stirred at the same temperature for 20 minutes, cooled to 0 ° C., and 2,2,2-trichloroacetonitrile (1.47 mL, 14.7 mmol) was added dropwise.
- the reaction solution was stirred at 0 ° C.
- Example 1-7 Synthesis of 2-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-hydroxyphenyl) propanoic acid (R) -methyl (compound 10, Fmoc-D-Tyr-OMe) Under a nitrogen atmosphere, (R) -2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -3- (4- (tert-butoxy) phenyl) propanoic acid (Fmoc-D-Tyr ( tBu) -OH, purchased from Watanabe Chemical, 5.0 g, 10.88 mmol) and methanol (8.80 mL, 218 mmol) and thionyl chloride (1.59 mL, 21.76 mmol) were added dropwise at 0 degrees.
- Example 1-8 (R) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-((2-phenylpropan-2-yl) oxy) phenyl) propanoic acid (Compound 11 , Fmoc-D-Tyr (Pis) -OH) 2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-hydroxyphenyl) propanoic acid (R) -methyl (Compound 10, Fmoc-D-Tyr-OMe, 100 mg , 0.24 mmol) in tetrahydrofuran (THF) (240 ⁇ L) separately prepared in 10M 2,2,2-trichloroacetimidic acid 2-phenylpropan-2-yl (compound 9) in cyclohexane solution (60 ⁇ L) and catalyst An amount of boron trifluoride-ethyl ether
- reaction solution was concentrated by an evaporator, t-butyl methyl ether (TBME, 1 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 2 mL) were added, and the mixture was stirred at 25 ° C. for 5 minutes. After separating the organic layer, the aqueous layer was extracted twice with t-butyl methyl ether (TBME, 1 mL). The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and further dried with a pump.
- TBME t-butyl methyl ether
- TBME t-butyl methyl ether
- Example 1-9 2-((((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-hydroxyphenyl) propanoic acid (S) -methyl (compound 12, Fmoc-Tyr (3- Synthesis of F) -OMe) 10% (S) -2-amino-3- (3-fluoro-4-hydroxyphenyl) propanoic acid (H 2 N-Tyr (3-F) -OH, purchased from Astatech, 2.0 g, 10.0 mmol) After dissolving in aqueous sodium carbonate solution, add (2,5-dioxopyrrolidin-1-yl) (9H-fluoren-9-yl) methyl carbonate (Fmoc-OSu, 3.39 g, 10.0 mmol) 1.4- A solution of dioxane (35 mL) was added at 0 degrees.
- the reaction mixture was stirred at 25 ° C. for 40 minutes, water (35 mL) and diethyl ether (70 mL) were added, and the mixture was washed 3 times with diethyl ether.
- the pH of the aqueous layer was adjusted to 2 to 3 with 5N aqueous hydrochloric acid solution, and extracted three times with ethyl acetate (100 mL ⁇ 3).
- the organic layer was dried over magnesium sulfate, the solvent was distilled off under reduced pressure, and further dried with a pump. The residue (4.08 g) obtained without further purification was used as such for the next reaction.
- Example 1-10 (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4- (tert-butoxy) -3-fluorophenyl) propanoic acid (Compound 13, Fmoc-Tyr Synthesis of (3-F, tBu) -OH) 2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-hydroxyphenyl) propanoic acid (S) -methyl (compound 12, Fmoc-Tyr (3- F) -OMe, 300 mg, 0.689 mmol) in tetrahydrofuran (THF) (690 ⁇ L) and 2,2,2-trichloroacetimidic acid tert-butyl (308 ⁇ L, 1.72 mmol) and a catalytic amount of boron trifluoride Ethyl ether complex (BF 3 -
- the organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and further dried with a pump.
- the obtained residue was purified by flash column chromatography (purif pack (registered trademark) SIZE 60, hexane / ethyl acetate), and 2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino was obtained as a mixture.
- -3- (4- (tert-butoxy) -3-fluorophenyl) propanoic acid (S) -methyl (Fmoc-Tyr (3-F, tBu) -OMe) was obtained.
- Example 1-11 Synthesis of pyrrolidine-1,2-dicarboxylic acid 2- (2-phenylpropan-2-yl) (S) -1-((9H-fluoren-9-yl) methyl) (compound 14, Fmoc-Pro-OPis)
- 2-phenyl-2-propanol (14.2 g, 104 mmol)
- dehydrated diethyl ether 35 mL
- 1.9 M NaHMDS tetrahydrofuran solution, 0.85 mL, 1.62 mmol
- reaction solution was ice-cooled to 0 ° C., and trichloroacetonitrile (11.5 mL, 115 mmol) was added dropwise over 5 minutes.
- the mixture was stirred at 0 ° C. for 10 minutes, then removed from the ice bath and stirred at room temperature for an additional hour.
- the resulting mixture was ice-cooled to 0 ° C. and (S) -1-(((9H-fluoren-9-yl) methoxy) carbonyl) pyrrolidine-2-carboxylic acid (Fmoc-Pro-OH, 42.3 g, 125 mmol) and dichloromethane (100 mL) were added over 15 minutes.
- Example 1-12 (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) (methyl) amino) -3- (4-chlorophenyl) propanoic acid (compound 16, Fmoc-MePhe (4-Cl)- OH) (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (4-chlorophenyl) propanoic acid (Fmoc-Phe (4-Cl) -OH, 170 g, 402.96 mmol) in toluene (2.5 L) were added paraformaldehyde (48 g, 1.60 mol) and 10-camphorsulfonic acid (CSA, 4.6 g, 19.83 mmol) and stirred at 110 degrees for 16 hours.
- paraformaldehyde 48 g, 1.60 mol
- 10-camphorsulfonic acid CSA, 4.6 g,
- reaction solution was washed twice with a saturated aqueous sodium hydrogen carbonate solution (1 L) and twice with a saturated aqueous sodium chloride solution (1 L).
- the organic layer was dried over sodium sulfate, the solid was removed by filtration, the solvent was distilled off under reduced pressure, and 160 g of 4- (4-chlorobenzyl) -5-oxooxazolidine-3-carboxylic acid (S) -(9H-Fluoren-9-yl) methyl was obtained.
- Example 1-13 2-((((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-((2-phenylpropan-2-yl) oxy) phenyl) propanoic acid (S) Of 2-methyl (compound 21, Fmoc-Tyr (3-F, Pis) -OMe) 2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-hydroxyphenyl) propanoic acid (S) -methyl (compound 12, Fmoc-Tyr (3- F) -OMe, 200 mg, 0.459 mmol) in THF (460 ⁇ L) and then separately prepared 2,2,2-trichloroacetimidic acid 2-phenylpropan-2-yl (compound 9, 322 mg, 1.15 mmol) and a catalytic amount of boron trifluoride-ethyl
- Example 1-14 (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-((2-phenylpropan-2-yl) oxy) phenyl) propane Of acid (compound 22, Fmoc-Tyr (3-F, Pis) -OH) 2-(((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -3- (3-fluoro-4-((2-phenylpropan-2-yl) oxy) phenyl) propanoic acid (S) -Methyl (compound 21, Fmoc-Tyr (3-F, Pis) -OMe, 210 mg, 0.379 mmol) was dissolved in dichloroethane (DCE) (1.26 mL) and trimethyltin (IV) hydroxide (Me 3 SnOH, 137 mg, 0.379 mmol) was
- reaction mixture was concentrated with an evaporator, t-butyl methyl ether (TBME, 2.0 mL) and 0.05 M aqueous phosphoric acid solution (pH 2.1, 4.0 mL) were added, and the mixture was stirred at 25 ° C. for 15 min. After separating the organic layer, the aqueous layer was extracted twice with t-butyl methyl ether (TBME, 1 mL). The organic layer was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and further dried with a pump.
- TBME t-butyl methyl ether
- TBME t-butyl methyl ether
- Example 1-15 (S) -3-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4-oxo-4- (piperidin-1-yl) butanoic acid-2-chlorotrityl resin (compound 50, Synthesis of Fmoc-Asp (O-Trt (2-Cl) -resin) -pip) (S) -3-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4-oxo-4- (piperidin-1-yl) butanoic acid-2-chlorotrityl resin (compound 50, Fmoc-Asp (O-Trt (2-Cl) -resin) -pip) was synthesized by a method described in the literature (literature: international publication number WO 2013/100132 A1).
- the polymer or the resin site may be indicated by ⁇ .
- the chemical structure of the reaction site may be indicated by connecting to ⁇ .
- the 2-chlorotrityl group of the resin is linked to the side chain carboxylic acid of Asp via an ester bond.
- Pip means piperidine, and in the above structure, the C-terminal carboxylic acid group forms an amide bond with piperidine.
- Example 1-16-1 3-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (4- (tert-butyl) piperidin-1-yl) -4-oxobutanoic acid (S) -tert-butyl ( Synthesis of Compound 53, Fmoc-Asp (OtBu) -piptBu) (piptBu means 4- (tert-butyl) piperidine, where the C-terminal carboxylic acid group is 4- (tert-butyl) piperidine and It shows that an amide bond is formed.) (S) -2-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (tert-butoxy) -4-oxobutanoic acid (10 g, 24.30 mmol) and 4- (tert- (Butyl) piperidine hydrochloride (4.10 g, 23.09 mmol)
- Example 1-16-2 (S) -3-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -4- (4- (tert-butyl) piperidin-1-yl) -4-oxobutanoic acid (Compound 51, Fmoc-Asp-piptBu) 3-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (4- (tert-butyl) piperidin-1-yl) -4-oxobutanoic acid (S) -tert-butyl ( Toluene was added to Compound 53, Fmoc-Asp (OtBu) -piptBu, 2.0 g, 3.74 mmol), and the solvent was distilled off under reduced pressure to remove water contained by azeotropy.
- Example 1-16-3 (S) -3-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -4- (4- (tert-butyl) piperidin-1-yl) -4-oxobutanoic acid-2-chloro Synthesis of trityl resin (compound 52, Fmoc-Asp (O-Trt (2-Cl) -resin) -piptBu) Place 2-chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1% DVB, purchased from Watanabe Chemical, 4.52 g, 7.23 mmol) and dehydrated dichloromethane (72 mL) in a reaction vessel with a filter at 25 degrees.
- trityl resin compound 52, Fmoc-Asp (O-Trt (2-Cl) -resin) -piptBu
- the obtained Fmoc-Asp (O-Trt (2-Cl) -resin) -piptBu (Compound 52, 16.5 mg) was put in a reaction vessel, and a 20% piperidine / DMF solution (1 mL) was added thereto at 25 ° C. Shake for 30 minutes. Remove 30 ⁇ L from the reaction mixture, dilute with DMF (2.97 mL), measure the absorbance (301.2 nm) (measured using Shimadzu, UV-1600PC (cell length 1.0 cm)), and use Fmoc-Asp.
- Example 1-17 Synthesis of compound (compound 55) bound to resin with side chain carboxylic acid of Fmoc-Asp-MeOctyl (compound 54)
- Example 1-17-1 3-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (methyl (octyl) amino) -4-oxobutanoic acid (S) -tert-butyl (compound 56, Fmoc-Asp ( OtBu) -MeOctyl) (MeOctyl means N-methyloctane-1-amine, where the C-terminal carboxylic acid group forms an amide bond with N-methyloctane-1-amine) It is shown that.) A 300 mL flask was charged with (S) -2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (tert-butoxy) -4-oxobutanoic acid (Fmoc-Asp (OtBu)- OH, 8.00 g, 19.44 mmol) and DMF (65 mL) were added
- Example 1-17-2 (S) -3-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (methyl (octyl) amino) -4-oxobutanoic acid (compound 54, Fmoc-Asp-MeOctyl) Composition 3-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (methyl (octyl) amino) -4-oxobutanoic acid (S) -tert-butyl (compound 56, Fmoc-Asp ( OtBu) -MeOctyl, 8.1 g, 15.09 mmol) was added with toluene, and the solvent was distilled off under reduced pressure to remove water contained by azeotropy.
- Example 1-17-3 (S) -3-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -4- (methyl (octyl) amino) -4-oxobutanoic acid-2-chlorotrityl resin (Compound 55, Fmoc -Asp (O-Trt (2-Cl) -resin) -MeOctyl) Place 2-chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1% DVB, purchased from Watanabe Chemical, 16.3 g, 26.1 mmol) and dehydrated dichloromethane (261 mL) in a reaction vessel with a filter at 25 degrees.
- 2-chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1% DVB, purchased from Watanabe Chemical, 16.3 g, 26.1 mmol
- Example 1-18 Synthesis of compound (compound 58) conjugated with resin with side chain carboxylic acid of Fmoc-Asp-Pro-OPis (compound 57)
- Example 1-18-1 1-((S) -2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (allyloxy) -4-oxobutanoyl) pyrrolidine-2-carboxylic acid (S)- Synthesis of 2-phenylpropan-2-yl (compound 59, Fmoc-Asp (OAll) -Pro-OPis) Pyrrolidine-1,2-dicarboxylic acid 2- (2-phenylpropan-2-yl) (S) -1-((9H-fluoren-9-yl) methyl) (Compound 14, A solution of Fmoc-Pro-OPis, 20.0 g, 43.9 mmol) in dehydrated DMF (40 mL) was cooled to 20 degrees in a water bath.
- Example 1-18-1 (S) -3-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -4-oxo-4-((S) -2-(((2-phenylpropan-2-yl) Synthesis of Oxy) carbonyl) pyrrolidin-1-yl) butanoic acid (Compound 57, Fmoc-Asp-Pro-OPis) 1-((S) -2-((((9H-fluoren-9-yl) methoxy) carbonyl) amino) -4- (allyloxy) -4-oxobutanoyl) pyrrolidine-2-carboxylic acid (S)- 2-Phenylpropan-2-yl (compound 59, Fmoc-Asp (OAll) -Pro-OPis, 24.16 g, 39.6 mmol) and tetrakis (triphenylphosphine) palladium (0) (Pd (
- Example 1-18-3 (S) -3-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) -4-oxo-4-((S) -2-(((2-phenylpropan-2-yl) Synthesis of Oxy) carbonyl) pyrrolidin-1-yl) butanoic acid-2-chlorotrityl resin (Compound 58, Fmoc-Asp (O-Trt (2-Cl) -resin) -Pro-OPis) Place 2-chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh, 1% DVB, purchased from Watanabe Chemical, 47.8 g, 76.48 mmol) and dehydrated dichloromethane (150 mL) in a reaction vessel with a filter at 25 ° C.
- 2-chlorotrityl chloride resin (1.60 mmol / g, 100-200mesh
- Fmoc-Asp (O-Trt (2-Cl) -resin) -Pro-OPis (Compound 58, 12.3 mg) was placed in a reaction vessel, DMF (0.2 mL) and piperidine (0.2 mL) were added, and 25 Shake for 30 minutes. After adding DMF (1.6 mL) to the reaction vessel, 0.4 mL was taken out from the reaction mixture, diluted with DMF (9.6 mL), and the absorbance (301.2 nm) was measured (Shimadzu, UV-1600PC (cell Measured using a length of 1.0 cm)).
- Example 2-1 Peptide solid phase synthesis by an automatic synthesizer
- Step A Peptide synthesis was performed by the Fmoc method using a peptide synthesizer (Multipep RS; manufactured by Intavis). The detailed procedure of operation was in accordance with the manual attached to the synthesizer.
- 2-chlorotrityl resin (100 mg per column) bound to the carboxylic acid moiety of the side chain of aspartic acid protected with Fmoc at the N-terminal, and various Fmoc-amino acids (0.6 mol / L, Fmoc-MeHis (Trt) -OH for 0.5 mol / L) and 1-hydroxy-7-azabenzotriazole (HOAt) or oxyma (0.375 mol / L) in NMP solution and diisopropylcarbodiimide (DIC) in N, N-dimethylformamide (DMF) ) Solution (10% v / v) was set in the synthesizer.
- Fmoc-amino acids 0.6 mol / L, Fmoc-MeHis (Trt) -OH for 0.5 mol / L) and 1-hydroxy-7-azabenzotriazole (HOAt) or oxyma (0.375 mol / L) in NMP solution
- Fmoc-amino acid is Fmoc-Ser (THP) -OH (Compound 1), Fmoc-Thr (THP) -OH (Compound 2), or Fmoc-MeSer (THP) -OH (Compound 6),
- Fmoc-amino acids were allowed to coexist with oxyma in the NMP solution, and molecular sieves 4A 1/8 (Wako Pure Chemical Industries) or molecular sieves 4A 1/16 (Wako Pure Chemical Industries) were added to the synthesizer.
- DBU diazabicycloundecene
- Example 2-2 Cutting out extended peptide from resin (step B) After removal of the N-terminal Fmoc group of the peptide extended by the above method on a peptide synthesizer, the resin was washed with DMF. Subsequently, after the resin was re-swelled with DCM, TFE / DCM (1/1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours. Subsequently, the resin in the tube was filtered through a synthesis column to remove the resin, and the remaining resin was further washed twice with TFE / DCM (1/1, v / v, 1 mL). All obtained cutting solutions were mixed and concentrated under reduced pressure.
- Example 2-3 Cyclization of excised peptide (Step C) After cutting, the residue concentrated under reduced pressure was dissolved in DMF / DCM (1/1, v / v, 8 mL). 0.5 M O- (7-aza-1H-benzotriazol-1-yl) -N, N, N, N-tetramethyluronium hexafluorophosphate (HATU) / DMF solution (moles on resin used (loading (Volume equal to 1.5 equivalents to the amount of resin used (usually 0.10 g) multiplied by the amount (mmol / g)) and DIPEA (1 to the number of moles on the resin used). 8 equivalents) was added and shaken at room temperature for 2 hours. Thereafter, the solvent was distilled off under reduced pressure. The production of the desired cyclic peptide was confirmed by LCMS measurement.
- peptides Pep1-Pep7 used for the examination of the deprotection reaction described later were synthesized.
- the sequences of Pep1 to Pep7 are shown in Table 2-1, the structure is shown in Table 2-2, and the LCMS data is shown in Table 2-3.
- Subsequent examination of deprotection conditions is based on the residue containing cyclic peptides obtained in this process. Evaluated.
- Example 3 Weak acid (pKa in water is 0-9) and solvent (YOTs value is positive, weak acidity (pKa in water is 5-14) and low nucleophilic solvent) Deprotection of protecting group of side chain functional group of peptide using weak acid solution (step D)
- Example 3-1 Deprotectability of Fmoc-amino acid side-chain functional group protecting group by weak acid solution described above Conditions under which Fmoc-amino acid side-chain functional group protecting group is weaker than TFA, i.e. pKa in water Can be deprotected in a solution in which the Y OTs value is positive, weakly acidic (pKa in water is 5 to 14), and dissolved in a low nucleophilic solvent. I examined whether or not.
- tetramethylammonium hydrogen sulfate (pKa 2.0) is used as a weak acid, and HFIP (Y OTs value is 3.82 (document value: Prog. Phys. Org. Chem. 1990, 17, 121-158) as a solvent.
- PKa 9.30 More specifically, either a 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) or a 0.05 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) was used.
- Example 3-1-1 Preparation of 0.1 M Tetramethylammonium Hydrogensulfate / HFIP Solution (2% TIPS) 0.1 M Tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) was prepared using HFIP (11.66 mL), TIPS ( 0.24 mL) and DCE (0.10 mL) were mixed to extract 4 mL, and 68.5 mg of tetrabutylammonium hydrogen sulfate was dissolved in the solution.
- Example 3-1-2 Preparation of 0.05 M Tetramethylammonium Hydrogensulfate / HFIP Solution (2% TIPS) 0.05 M Tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) was prepared using HFIP (11.66 mL), TIPS ( 0.24 mL) and DCE (0.10 mL) were mixed to extract 4 mL, and 34.3 mg of tetrabutylammonium hydrogen sulfate was dissolved in the solution.
- the following method A or method ⁇ ⁇ ⁇ ⁇ B was used to deprotect Fmoc-amino acids with protecting groups on the side chains or peptides containing amino acid residues with protecting groups on the side chains.
- Example 3-1-3 method A 0.1% for a mixture of Fmoc-amino acid (4.0 umol) with side chain protecting group and peptide (any of the previously synthesized cyclic peptides Pep 1 to Pep 6 (residue after cyclization); maximum 3.66 umol)
- the LCMS (FA05) was measured after a certain time. The progress of deprotection was calculated from the UV area ratio between the deprotected body and the protected body.
- Example 3-1-4 method B 0.1 M tetramethyl hydrogensulfate for peptides containing amino acid residues with protecting groups in the side chains (any of the previously synthesized cyclic peptides Pep 1 to Pep 6 (residue after cyclization); maximum 3.66 umol)
- ammonium / HFIP 2% TIPS
- 0.05 M tetramethylammonium hydrogensulfate / HFIP 2% TIPS
- LCMS (FA05) was measured after time. The progress of deprotection was calculated from the UV area ratio between the deprotected body and the protected body.
- the peptides used in method A and method B were subjected to extension and excision from the resin by the method described above, and after cyclization reaction by the method already described, the residue concentrated under reduced pressure was dissolved in dichloromethane and tested. After the tube was divided into 10 equal parts, the solvent was again concentrated under reduced pressure.
- the side chain protecting group is either TFE-DCM (1/1, v / v) solution or TFE-DCM (1/1, v / v) / DIPEA (the amount of resin used for the loading amount of the resin used).
- the peptide excision conditions using the solution are not affected by the addition of 1.8 equiv. Therefore, in the intramolecular cyclization at the N-terminal of the peptide main chain and the carboxylic acid site of the Asp side chain following the excision step, the amino acid side chain functional group is kept protected. Thereby, the undesirable cyclization reaction in which the functional group of the amino acid side chain acts as a nucleophile can be suppressed.
- Example 3-2-1 H-Ala-Trp-Nle-Trp-D-Tyr (tBu) -MeGly-MeAla-MePhe (3-Cl) -MeGly-nPrGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid amide
- Example 3-2-2 H-Ala-Trp-Nle-Trp-D-Tyr (tBu) -MeGly-MeAla-MePhe (3-Cl) -MeGly-nPrGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid amide
- a deprotected compound 101 Pep1
- a 0.05 M tetramethylammonium hydrogensulfate / HFIP solution 2% TIPS
- HFIP 0.05 M tetramethylammonium hydrogensulfate / HFIP solution
- test tube was capped with a rubber septum, shaken for 3 minutes, allowed to stand at 25 ° C. for 24 hours, and the reaction was confirmed by LCMS (FA05).
- deprotection of the side chain (deprotection of tBu group of D-Tyr (tBu)) progressed 81%.
- TM + H 2 O represents a compound in which one of the amide bonds of the target product has undergone hydrolysis.
- TM + HFIP represents a compound in which one of the amide bonds of the target product has undergone solvolysis by HFIP.
- Target peptide compound 131
- LCMS (ESI) m / z 1424.1 (M + H) + Retention time: 0.79 minutes (analysis condition SQDFA05)
- Hydrolyzate LCMS (ESI) m / z 1442.0 (M + H) + Retention time: 0.61 minutes (analysis condition SQDFA05)
- Solvolytic LCMS (ESI) m / z 1592.0 (M + H) + by HFIP + Retention time: 0.69 minutes, 0.71 minutes (analysis condition SQDFA05)
- hydrolyzate (and solvolyzate) can be obtained by using 0.1 M or 0.05 M tetramethylammonium hydrogen sulfate / HFIP (2% TIPS) instead of 5% TFA for the same peptide sequence. )
- 0.1 M or 0.05 M tetramethylammonium hydrogen sulfate / HFIP 20% TIPS
- TFA 5% trifluoride
- Example 3-2-3 Hg-EtAbu-MeSer (DMT) -Hyp (Et) -Ile-MePhe (3-Cl) -Ser (Trt) -Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl Deprotected Fmoc-Asp (O-Trt (O-Trt ( ), a cyclic compound (compound 103, Pep3) formed with an acid using 0.05 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) as deprotection conditions) 2-Cl) -resin) -pip (compound 50, loading: 0.316 mmol / g, 100 mg) was used as the resin, and Hg-EtAbu-MeSer (DMT) -Hyp (Et) -Ile- A cyclic compound in which an amide bond
- test tube was capped with a rubber septum, shaken for 3 minutes, then allowed to stand at 25 ° C., and the reaction was confirmed by LCMS (SQDFA05) at a stage of 4 hours.
- side chain deprotection deprotection of the DMT group of MeSer (DMT) and deprotection of the Trt group of Ser (Trt) was confirmed.
- the deprotected target peptide (compound 133, N of Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip
- the UV area ratio in LC of the N ⁇ O-acyl shifter (depsipeptide) of the target peptide and the N ⁇ O-acyl shifter of the target peptide was 96: 4 (cyclic compound in which an amide bond was formed between the terminal amino group and the side chain carboxylic acid of Asp) .
- Example 3-2-4 H-Ala-Trp-Nle-Trp-D-Tyr (tBu) -MeGly-MeAla-MePhe (3-Cl) -MeGly-nPrGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid amide
- a 0.05 M oxalic acid / HFIP solution 2% TIPS
- HFIP 11.66 mL
- TIPS 0.24 mL
- DCE 0.10 mL
- TM + H 2 O represents a compound in which one of the amide bonds of the target product has undergone hydrolysis.
- TM + HFIP represents a compound in which one of the amide bonds of the target product has undergone solvolysis by HFIP.
- Target peptide compound 131
- LCMS (ESI) m / z 1423.5 (M + H) + Retention time: 0.79 minutes (analysis condition SQDFA05)
- Hydrolyzate LCMS (ESI) m / z 1441.5 (M + H) + Retention time: 0.61 minutes (analysis condition SQDFA05)
- Solvated lysate LCMS (ESI) m / z 1591.5 (M + H) + by HFIP Retention time: 0.68 minutes, 0.71 minutes (analysis condition SQDFA05)
- Example 3-2-5 H-Ala-Trp-Nle-Trp-D-Tyr (tBu) -MeGly-MeAla-MePhe (3-Cl) -MeGly-nPrGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid amide
- a 0.05 M maleic acid / HFIP solution 2% TIPS
- HFIP 11.66 mL
- TIPS 0.24 mL
- DCE 0.10 mL
- TM + H 2 O represents a compound in which one of the amide bonds of the target product has undergone hydrolysis.
- TM + HFIP represents a compound in which one of the amide bonds of the target product has undergone solvolysis by HFIP.
- Target peptide compound 131
- LCMS (ESI) m / z 1423.5 (M + H) + Retention time: 0.79 minutes (analysis condition SQDFA05)
- Hydrolyzate LCMS (ESI) m / z 1441.5 (M + H) + Retention time: 0.61 minutes (analysis condition SQDFA05)
- Solvolytic LCMS (ESI) m / z 1591.4 (M + H) + by HFIP + Retention time: 0.68 minutes, 0.71 minutes (analysis condition SQDFA05)
- Example 3-2-6 Hg-EtAbu-MeSer (DMT) -Hyp (Et) -Ile-MePhe (3-Cl) -Ser (Trt) -Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl
- test tube was capped with a rubber septum, shaken for 3 minutes, allowed to stand at 25 ° C. for 4 hours, and the reaction was confirmed by LCMS (SQDFA05). As a result, completion of side chain deprotection (deprotection of the DMT group of MeSer (DMT) and deprotection of the Trt group of Ser (Trt)) was confirmed.
- the deprotected target peptide (compound 133, N of Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip
- the UV area ratio at LC of the N ⁇ O-acyl shift product (depsipeptide) of the target peptide and the N ⁇ O-acyl shift product (depsipeptide) of the target peptide was 86:14. (FIG. 7).
- Example 3-2-7 Hg-EtAbu-MeSer (DMT) -Hyp (Et) -Ile-MePhe (3-Cl) -Ser (Trt) -Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl
- a deprotected compound 103 Pep3
- a 0.05 M maleic acid / HFIP solution 2% TIPS
- 4 mL was taken out from the mixed solution of 0.05 M maleic acid / HFIP solution (2% TIPS) (HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mL) for another one divided into 10 equal parts in the operation of 0.42 mL of 23.2 mg of oxalic acid dissolved therein was added
- test tube was capped with a rubber septum, shaken for 3 minutes, allowed to stand at 25 ° C. for 4 hours, and the reaction was confirmed by LCMS (SQDFA05). As a result, completion of side chain deprotection (deprotection of the DMT group of MeSer (DMT) and deprotection of the Trt group of Ser (Trt)) was confirmed.
- the deprotected target peptide (compound 133, N of Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip
- the UV area ratio at LC of the N ⁇ O-acyl shift product (depsipeptide) of the target peptide and the N ⁇ O-acyl shift product (depsipeptide) of the target peptide was 86:14. (FIG. 8).
- Example 3-2-8 H-Ala-Phe (4-CF3) -Trp-Trp-MeLeu-MeGly-MeGly-Pro-Hyp (Et) -Ser (Trt) -Asp-pip (tBu) N-terminal amino group and Asp side chain carboxyl Deprotection of a cyclic compound (compound 107, Pep7) that formed an amide bond with an acid using 0.05 M tetramethylammonium hydrogensulfate / HFIP (2% TIPS) as deprotection conditions, and 0.05 M tetramethylammonium hydrogensulfate Comparison with deprotection using / TFE (2% TIPS) as deprotection conditions Fmoc-Asp (O-Trt (2-Cl) -resin) -piptBu (Compound 52, loading: 0.356 mmol / g, 100 mg) H-Ala-Phe (4-CF3) -T
- the solvolysis product (TFE in which any amide bond of the peptide is a solvent)
- the compound which shows the mass of the product solvolyzed at ⁇ is below the detection limit by LCMS.
- the side chain deprotection deprotection of the Trt group of Ser (Trt)
- the deprotected target peptide compound 137
- the solvolyzed product were obtained.
- the UV area ratio with respect to (a compound showing a mass of any peptide solvated with TFE as a solvent) was 97: 3 (FIG. 10).
- “TM + TFE” described in this example represents a compound in which the target product (TM) is solvated by TFE (a compound in which one of arbitrary amide bonds has undergone solvolysis by TFE). .
- Example 3-2-9 Deprotection using 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) as deprotection conditions, and termination of the reaction by adding base (DIPEA) to the solution Fmoc-Asp (O-Trt (2-Cl ) -resin) -pip (compound 50, loading: 0.342 mmol / g, 100 mg) as the resin, and H-Ala-Trp-Nle-Trp-Ser (Trt) -Gly-MeAla- A cyclic compound (compound 105, Pep5) in which an amide bond was formed between the N-terminal amino group of MePhe (3-Cl) -MeGly-Pro-Asp-pip and the side chain carboxylic acid of Asp was synthesized.
- DIPEA base
- Fmoc-Asp O-Trt (2-Cl ) -resin
- Diisopropylethylamine (DIPEA, 14 ⁇ L, 2 equivalents relative to tetramethylammonium hydrogen sulfate) was added to the reaction mixture, and one test tube was allowed to stand at 25 ° C. for 18 hours. The other test tube was Concentration was performed under reduced pressure. When these LCMS (SQDFA05) were measured, no peak indicating a mass of a solvolyzed product or a hydrolysed product other than the deprotected target peptide was detected even at this time (FIG. 11).
- Example 3-2-10 Deprotection using 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) as deprotection conditions, and termination of the reaction by adding base (DIPEA) to the solution Fmoc-Asp (O-Trt (2-Cl ) -resin) -pip (compound 50, loading: 0.316 mmol / g, 100 mg) as the resin and Hg-EtAbu-MeSer (DMT) -Hyp (Et) -Ile-MePhe (3 -Cl) -Ser (Trt) -Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid formed a cyclic compound (Compound 103, Pep3) .
- DIPEA base
- Fmoc-Asp O-Trt (2-Cl ) -resin
- the UV area ratio of the target peptide and its N ⁇ O-acyl shift product did not change for those left standing for 18 hours, and the target peptide for those concentrated under reduced pressure.
- the UV area ratio of the N ⁇ O-acyl shifter was 98: 2 (FIG. 12).
- Example 4 When THP is used as a protecting group for the side chain hydroxyl group, Thr and MeSer are reactive. When THP is used as a protecting group for the side chain hydroxyl group of Thr and MeSer. The following experiment was conducted on the reactivity of.
- Example 4-1 A peptide that is elongated on the resin and has an N-methylamino group at the N-terminus (H-MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp (O -2-Cl-Trt-resin) -pip Comparative evaluation of extension reactivity of Fmoc-Thr (Trt) -OH and Fmoc-Thr (THP) -OH (compound 2) was carried out with a sequence having MePhe (3-Cl) having low amino group reactivity at the N-terminus.
- Fmoc-MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp (O-Trt (2-Cl) -resin) -pip (compound 108) is a method already described Fmoc-Asp (O-Trt (2-Cl) -resin) -pip (compound 50, loading: 0.329 mmol / g, 100 mg) prepared in (1) was used as the resin and synthesized by the method described above.
- Fmoc-MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp (O-Trt (2-Cl) -resin) -pip (compound 108) was added to dichloromethane. (600 uL) was added and allowed to stand for 30 minutes to swell the resin. After removing the liquid phase, the resin was subsequently washed three times with DMF (600 uL). To the obtained resin, 2% DBU / DMF (v / v, 600 uL) was added and shaken for 20 minutes to remove the liquid phase. The resin was washed 3 times with DMF (600 uL).
- the ratio of unreacted material / elongated material in the table indicates the UV area ratio of LC.
- the unreacted substance in the table means H-MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp-pip (compound 109), and the extension is H- Thr (Trt) -MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp-pip (Compound 110: When Fmoc-Thr (Trt) -OH is added) or H-Thr (THP) -MePhe (3-Cl) -D-Tyr (tBu) -Trp-MePhe-Trp-MePhe-Ile-Asp-pip (Compound 111: Fmoc-
- Example 4-2 Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr (PG) -MePhe-MeAla-MeLeu-MePhe-Asp (O-Trt (2-Cl) -resin) -pip Fmoc-Thr (Trt) -OH or Fmoc-Thr (THP) -OH (compound 2) has a steric hindrance to the N-terminal sequence of MePhe, which has low reactivity due to elongation-reactive steric hindrance, and Thr amino group The elongation reactivity was examined by extending Thr to a sequence having a bulky MeLeu at the N-terminus.
- Fmoc-Thr (Trt) -OH or Fmoc-Thr (THP) -OH (compound 2) was used for Thr elongation.
- the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DMF and DCM.
- TFE / DCM (1/1, v / v, 2 mL) was added to the resin and shaken at room temperature for 2 hours to excise the peptide from the resin.
- the LCMS result of this product is shown in FIG.
- the target peptide (Compound 112, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr-MePhe-MeAla-MeLeu-MePhe-Asp-pip) and the target peptide without Thr (Compound 113, Hb-MeAla -Ile-MeLeu-MeAla-MeLeu- MePhe-MeAla-MeLeu-MePhe-Asp-pip) was seen at the same retention time of 0.69 minutes. Further, from MS (negative mode), about 30% of peptides from which Thr was lost were contained.
- Target-Thr Compound 113, Hb-MeAla-Ile-MeLeu-MeAla-MeLeu- MePhe-MeAla-MeLeu-MePhe-Asp-pip
- Example 4-2 H-MeSer (PG) -MeVal-MeHis (Trt) -Tyr (3-F, tBu) -Pro-MeHis (Trt) -Pro-Trp-MePhe (4-Cl) -Asp (O-Trt (2-Cl ) -resin) -Pro-OPis synthesized with a synthesizer using Fmoc-MeSer (DMT) -OH or Fmoc-MeSer (THP) -OH (compound 6) Checking H-MeSer (PG) -MeVal- MeHis (Trt) -Tyr (3-F, tBu) -Pro-MeHis (Trt) -Pro-Trp-MePhe (4-Cl) -Asp (O-Trt (2 -Cl) -resin) -Pro-OPis (PG on the MeSer side chain
- FIG. 15 shows the results of LCMS in the case of synthesis using Fmoc-MeSer (DMT) -OH ⁇ 0.75 DIPEA.
- DMT Fmoc-MeSer
- FIG. 16 shows the LCMS results when synthesis was performed using Fmoc-MeSer (THP) -OH (Compound 6).
- THP Fmoc-MeSer
- the solvent was distilled off under reduced pressure, and the residue was subjected to LCMS (FA05) measurement.
- the target product, H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe (3-Cl)- MeGly-nPrGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid formed a compound (compound 131) and its hydrolyzate (one of which amide bond was hydrolyzed) MS was confirmed and the corresponding UV area ratio was 13:87 (FIG. 17).
- the measurement result of LC is shown in FIG. Note that “TM + H 2 O” described in the examples represents a compound in which one of the amide bonds of the target product has undergone hydrolysis.
- the percentage was calculated by the UV UV area ratio. Thereafter, the solvent was distilled off under reduced pressure, and the residue was dissolved in dichloromethane and divided into 10 equal portions in a test tube. These were concentrated under reduced pressure to remove dichloromethane.
- the “residue after cyclization” used in the above-mentioned examples refers to a residue obtained by dividing into 10 equal parts and then concentrating under reduced pressure. Add 5% TFA / DCE (5% TIPS) (0.8 mL, water content 32.5 ppm, measured by Karl Fischer) to one of the test tubes, shake for 3 minutes, and then 2 at 25 degrees. Let stand for hours.
- the solvent was distilled off under reduced pressure, and the residue was subjected to LCMS (FA05) measurement.
- the target product, Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp -Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxylic acid formed an amide bond (compound 133), target N ⁇ O-acyl shifter, target hydroxyl It was confirmed that the UV area ratio was 17: 46: 32: 5 when the group was TFA esterified and when the two hydroxyl groups of the target product were TFA esterified.
- the measurement result of LC is shown in FIG.
- the target peptide (compound 133, Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl Compound that formed amide bond with acid)
- N ⁇ O-acyl shift product of the target compound (compound in which N ⁇ O-acyl shift has progressed at one or both of the two hydroxyl groups of the target product)
- Compound in which one hydroxyl group of the target compound is TFA esterified LCMS (ESI
- N ⁇ O-acyl shift proceeds in deprotection using 5% TFA / DCE (5% TIPS). It was confirmed that in addition, it was confirmed that in the deprotection under these conditions, either one or both of the two side chain hydroxyl groups were TFA esterified. It was confirmed that these undesirable reactions make it difficult to obtain the target product.
- the target peptide (compound 133, Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl Compound that formed amide bond with acid)
- N ⁇ O-acyl shift product of the target compound (compound in which N ⁇ O-acyl shift has progressed at one or both of the two hydroxyl groups of the target product)
- LCMS (ESI) m / z 1473.7 (M + H) + Retention time: 0.65 minutes (analysis condition SQDFA05)
- Compound in which one hydroxyl group of the target compound is TFA esterified LCMS (ESI)
- the target peptide (compound 133, Hg-EtAbu-MeSer-Hyp (Et) -Ile-MePhe (3-Cl) -Ser-Trp-Trp-Pro-MeGly-Asp-pip N-terminal amino group and Asp side chain carboxyl Compound that formed amide bond with acid)
- N ⁇ O-acyl shift product of the target compound (compound in which N ⁇ O-acyl shift has progressed at one or both of the two hydroxyl groups of the target product)
- Compound in which one hydroxyl group of the target compound is TFA esterified LCMS (ESI
- Example 6-1 Synthesis of peptides amide cyclized with N-terminal amino group and side chain carboxylic acid group of aspartic acid C-terminal amidation (piperidine, 4- (tert-butyl) piperidine, N-methyloctane-1-amine A group of peptides in which the side chain carboxylic acid group of aspartic acid to which proline is bonded to the C-terminal and the N-terminal main chain amino group are cyclized by an amide bond. Synthesized.
- Compound 50 (2-chlorotrityl resin carrying compound 48 (Fmoc-Asp-pip)) or compound 52 (2-chlorotrityl resin carrying compound 51 (Fmoc-Asp-piptBu)) or compound 55 (compound 100 mg of either 54 (2-chlorotrityl resin carrying Fmoc-Asp-MeOctyl) or compound 58 (compound 57 (2-chlorotrityl resin carrying Fmoc-Asp-Pro-OPis)) was used.
- Fmoc-MeSer (DMT) -OH (compound 5) is used in PS-53, PS-54 (Table 5-1), and Fmoc-MeSer (THP) -OH (compound 6) was used.
- the peptide was already extended according to the peptide synthesis method by the Fmoc method described in the Examples. After extending the peptide, the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DMF.
- the resin was mixed with TFE / DCM (1/1, v / v, 2 mL) and diisopropylethylamine (DIPEA, moles on the resin used (loading amount (mmol / g ) was added to the amount of resin used (usually 0.10 g)) and shaken at room temperature for 2 hours to excise the peptide from the resin. .
- the resin in the tube was filtered through a synthesis column to remove the resin, and the remaining resin was further washed twice with TFE / DCM (1/1, v / v, 1 mL). All obtained cutting solutions were mixed and concentrated under reduced pressure.
- Deprotection was performed on the obtained residue as follows.
- Tyr (3-F, tBu) was included in the sequence, 2 mL of 0.1 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) prepared by the method described above was added to dissolve the residue. Then, it was left still at room temperature or 30 degrees for 24 hours. If the sequence does not contain Tyr (3-F), add 4 mL of 0.05 M tetramethylammonium hydrogensulfate / HFIP solution (2% TIPS) prepared by the method described above, and dissolve the residue. And left at room temperature for 4 hours. After standing for a certain time, diisopropylethylamine (DIPEA, 70 ⁇ L) was added, and the solvent was distilled off under reduced pressure.
- DIPEA diisopropylethylamine
- PS-1 to PS-54 The sequence of PS-1 to PS-54 is shown in Table 5-1, the structure is shown in Table 5-2, and the mass spectrum value, retention time, purity and yield of the obtained liquid chromatography are shown in Table 5- 3 respectively.
- Example 7 Application to the liquid phase method of the present invention A synthesis including an extension reaction in the liquid phase method is shown below.
- Example 7-1 Synthesis of H-Trp-Nle-Trp-Ser (THP) -nPrGly-MePhe (3-Cl) -MeHis (Trt) -MeGly-Pro-Asp-Pro-OPis (Compound 151) Using Fmoc-Asp (O-Trt (2-Cl) -resin) -Pro-OPis (compound 58, loading amount 0.3736 mmol / g, 200 mg) synthesized by the method already described, it has already been described in the examples. The peptide was elongated according to the peptide synthesis method by Fmoc method.
- the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was washed with DMF. After re-swelling the resin with DCM, add TFE / DCM (1/1, v / v, 4 mL) and diisopropylethylamine (24 ⁇ L) to the resin and shake at room temperature for 2 hours to obtain the peptide. Was cut out from the resin. Subsequently, the resin in the tube was filtered through a synthesis column to remove the resin, and the remaining resin was further washed twice with TFE / DCM (1/1, v / v, 2 mL).
- Example 7-2 Synthesis of 2-(((((9H-fluoren-9-yl) methoxy) carbonyl) amino) propanoic acid (S) -2,5-dioxopyrrolidin-1-yl (Compound 152, Fmoc-Ala-OSu) (S) -2-((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) propanoic acid (Fmoc-Ala-OH, 1.00 g, 3.21 mmol) and 1-hydroxypyrrolidine-2,5-dione (HOSu, 0.554 g, 4.82 mmol) and dichloromethane (6.4 mL) were mixed under a nitrogen atmosphere.
- Example 7-3 2-((((((9H-Fluoren-9-yl) methoxy) carbonyl) amino) propanoic acid (S) -2,5-dioxopyrrolidin-1-yl (compound 152, Fmoc-Ala-OSu) and H- Coupling with Trp-Nle-Trp-Ser (THP) -nPrGly-MePhe (3-Cl) -MeHis (Trt) -MeGly-Pro-Asp-Pro-OPis (compound 151), followed by de-Fmoc reaction The resulting H-Trp-Nle-Trp-Ser (THP) -nPrGly-MePhe (3-Cl) -MeHis (Trt) -MeGly-Pro-Asp-Pro-OPis (Compound 151, 113.8 mg) in dichloromethane (245 ⁇ L) was added to the solution of
- reaction solution was purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution), and the obtained fraction was lyophilized.
- Example 7-4 H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe (3-Cl) -MeHis-MeGly-Pro-Asp-Pro-OH N-terminal amino group and Asp side chain carboxylic acid group amide cyclization Of compound (compound 154) (cyclization reaction of compound 153 followed by deprotection reaction) The resulting H-Ala-Trp-Nle-Trp-Ser (THP) -nPrGly-MePhe (3-Cl) -MeHis (Trt) -MeGly-Pro-Asp-Pro-OPis (compound 153, 79.3 mg, 0.041 mmol ) was dissolved in DMF (20 mL) and dichloromethane (20 mL), HATU (17.2 mg, 0.045 mmol) and diisopropylethylamine (10.8 ⁇ L, 0.062 mmol) were added
- a 0.05 M tetramethylammonium hydrogensulfate / HFIP (2% TIPS) solution prepared by the method already described in this example, 8 mL was added to 25 ° C. Left for 1 hour.
- Diisopropylethylamine (140 ⁇ L) was added to the resulting reaction solution, and the solvent was distilled off under reduced pressure.
- the synthesis method of the present invention can also be applied to the liquid phase method.
- a peptide containing an N-substituted amino acid that can be expected to be useful as a pharmaceutical can be synthesized with high purity and high synthesis efficiency.
- the present invention is useful in the field of industrial production of peptides containing N-substituted amino acids that can be used as raw materials for pharmaceuticals.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(1)酸添加時(固相からの切り離し反応時および側鎖脱保護反応時)の加水分解、特にN-置換されたアミノ基に由来する加水分解を抑制するために必要な反応条件を見出すこと、
(2)酸添加時の実用的な後処理が可能となる反応条件を見出すこと、
(3)非天然型ペプチド化合物の特異な溶解性を考慮した溶媒を含む反応条件を見出すこと、
(4)非天然型ペプチド化合物が、ヒドロキシル基などの官能基を含む場合に、脱保護後の副反応(N→Oアシルシフトやヒドロキシル基と反応試薬との副反応(例えばTFAを試薬とした場合のTFAアシル化反応)を抑制すること、
を課題とする。
加えて、アミノ酸側鎖の各官能基に対して、上記4つの条件を満足する保護基を見出すことを課題とする。
さらに、N-置換されたアミノ酸を含むペプチド化合物の工業的な生産をも考慮し、特定の配列に対する最適化にも適用可能な製造方法を見出すことも課題とする。
〔1〕 以下の工程:
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)工程1)で準備されたFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを固相に担持する工程、
3)固相に担持されたFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
4)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程、及び、
5)工程4)で得られたペプチドを、TFAよりも弱酸となる条件下で固相から切り出す工程、
を含む、少なくとも1つのN-置換アミノ酸又はN-置換アミノ酸類縁体を含むペプチドの製造方法。
〔2〕 前記工程4)で得られたペプチドを構成するアミノ酸またはアミノ酸類縁体の少なくとも1つの側鎖が、塩基性条件下では脱保護されず、かつ第1の酸で脱保護される保護基で保護されており、前記工程5)の前又は後で、該第1の酸にて該保護基を脱保護する工程をさらに含み、かつ
前記工程5)において、第2の酸を用いてペプチドを切り出す、〔1〕に記載の製造方法であって、
第1の酸および第2の酸がいずれもTFAよりも弱酸であり、かつ第1の酸の酸度が第2の酸の酸度よりも高い、製造方法。
〔3〕 以下の工程:
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)Fmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
3)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程であって、この工程で得られるペプチドを構成するアミノ酸またはアミノ酸類縁体の少なくとも1つの側鎖が、塩基性条件下では脱保護されずTFAよりも弱酸となる条件下で脱保護される保護基を有する工程、及び、
4)前記側鎖の保護基を、TFAよりも弱酸となる条件下で脱保護する工程、
を含む、少なくとも1つのN-置換アミノ酸又はN-置換アミノ酸類縁体を含むペプチドの製造方法。
〔4〕 ペプチドの製造が固相法によって行われる、〔3〕に記載の製造方法。
〔5〕 前記工程3)で得られたペプチドを、前記工程4)の前又は後で前記工程4)で用いられる弱酸条件よりも更に弱酸となる条件下で固相から切り出す工程をさらに含む、〔4〕に記載の製造方法。
〔6〕 ペプチドの製造が液相法によって行われる、〔3〕に記載の製造方法。
〔7〕 〔1〕の工程4)又は〔3〕の工程3)が、
新たに添加したFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護してアミノ基を露出する工程、および
更に新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程をさらに含み、
これらの工程を1回または複数回繰り返す、〔1〕から〔6〕のいずれかに記載の製造方法。
〔8〕 製造されたペプチドが、1つの反応点を有するアミノ酸残基又はアミノ酸類縁体残基をC末端側に含み、かつもう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体をN末端側に含む、〔1〕から〔7〕のいずれかに記載の製造方法。
〔9〕 前記1つの反応点と前記もう一つの反応点とを結合させ、前記ペプチドを環化させる工程をさらに含む、〔8〕に記載の製造方法。
〔10〕 前記もう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体がN末端にあり、かつ前記結合がアミド結合である、〔9〕に記載の製造方法。
〔11〕 前記もう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体がN末端にあり、かつ前記結合が炭素-炭素結合である、〔9〕に記載の製造方法。
〔12〕 TFAよりも弱酸となる条件下で行われる工程が、水中でのpKaの値が0~9である弱酸を、イオン化能YOTs値が正の値で水中でのpKaが5~14である溶媒に含む、弱酸溶液を用いて行われる、〔1〕から〔11〕のいずれかに記載の製造方法。
〔13〕 溶媒がフルオロアルコールである、〔12〕に記載の製造方法。
〔14〕 フルオロアルコールがTFE又はHFIPである、〔13〕に記載の製造方法。
〔15〕 側鎖の保護基が、pH1からpH7の範囲で脱保護される保護基であるか、又は10%以下のTFAにおいて脱保護される保護基である、〔2〕から〔14〕のいずれかに記載の製造方法。
〔16〕 側鎖の保護基が以下のa)~d)から選択される、〔2〕から〔15〕のいずれかに記載の製造方法:
a)側鎖の保護基がSer、Thr、Hyp、及び、それらの誘導体の側鎖のヒドロキシル基の保護基である場合、以下の一般式で表わされるMOM骨格基、Bn骨格、Dpm骨格、Trt骨格、シリル骨格及びBoc骨格から選ばれるいずれかの保護基;
b)側鎖の保護基がTyr及びその誘導体の側鎖のヒドロキシル基の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格、Dpm骨格、Trt骨格、シリル骨格、Boc骨格及びtBu骨格から選ばれるいずれかの保護基;
c)前記側鎖の保護基がHis及びその誘導体の側鎖のイミダゾール環の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格及びTrt骨格から選ばれるいずれかの保護基;
d)前記側鎖の保護基がAsp、Glu、及び、それらの誘導体の側鎖のカルボン酸基の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格、Dpm骨格、Trt骨格、tBu骨格、フェニル-EDOTn骨格及び保護をするカルボン酸基の炭素原子を3つのアルコキシ基が置換した骨格に変換したオルトエステル骨格から選ばれるいずれかの保護基;
<MOM骨格を有する保護基>
R1はHであり、R2はHであり、かつXはメチル、ベンジル、4-メトキシベンジル、2,4-ジメトキシベンジル、3,4-ジメトキシベンジル、または2-トリメチルシリルエチルであるか、
R1はメチルであり、R2はHであり、かつXはエチルであるか、
R1、R2、R3は、いずれもメチルであるか、または
R1とXは、一緒になって-CH2-CH2-CH2-または-CH2-CH2-CH2-CH2-を形成し、かつR2はHであり
ここで、R1、R2、およびXのいずれかがメチルまたはエチルである場合、これらの基はさらにアルキル、ベンジル、またはアリールで置換されていてもよい。)
<Bn骨格を有する保護基>
R1~R5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR6およびR7はアルキルであるか、
R1、R2、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、R3はメトキシであり、かつR6およびR7はHであるか、
R1およびR3がメトキシであり、R2、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR6およびR7はHであるか、または
R1、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR2とR3は一緒になって-O-CH2-O-を形成する。)
<Dpm骨格を有する保護基>
R1~R10は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、または
R1~R4およびR7~R10は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR5およびR6は一緒になって-O-または-CH2-CH2-を形成する。)
<Trt骨格を有する保護基>
R1~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、
R1、R2、およびR4~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR3は、メチルまたはメトキシであるか、
R1はClであり、かつR2~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、または
R1~R4、およびR7~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR5とR6は一緒になって-O-を形成する。)
<シリル骨格を有する保護基>
R1~R3は、それぞれ独立してアルキル、またはアリールである。)
<Boc骨格を有する保護基>
R1~R9は、それぞれ独立してH、アルキル、またはアリールである。)
<tBu骨格を有する保護基>
R1~R9は、それぞれ独立してH、アルキル、またはアリールである。)
<フェニル-EDOTn骨格を有する保護基>
R1~R3は、それぞれ独立して、H、またはメトキシである)。
(1)本発明によって見出した、TFAに比べて弱酸である酸とイオン化能を示す溶媒との組み合わせによって、ペプチド鎖の酸加水分解や、β-ヒドロキシ-α-アミノ酸(例えば、Ser、Thr、及び、それらの誘導体)が含まれている配列において起こり得るN→O-アシルシフトやTFAエステル化などを最小限に抑制して脱保護でき、かつ
(2)当該アミノ酸をアミド結合形成反応にて伸長する際に、一般的なペプチド合成に用いられている保護基を有している場合に比べて、反応速度および反応効率を改善できる。
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)工程1)で準備したFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを固相に担持する工程、
3)固相に担持したFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
4)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程、及び、
5)工程4)で得られたペプチドを、TFAよりも弱酸となる条件下で固相から切り出す工程。
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)Fmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
3)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程であって、この工程で得られるペプチドを構成するアミノ酸またはアミノ酸類縁体の少なくとも1つの側鎖が、塩基性条件下では脱保護されずTFAよりも弱酸となる条件下で脱保護される保護基を有する工程、及び、
4)前記側鎖の保護基を、TFAよりも弱酸となる条件下で脱保護する工程。
上記ペプチドの製造は、固相法によって行われていても、液相法によって行われていてもよい。
本発明におけるペプチドは、直鎖ペプチドでも環状ペプチドでも良く、環状ペプチドであることが好ましい。
このようなN-置換アミノ酸として具体的には、アルキル基、アラルキル基、シクロアルキル基などが好ましく用いられる。
(-C=O-OR)
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基。
非特許文献i)Greene’s Protective Groups in Organic Synthesis, Fourth Edition,
非特許文献ii)Chemical Reviews, 2009, 109(6), 2455-2504.
また、R5とR6の間で架橋したもの、例えば酸素原子を介して架橋されたXan基や、炭素原子2つを介して架橋されたジベンゾスベリル基などを用いてもよい。
また、R5とR6の間で架橋したもの、例えば酸素原子を介して架橋されたピキシル(Pixyl)基を用いることもできる。
また、R5とR6の間で架橋したもの、例えば酸素原子を介して架橋されたXan基や、炭素原子2つを介して架橋されたジベンゾスベリル基などを用いてもよい。
また、R5とR6の間で架橋したもの、例えば酸素原子を介して架橋されたピキシル(Pixyl)基を用いることもできる。
また、R5とR6の間で架橋したもの、例えば炭素原子2つを介して架橋されたジベンゾスベリル基などを用いてもよい。
また、R5とR6の間で架橋したもの、例えば酸素原子を介して架橋されたピキシル(Pixyl)基を用いることもできる。
樹脂を構成するポリマーの種類についても特に限定されない。ポリスチレンで構成される樹脂の場合には、100-200meshもしくは200-400meshのいずれを用いても良い。また、架橋率についても特に限定されないが、1%DVB(ジビニルベンゼン)架橋のものが好ましい。
更に新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程をさらに含む。これらの工程は1回または複数回繰り返してもよい。本発明の方法は、Fmoc骨格を有する保護基の脱保護と、次の新しいFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドとの縮合反応を繰り返すことによって目的のペプチド配列を得ることが可能である。
合成されたペプチドの側鎖の保護基を脱保護した後に切り出し工程を行う場合、切り出しに用いられる弱酸は、TFAより弱酸であれば特に限定されない。
なお、本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
DCM ジクロロメタン
DCE 1,2-ジクロロエタン
DMF N,N-ジメチルホルムアミド
DIC N,N’-ジイソプロピルカルボジイミド
DIPEA N,N-ジイソプロピルエチルアミン
DBU 1,8-ジアザビシクロ[5.4.0]-7-ウンデセ
ン
NMP N-メチル-2-ピロリドン
FA ギ酸
TFA トリフルオロ酢酸
TFE 2,2,2-トリフルオロエタノール
HFIP 1,1,1,3,3,3-ヘキサフルオロイソプロピル
アルコール
HOAt 1-ヒドロキシ-7-アザベンゾトリアゾール
HOBt 1-ヒドロキシベンゾトリアゾール
WSCI・HCl 1-エチル-3-(3-ジメチルアミノプロピル)
カルボジイミド塩酸塩
TBME t-ブチルメチルエーテル
TIPS トリイソプロピルシラン
HATU O-(7-アザ-1H-ベンゾトリアゾール-1-イル
)-N,N,N’,N’-テトラメチルウロニウムヘキ
サフルオロリン酸塩
N-メチルアミノ酸を配列中に含む環状ペプチドの合成は、Fmoc法による固相合成を採用し、以下の5段階の工程による図1に記載の合成ルートで行った。
A)ペプチド合成機を用いFmoc法によって、その側鎖のカルボン酸を2-クロロトリチルレジンに担持させたAspのN末端からペプチドを伸長する工程
B)2-クロロトリチルレジンからペプチドを切り出す工程
C)切り出したペプチドのAspの側鎖のカルボン酸(白丸ユニット)と、ペプチド鎖N末端(三角ユニット)のアミノ基とを縮合し、アミド結合によって環化する工程
D)ペプチド鎖に含まれる側鎖官能基の保護基を脱保護する工程
E)分取HPLCによって化合物を精製する工程。
本実施例に記載するペプチド合成において、ペプチド合成機による合成(前記工程A)には、以下のFmoc-アミノ酸を用いた。
これらは渡辺化学、Chempep社、またはChem-Impex社などから購入した。
これらは、文献記載の方法にて合成した(文献:国際公開番号 WO 2013/100132 A1)。
これらは以下のとおり合成した。なお、これらの合成したFmoc-アミノ酸は、ペプチド合成だけでなく、側鎖官能基の保護基もしくはC末端カルボン酸基の保護基の脱保護検討にも用いた。
(2S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)プロパン酸(化合物1、Fmoc-Ser(THP)-OH)の合成
得られた残渣をテトラヒドロフラン(THF、12.2 mL)に溶解させ、次いでpH 8.0に調製した1.0 M リン酸緩衝液(12.2 mL)を加えた。この混合物を50度で3時間攪拌した。25度まで冷却した後、酢酸エチル(12.2 mL)を加え、有機層と水層を分離した。水層に酢酸エチル(12.2 mL)を加えて抽出を行った後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(12.2 mL)で2度洗浄した。有機層を硫酸ナトリウムで乾燥させ、溶媒を減圧下留去し、さらにポンプにて減圧下、25度で30分乾燥させた。
得られた残渣をジクロロメタン(7 mL)に溶解させ、次いでヘプタン(16.6 mL)を加えた。制御した減圧下(~100 hPa)、ジクロロメタンのみを留去し、得られた混合物をろ過して固体を得た。このヘプタンでの洗浄操作を2度繰り返した。得られた固体をポンプにて減圧下、25度で2時間乾燥させ、1.40 gの残渣を得た。
得られた残渣にt-ブチルメチルエーテル(TBME、25 mL)とpH 2.1の0.05 M リン酸水溶液(70 mL)を加えて、25度にて5分間攪拌した後、有機層と水層を分離した。水層にt-ブチルメチルエーテル(TBME、25 mL)を加えて抽出した後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(25 mL)にて2度洗浄した。有機層を硫酸ナトリウムにて乾燥させ、減圧下溶媒を留去した。残渣をポンプにて減圧下、25度で2時間乾燥させることで、(2S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)プロパン酸(化合物1、Fmoc-Ser(THP)-OH、1.22 g, 30 mol%のt-ブチルメチルエーテル(TBME)が残留)を得た。得られたFmoc-Ser(THP)-OHは-25度の冷凍庫にて保存した。
LCMS(ESI)m/z=410.2(M-H)-
保持時間:0.81分(分析条件SQDFA05)
(2S,3R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)ブタン酸(化合物2、Fmoc-Thr(THP)-OH)の合成
得られた粗生成物のうち、4.65 gをテトラヒドロフラン(THF、30 mL)に溶解させ、次いでpH 8.0に調製した1.0 M リン酸緩衝液(30 mL)を加えた。この混合物を50度で4時間攪拌した。25度まで冷却した後、酢酸エチル(30 mL)を加え、有機層と水層を分離した。水層に酢酸エチル(30 mL)を加えて抽出を行った後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(30 mL)で2度洗浄した。有機層を硫酸ナトリウムで乾燥させ、溶媒を減圧下留去し、さらにポンプにて減圧下、25度で30分乾燥させた。
得られた残渣をジエチルエーテル(50 mL)に溶解させ、次いでヘプタン(50 mL)を加えた。制御した減圧下(~100 hPa)、ジエチルエーテルのみを留去し、得られた混合物をろ過して固体を得た。このヘプタンでの洗浄操作を2度繰り返した。得られた固体をポンプにて減圧下、25度で2時間乾燥させ、Fmoc-Thr(THP)-OHのナトリウム塩(2.80 g, 6.26 mmol)を得た。
得られた全量のFmoc-Thr(THP)-OHのナトリウム塩に酢酸エチル(50 mL)とpH 2.1の0.05 M リン酸水溶液(140 mL)を加えて、25度にて5分間攪拌した後、有機層と水層を分離した。水層に酢酸エチル(50 mL)を加えて抽出した後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(50 mL)にて2度洗浄した。有機層を硫酸ナトリウムにて乾燥させ、減圧下溶媒を留去した。残渣をポンプにて減圧下、25度で2時間乾燥させた後、得られた固体をt-ブチルメチルエーテル(TBME、50 mL)に溶解させ、溶媒を減圧下留去した。さらにポンプにて減圧下、25度で1時間乾燥させることで、(2S,3R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)ブタン酸(化合物2、Fmoc-Thr(THP)-OH、2.70 g, 30mol%のt-ブチルメチルエーテル(TBME)が残留)をTHP保護上の不斉炭素に由来するジアステレオマーとして得た。得られたFmoc-Thr(THP)-OHは-25度の冷凍庫にて保存した。
LCMS(ESI)m/z=424.2(M-H)-
保持時間:0.84分、0.85分(分析条件SQDFA05)
(2S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)プロパン酸(化合物6、Fmoc-MeSer(THP)-OH)の合成
得られた残渣のうち、15.0 gをテトラヒドロフラン(175 mL)に溶解させ、次いでpH 8.0に調製した1.0 M リン酸緩衝液(175 mL)を加えた。この混合物を50度で3時間攪拌した。25度まで冷却した後、酢酸エチル(175 mL)を加え、有機層と水層を分離した。水層に酢酸エチル(175 mL)を加えて抽出を行った後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(175 mL)で2度洗浄した。有機層を硫酸ナトリウムで乾燥させ、溶媒を減圧下留去した。
得られた残渣をジクロロメタン(100 mL)に溶解させ、次いでヘプタン(250 mL)を加えた。制御した減圧下(~100 hPa)、ジクロロメタンのみを留去し、得られた混合物をろ過して固体を得た。このヘプタンでの洗浄操作を2度繰り返した。得られた固体をポンプにて減圧下、25度で2時間乾燥させた。
得られた残渣にt-ブチルメチルエーテル(TBME、250 mL)とpH 2.1の0.05 M リン酸水溶液(700 mL)を加えて、25度にて5分間攪拌した後、有機層と水層を分離した。水層にt-ブチルメチルエーテル(TBME、250 mL)を加えて抽出した後、得られた全ての有機層を混合し、飽和塩化ナトリウム水溶液(250 mL)にて2度洗浄した。有機層を硫酸ナトリウムにて乾燥させ、減圧下溶媒を留去した。残渣をポンプにて減圧下、25度で2時間乾燥させることで、(2S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-((テトラヒドロ-2H-ピラン-2-イル)オキシ)プロパン酸(化合物6、Fmoc-MeSer(THP)-OH、9.0 g、30mol%のt-ブチルメチルエーテル(TBME)が残留)を得た。得られたFmoc-MeSer(THP)-OHは-25度の冷凍庫にて保存した。
LCMS(ESI)m/z=426.4(M+H)+
保持時間:0.86分(分析条件SQDFA05)
(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-(1-トリチル-1H-イミダゾール-4-イル)プロパン酸(化合物7、Fmoc-MeHis(Trt)-OH)の合成
得られた固体に1,4-ジオキサン(1000 mL)、炭酸カリウム(84 g、603.39 mmol)、水(1000 mL)を加えた。さらに炭酸 (2,5-ジオキソピロリジン-1-イル) (9H-フルオレン-9-イル)メチル(Fmoc-OSu、102 g、302.38 mmol)を加えて、0度にて2時間攪拌した。得られた反応溶液をジエチルエーテル(2000 mL)にて洗浄した後、酢酸を用いて溶液のpHを6~7に調整した。得られた固体をろ過することで、(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-(1-トリチル-1H-イミダゾール-4-イル)プロパン酸(化合物7、Fmoc-MeHis(Trt)-OH、155 g)を得た。
LCMS(ESI)m/z=634.4(M+H)+
保持時間:1.07分(分析条件SQDAA05)
(2R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-((テトラヒドロ-2H-ピラン-2-イル)オキシ)フェニル)プロパン酸(化合物8、Fmoc-D-Tyr(THP)-OH)の合成
得られた残渣 (300 mg)をテトラヒドロフラン (THF) (2.5 mL)に溶解させ、1.0 Mのリン酸水溶液 (pH 8.0, 2.5 mL)を加えて50度で3時間攪拌した。反応液に酢酸エチル(3 mL)を加え、有機層と水層を分離し、水層を酢酸エチル (3 mL)で抽出した。得られた全ての有機層を混合し、飽和食塩水 (3 mL)で2回洗浄した。有機層を硫酸ナトリウムで乾燥させた後、溶媒を減圧下留去し、さらにポンプで減圧下30分乾燥させた。
得られた残渣をジクロロメタン (DCM) (2 mL)に溶解させ、ヘプタン (5 mL)を加えた。ジクロロメタン (DCM)のみをエバポレーターにより除去し、得られた白色固体をろ過により集めた。得られた白色固体に対して、同様の操作を2回繰り返した。そのようにして得られた白色固体をポンプで減圧下2時間乾燥させた。
上記の白色固体にt-ブチルメチルエーテル (TBME) (4.6 mL)と0.05 Mリン酸水溶液 (pH 2.1, 13 mL)を加え、25度で5分攪拌した。有機層を分離した後、水層をt-ブチルメチルエーテル (TBME) (4.6 mL)で抽出した。得られた有機層を集め、飽和食塩水 (4.6 mL)で2回洗浄した。有機層を硫酸ナトリウムにて乾燥させ、減圧下溶媒を留去した。得られた残渣を逆相クロマトグラフィー(Wakosil 25C18 10 g, 水/アセトニトリル)により精製することで(2R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-((テトラヒドロ-2H-ピラン-2-イル)オキシ)フェニル)プロパン酸(化合物8、Fmoc-D-Tyr(THP)-OH, 173 mg)をTHP保護上の不斉炭素に由来するジアステレオマーとして57%の収率で得た。
LCMS(ESI)m/z=488.4(M+H)+
保持時間:0.92分(分析条件SQDFA05)
2,2,2-トリクロロアセトイミド酸 2-フェニルプロパン-2-イル(化合物9)の合成
1H NMR (Varian 400-MR, 400 MHz, CDCl3) δ 1.89 (6H, s), 7.28 (1H, m), 7.36 (2H, m), 7.43 (2H, m), 8.20 (1H, brs)
2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-ヒドロキシフェニル)プロパン酸 (R)-メチル(化合物10、Fmoc-D-Tyr-OMe)の合成
LCMS(ESI)m/z=418.3(M+H)+
保持時間:0.81分(分析条件SQDFA05)
(R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-((2-フェニルプロパン-2-イル)オキシ)フェニル)プロパン酸 (化合物11, Fmoc-D-Tyr(Pis)-OH)の合成
上述の得られた混合物をジクロロエタン(DCE) (535 μL)に溶解させ、水酸化トリメチルスズ(IV) (Me3SnOH, 58.1 mg, 0.321 mmol)を加え、60度で7時間攪拌した。反応液に水酸化トリメチルスズ(IV) (Me3SnOH, 29.1 mg, 0.161 mmol)をさらに加え、60度で15時間攪拌した。反応液をエバポレーターにより濃縮し、t-ブチルメチルエーテル (TBME、1 mL)と0.05 Mリン酸水溶液 (pH 2.1, 2 mL)を加え、25度で5分攪拌した。有機層を分離した後、水層をt-ブチルメチルエーテル (TBME、1 mL)で2回抽出した。有機層を硫酸ナトリウムで乾燥させ、溶媒を減圧下留去し、さらにポンプで乾燥させた。得られた残渣をカラムクロマトグラフィー(purif pack(登録商標) SIZE 20, ジクロロメタン/メタノール)で精製し、(R)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-((2-フェニルプロパン-2-イル)オキシ)フェニル)プロパン酸 (化合物11, Fmoc-D-Tyr(Pis)-OH, 33 mg)を2段階収率39%で得た。
LCMS(ESI)m/z=522.4(M+H)+
保持時間:1.00分(分析条件SQDFA05)
2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(3-フルオロ-4-ヒドロキシフェニル)プロパン酸 (S)-メチル(化合物12、Fmoc-Tyr(3-F)-OMe)の合成
上記の残渣(1.04 g)をメタノール(10 mL)に溶かし、チオニルクロライド(SOCl2, 539 μL, 7.38 mmol)を滴下しながら0度で加えた。反応液を60度で1時間攪拌した後、室温に冷却し、エバポレーターを用いて溶媒を留去した。得られた残渣に酢酸エチル、水を加え、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄し、硫酸マグネシウムで乾燥させ、溶媒を減圧下留去し、さらにポンプで乾燥させた。得られた残渣をフラッシュカラムクロマトグラフィー(purif pack(登録商標) SIZE 200, ヘキサン/酢酸エチル)で精製し、2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(3-フルオロ-4-ヒドロキシフェニル)プロパン酸 (S)-メチル (化合物12、Fmoc-Tyr(3-F)-OMe, 900mg, 2.07 mmol)を2段階収率84%で得た。
LCMS(ESI)m/z=436.4(M+H)+
保持時間:0.82分(分析条件SQDFA05)
(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-(tert-ブトキシ)-3-フルオロフェニル)プロパン酸(化合物13、Fmoc-Tyr(3-F,tBu)-OH)の合成
上述の得られた混合物(40 mg)をジクロロエタン(DCE) (810 μL)に溶解させ、水酸化トリメチルスズ(IV) (Me3SnOH, 29.4 mg, 0.163 mmol)を加え、60度で1時間攪拌した。反応液にギ酸 (15.35 μL, 0.407 mmol)を加えた後、逆相クロマトグラフィー(Wakosil 25C18 10 g, 0.1% ギ酸水溶液/0.1% ギ酸アセトニトリル溶液)により精製することで(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(4-(tert-ブトキシ)-3-フルオロフェニル)プロパン酸(化合物13、Fmoc-Tyr(3-F,tBu)-OH, 27mg, 56.5μmol)を2段階収率93%で得た。
LCMS(ESI)m/z=478.3(M+H)+
保持時間:0.94分(分析条件SQDFA05)
ピロリジン-1,2-ジカルボン酸 2-(2-フェニルプロパン-2-イル) (S)-1-((9H-フルオレン-9-イル)メチル) (化合物14、Fmoc-Pro-OPis)の合成
続いて、反応液を0度に氷冷し、トリクロロアセトニトリル(11.5 mL, 115 mmol)を5分以上かけて滴下した。混合物を0度にて10分間、その後氷浴から外して室温にてさらに1時間攪拌した。得られた混合物を0度に氷冷し、(S)-1-(((9H-フルオレン-9-イル)メトキシ)カルボニル)ピロリジン-2-カルボン酸(Fmoc-Pro-OH、42.3 g, 125 mmol)とジクロロメタン(100 mL)との混合物を15分かけて加えた。0度にて30分攪拌した後、ろ過し、ヘキサン-ジクロロメタン(5/1)溶液にて洗浄し、続いて減圧下、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン-酢酸エチル)にて精製し、ピロリジン-1,2-ジカルボン酸 2-(2-フェニルプロパン-2-イル) (S)-1-((9H-フルオレン-9-イル)メチル) (化合物14、Fmoc-Pro-OPis、26.3 g, 57.7 mmol)を得た。
LCMS(ESI)m/z=456.4(M+H)+
保持時間:0.76分(分析条件SQDAA50)
(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-(4-クロロフェニル)プロパン酸(化合物16、Fmoc-MePhe(4-Cl)-OH)の合成
同様の操作にて調製した別ロットと混合した4-(4-クロロベンジル)-5-オキソオキサゾリジン-3-カルボン酸 (S)-(9H-フルオレン-9-イル)メチル(230 g、530.10 mmol)のジクロロメタン(2.5 L)溶液にトリエチルシラン(881 g、7.58 mol)とトリフルオロ酢酸(TFA、2518 g、22.28 mol)を混合し、30度にて12時間攪拌した。続いて減圧下、溶媒を留去し、得られた残渣をジクロロメタン/ヘキサン(1/10, v/v)にて再結晶することにより、(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)(メチル)アミノ)-3-(4-クロロフェニル)プロパン酸(化合物16、Fmoc-MePhe(4-Cl)-OH、205 g)を得た。
LCMS(ESI)m/z=436.3(M+H)+
保持時間:0.99分(分析条件SQDAA05)
2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(3-フルオロ-4-((2-フェニルプロパン-2-イル)オキシ)フェニル)プロパン酸 (S)-メチル(化合物21、Fmoc-Tyr(3-F,Pis)-OMe)の合成
LCMS(ESI)m/z=554.4(M+H)+
保持時間:1.09分(分析条件SQDFA05)
(S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-3-(3-フルオロ-4-((2-フェニルプロパン-2-イル)オキシ)フェニル)プロパン酸(化合物22、Fmoc-Tyr(3-F,Pis)-OH)の合成
LCMS(ESI)m/z=538.2(M-H)-
保持時間:1.00分(分析条件SQDFA05)
ペプチド合成機によるペプチド合成に用いるレジンとFmoc-アミノ酸との結合体は、以下のとおり合成した。
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-オキソ-4-(ピペリジン-1-イル)ブタン酸-2-クロロトリチルレジン(化合物50、Fmoc-Asp(O-Trt(2-Cl)-resin)-pip)の合成
Fmoc-Asp-piptBu(化合物51)の側鎖カルボン酸にてレジンと結合させた化合物(化合物52)の合成
3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(4-(tert-ブチル)ピペリジン-1-イル)-4-オキソブタン酸 (S)-tert-ブチル(化合物53、Fmoc-Asp(OtBu)-piptBu)の合成(なお、piptBuとは4-(tert-ブチル)ピペリジンを意味し、ここではC末端のカルボン酸基が4-(tert-ブチル)ピペリジンとアミド結合を形成していることを示している。)
LCMS(ESI)m/z=535.4(M+H)+
保持時間:1.17分(分析条件SQDAA05)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(4-(tert-ブチル)ピペリジン-1-イル)-4-オキソブタン酸(化合物51、Fmoc-Asp-piptBu)の合成
LCMS(ESI)m/z=479.4(M+H)+
保持時間:1.00分(分析条件SQDAA05)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(4-(tert-ブチル)ピペリジン-1-イル)-4-オキソブタン酸-2-クロロトリチルレジン(化合物52、Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu)の合成
得られたFmoc-Asp(O-Trt(2-Cl)-resin)-piptBu(化合物52、16.5 mg)を反応容器に入れ、20%ピペリジン/DMF溶液 (1 mL)を加え、25度にて30分間振とうした。反応混合液から30 μLを取りだし、これをDMF (2.97 mL)で希釈し、その吸光度(301.2 nm)を測定し(Shimadzu, UV-1600PC(セル長1.0 cm)を用いて測定)、Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu(化合物52)のローディング量を0.356 mmol/gと算出した。
なお、同様に合成したローディング量が異なる別ロットについてもペプチド合成に使用した。
Fmoc-Asp-MeOctyl(化合物54)の側鎖カルボン酸にてレジンと結合させた化合物(化合物55)の合成
3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(メチル(オクチル)アミノ)-4-オキソブタン酸 (S)-tert-ブチル(化合物56、Fmoc-Asp(OtBu)-MeOctyl)の合成(なお、MeOctylとはN-メチルオクタン-1-アミンを意味し、ここではC末端のカルボン酸基がN-メチルオクタン-1-アミンとアミド結合を形成していることを示している。)
LCMS(ESI)m/z=537.5(M+H)+
保持時間:0.84分(分析条件SQDFA50)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(メチル(オクチル)アミノ)-4-オキソブタン酸(化合物54、Fmoc-Asp-MeOctyl)の合成
LCMS(ESI)m/z=481.4(M+H)+
保持時間:0.65分(分析条件SQDAA50)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(メチル(オクチル)アミノ)-4-オキソブタン酸-2-クロロトリチルレジン(化合物55、Fmoc-Asp(O-Trt(2-Cl)-resin)-MeOctyl)の合成
ローディング量:0.366 mmol/g
なお、同様に合成したローディング量が異なる別ロットについてもペプチド合成に使用した。
Fmoc-Asp-Pro-OPis(化合物57)の側鎖カルボン酸にてレジンと結合させた化合物(化合物58)の合成
1-((S)-2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-(アリルオキシ)-4-オキソブタノイル)ピロリジン-2-カルボン酸 (S)-2-フェニルプロパン-2-イル(化合物59、Fmoc-Asp(OAll)-Pro-OPis)の合成
LCMS(ESI)m/z=611.4(M+H)+
保持時間:1.03分(分析条件SQDFA05)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-オキソ-4-((S)-2-(((2-フェニルプロパン-2-イル)オキシ)カルボニル)ピロリジン-1-イル)ブタン酸(化合物57、Fmoc-Asp-Pro-OPis)の合成
LCMS(ESI)m/z=571.3(M+H)+
保持時間:0.88分(分析条件SQDFA05)
(S)-3-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)-4-オキソ-4-((S)-2-(((2-フェニルプロパン-2-イル)オキシ)カルボニル)ピロリジン-1-イル)ブタン酸-2-クロロトリチルレジン(化合物58、Fmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis)の合成
得られたFmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis(化合物58、12.3 mg)を反応容器に入れ、DMF (0.2 mL)およびピペリジン (0.2 mL)を加え、25度にて30分間振とうした。反応容器にDMF (1.6mL)を加えた後、反応混合液から0.4 mLを取りだし、これをDMF (9.6 mL)で希釈し、その吸光度(301.2 nm)を測定した(Shimadzu, UV-1600PC(セル長1.0 cm)を用いて測定)。次の計算式により、Fmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis(化合物58)のローディング量を0.3736 mmol/gと算出した。
(吸光度(301.2 nm) ×1000×50)/(レジン重量(mg)×7800) = (0.717×1000×50)/(12.3×7800) = 0.3736 mmol/g
なお、同様に合成したローディング量が異なる別ロットについてもペプチド合成に使用した。
特別な記載がない限り、上記の基本合成ルートでのペプチド合成は以下の方法にて行った。
ペプチド合成機(Multipep RS; Intavis社製)を用いて、Fmoc法によりペプチド合成を行った。操作の詳細な手順については合成機に付属のマニュアルに従った。
上記の方法によって伸長したペプチドのN末端のFmoc基の除去をペプチド合成機上にて行った後、レジンをDMFにて洗浄した。続いてDCMにてレジンを再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 2 mL)を加えて室温にて2時間振とうした。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 1 mL)にて2回洗浄した。得られた全ての切り出し溶液を混合し、減圧下濃縮した。
切り出し後に減圧下濃縮した残渣をDMF/DCM (1/1, v/v, 8 mL)に溶解した。0.5 M O-(7-アザ-1H-ベンゾトリアゾール-1-イル)-N,N,N,N-テトラメチルウロニウム ヘキサフルオロホスフェート(HATU)/DMF溶液(用いたレジン上のモル数(ローディング量(mmol/g)に使用したレジン量(通常は0.10 g)をかけたもの)に対して1.5等量となる容量)と、DIPEA(用いたレジン上のモル数に対して1.8等量)を加え、室温にて2時間振とうした。その後、減圧下溶媒を留去した。目的の環状ペプチドの生成をLCMS測定によって確認した。
ペプチド合成に用いるFmoc-アミノ酸の側鎖官能基の保護基が、TFAよりも弱酸となる条件、すなわち水中でのpKaが0~9である弱酸を、YOTs値が正の値であり、弱酸性であり(水中でのpKaが5~14)、かつ求核性が低い溶媒に溶解した溶液中で脱保護可能かどうかを検討した。
0.1 M 硫酸水素テトラメチルアンモニウム/HFIP溶液(2% TIPS)は、HFIP (11.66 mL), TIPS (0.24 mL), DCE (0.10 mL)を混合した溶液から4 mLを抜き取り、これに68.5 mgの硫酸水素テトラブチルアンモニウムを溶解させて調製した。
0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)は、HFIP (11.66 mL), TIPS (0.24 mL), DCE (0.10 mL)を混合した溶液から4 mLを抜き取り、これに34.3 mgの硫酸水素テトラブチルアンモニウムを溶解させて調製した。
側鎖に保護基の付いたFmoc-アミノ酸(4.0 umol)とペプチド(既に合成した環状ペプチドPep 1~Pep 6のいずれか(環化後の残渣);最大で3.66 umol)の混合物に対し、0.1 M硫酸水素テトラメチルアンモニウム/HFIP溶液 (2% TIPS) (0.20 mL)もしくは0.05 M硫酸水素テトラメチルアンモニウム/HFIP溶液 (2% TIPS) (0.40 mL)を加えて3分間振とうし、その後25度にて静置し、一定時間後にLCMS(FA05)を測定した。脱保護の進行は、脱保護体と被保護体のUVエリア比より算出した。
側鎖に保護基の付いたアミノ酸残基を含むペプチド(既に合成した環状ペプチドPep 1~Pep 6のいずれか(環化後の残渣);最大で3.66 umol)に対し、0.1 M硫酸水素テトラメチルアンモニウム/HFIP (2% TIPS) (0.20 mL)もしくは0.05 M硫酸水素テトラメチルアンモニウム/HFIP (2% TIPS) (0.40 mL)を加えて3分間振とうし、その後25度にて静置し、一定時間後にLCMS(FA05)を測定した。脱保護の進行は、脱保護体と被保護体のUVエリア比より算出した。
Fmoc-Tyr(3-F)-OH (run3、run4、run15の脱保護生成物)
LCMS(ESI)m/z=422.3(M+H)+
保持時間:0.73分(分析条件SQDFA05)
Fmoc-MeHis-OH (run5の脱保護生成物)
LCMS(ESI)m/z=392.3(M+H)+
保持時間:0.47分(分析条件SQDFA05)
Fmoc-MeSer-OH (run8の脱保護生成物)
LCMS(ESI)m/z=342.3(M+H)+
保持時間:0.67分(分析条件SQDFA05)
Fmoc-Ser-OH (run10の脱保護生成物)
LCMS(ESI)m/z=328.2(M+H)+
保持時間:0.64分(分析条件SQDFA05)
Fmoc-Pro-OH (run11の脱保護生成物)
LCMS(ESI)m/z=338.3(M+H)+
保持時間:0.75分(分析条件SQDFA05)
Fmoc-D-Tyr-OH (run12~14の脱保護生成物)
LCMS(ESI)m/z=404.3(M+H)+
保持時間:0.72分(分析条件SQDFA05)
H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物101、Pep1)の、0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (化合物50、レジン担持量:0.342 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にてH-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物101)を合成した。環化後、減圧下濃縮を行った残渣をジクロロメタンに溶解して試験管に10等分した後、溶媒を再び減圧下濃縮を行った。
この10等分した1つの試験管に対し、0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに68.5 mgの硫酸水素テトラメチルアンモニウムを溶解させたもの)を0.20 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて24時間静置し、LCMS(FA05)にて反応の確認を行ったところ、側鎖の脱保護(D-Tyr(tBu)のtBu基の脱保護)の完結が確認できた。またこのとき、目的の脱保護されたペプチド(化合物131)と、加溶媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマススペクトルを示す化合物)と、加水分解体(ペプチドのいずれかのアミド結合が水分にて加溶媒分解されたもののマススペクトルを示す化合物)の比は72:10:18であった(図2)。なお、本実施例に記載の「TM+H2O」とは、目的物のいずれかのアミド結合の1つが加水分解を受けた化合物を表し、「TM+HFIP」とは、目的物のいずれかのアミド結合の1つがHFIPによって加溶媒分解を受けた化合物を表す。
目的のペプチド(化合物131)
LCMS(ESI)m/z=1424.0(M+H)+
保持時間:0.79分(分析条件SQDFA05)
加水分解体(TM+H2O)
LCMS(ESI)m/z=1442.0(M+H)+
保持時間:0.61分(分析条件SQDFA05)
HFIPによる加溶媒分解体(TM+ HFIP)
LCMS(ESI)m/z=1592.0(M+H)+
保持時間:0.69分、0.71分(分析条件SQDFA05)
H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物101、Pep1)の、0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
化合物101(Pep1)を合成した後、上記の操作において10等分した別の1つに対し、0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに34.3 mgの硫酸水素テトラメチルアンモニウムを溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて24時間静置し、LCMS(FA05)にて反応の確認を行った。その結果、側鎖の脱保護(D-Tyr(tBu)のtBu基の脱保護)は81%進行し、このとき、目的の脱保護されたペプチド(化合物131)と、加溶媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマスを示す化合物)と、加水分解体(ペプチドのいずれかのアミド結合が水分にて加水分解されたもののマスを示す化合物)の比は93:3:4であった(図3)。なお、「TM+H2O」とは、目的物のいずれかのアミド結合の1つが加水分解を受けた化合物を表す。同様に、「TM+HFIP」とは、目的物のいずれかのアミド結合の1つがHFIPによって加溶媒分解を受けた化合物を表す。
目的のペプチド(化合物131)
LCMS(ESI)m/z=1424.1(M+H)+
保持時間:0.79分(分析条件SQDFA05)
加水分解体
LCMS(ESI)m/z=1442.0(M+H)+
保持時間:0.61分(分析条件SQDFA05)
HFIPによる加溶媒分解体
LCMS(ESI)m/z=1592.0(M+H)+
保持時間:0.69分、0.71分(分析条件SQDFA05)
これに対して、同じペプチド配列に対して、5% TFAの替わりに0.1 Mまたは0.05 Mの硫酸水素テトラメチルアンモニウム/HFIP (2% TIPS)を用いることで、加水分解体(および加溶媒分解体)の生成を大幅に低減することができた。またこの結果は、TFAよりも弱酸となる条件を満たせば、弱酸の濃度を任意に調節できる可能性を示唆する。
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物103、Pep3)の、0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (化合物50、ローディング:0.316 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にてH-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物103、Pep3)を合成した。環化後、減圧下濃縮を行った残渣をジクロロメタンに溶解して試験管に10等分した後、溶媒を再び減圧下濃縮を行った。
この10等分した1つの試験管に対し、0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに34.3 mgの硫酸水素テトラメチルアンモニウムを溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて静置し、4時間の段階でLCMS(SQDFA05)にて反応の確認を行った。その結果、側鎖の脱保護(MeSer(DMT)のDMT基の脱保護、およびSer(Trt)のTrt基の脱保護)の完結が確認できた。またこのとき、脱保護された目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)と、目的のペプチドのN→O-アシルシフト体(デプシペプチド)のLCでのUVエリア比は、96:4であった。反応開始から22時間、25度で静置した段階でLCMS(SQDFA05)の測定を行った結果は、脱保護された目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)と、目的のペプチドのN→O-アシルシフト体(デプシペプチド)のLCでのUVエリア比は、83:17であった(図4)。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)
LCMS(ESI)m/z=1474.1(M+H)+
保持時間:0.78分(分析条件SQDFA05)
N→O-アシルシフト体
LCMS(ESI)m/z=1474.1(M+H)+
保持時間:0.64分(分析条件SQDFA05)
これに対し、同じペプチド配列に対して、5% TFAの替わりに0.05 Mの硫酸水素テトラメチルアンモニウム/HFIP (2% TIPS)を用いることで、N→O-アシルシフト体の生成を大幅に低減することができた。
H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物101、Pep1)の、0.05 M シュウ酸/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
化合物101(Pep1)を合成した後、上記の操作において10等分した別の1つに対し、0.05 M シュウ酸/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに18.0 mgのシュウ酸を溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(FA05)にて反応の確認を行った。その結果、側鎖の脱保護(D-Tyr(tBu)のtBu基の脱保護)は完結し、このとき、目的の脱保護されたペプチド(化合物131)と、加溶媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマスを示す化合物)と、加水分解体(ペプチドのいずれかのアミド結合が水分にて加水分解されたもののマスを示す化合物)の比は79:17:4であった(図5)。なお、「TM+H2O」とは、目的物のいずれかのアミド結合の1つが加水分解を受けた化合物を表す。同様に、「TM+HFIP」とは、目的物のいずれかのアミド結合の1つがHFIPによって加溶媒分解を受けた化合物を表す。
目的のペプチド(化合物131)
LCMS(ESI)m/z=1423.5(M+H)+
保持時間:0.79分(分析条件SQDFA05)
加水分解体
LCMS(ESI)m/z=1441.5(M+H)+
保持時間:0.61分(分析条件SQDFA05)
HFIPによる加溶媒分解体
LCMS(ESI)m/z=1591.5(M+H)+
保持時間:0.68分、0.71分(分析条件SQDFA05)
H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物101、Pep1)の、0.05 M マレイン酸/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
化合物101(Pep1)を合成した後、上記の操作において10等分した別の1つに対し、0.05 M マレイン酸/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに23.2 mgのシュウ酸を溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(FA05)にて反応の確認を行った。その結果、側鎖の脱保護(D-Tyr(tBu)のtBu基の脱保護)は完結し、このとき、目的の脱保護されたペプチド(化合物131)と、加溶媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマスを示す化合物)と、加水分解体(ペプチドのいずれかのアミド結合が水分にて加水分解されたもののマスを示す化合物)の比は81:12:7であった(図6)。なお、「TM+H2O」とは、目的物のいずれかのアミド結合の1つが加水分解を受けた化合物を表す。同様に、「TM+HFIP」とは、目的物のいずれかのアミド結合の1つがHFIPによって加溶媒分解を受けた化合物を表す。
目的のペプチド(化合物131)
LCMS(ESI)m/z=1423.5(M+H)+
保持時間:0.79分(分析条件SQDFA05)
加水分解体
LCMS(ESI)m/z=1441.5(M+H)+
保持時間:0.61分(分析条件SQDFA05)
HFIPによる加溶媒分解体
LCMS(ESI)m/z=1591.4(M+H)+
保持時間:0.68分、0.71分(分析条件SQDFA05)
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物103、Pep3)の、0.05 M シュウ酸/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
化合物103(Pep3)を合成した後、上記の操作において10等分した別の1つに対し、0.05 M シュウ酸/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに18.0 mgのシュウ酸を溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(SQDFA05)にて反応の確認を行った。その結果、側鎖の脱保護(MeSer(DMT)のDMT基の脱保護、およびSer(Trt)のTrt基の脱保護)の完結が確認できた。またこのとき、脱保護された目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)と、目的のペプチドのN→O-アシルシフト体(デプシペプチド)のLCでのUVエリア比は、86:14であった(図7)。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)
LCMS(ESI)m/z=1473.5(M+H)+
保持時間:0.78分(分析条件SQDFA05)
N→O-アシルシフト体
LCMS(ESI)m/z=1473.5(M+H)+
保持時間:0.64分(分析条件SQDFA05)
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物103、Pep3)の、0.05 M マレイン酸/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護
化合物103(Pep3)を合成した後、上記の操作において10等分した別の1つに対し、0.05 M マレイン酸/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに23.2 mgのシュウ酸を溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(SQDFA05)にて反応の確認を行った。その結果、側鎖の脱保護(MeSer(DMT)のDMT基の脱保護、およびSer(Trt)のTrt基の脱保護)の完結が確認できた。またこのとき、脱保護された目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)と、目的のペプチドのN→O-アシルシフト体(デプシペプチド)のLCでのUVエリア比は、86:14であった(図8)。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物)
LCMS(ESI)m/z=1473.5(M+H)+
保持時間:0.79分(分析条件SQDFA05)
N→O-アシルシフト体
LCMS(ESI)m/z=1473.5(M+H)+
保持時間:0.64分(分析条件SQDFA05)
H-Ala-Phe(4-CF3)-Trp-Trp-MeLeu-MeGly-MeGly-Pro-Hyp(Et)-Ser(Trt)-Asp-pip(tBu)のN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物107、Pep7)の、0.05 M 硫酸水素テトラメチルアンモニウム/HFIP (2% TIPS)を脱保護条件として用いた脱保護と、0.05 M 硫酸水素テトラメチルアンモニウム/TFE (2% TIPS)を脱保護条件として用いた脱保護との比較
Fmoc-Asp(O-Trt(2-Cl)-resin)-piptBu (化合物52、ローディング:0.356 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にてH-Ala-Phe(4-CF3)-Trp-Trp-MeLeu-MeGly-MeGly-Pro-Hyp(Et)-Ser(Trt)-Asp-pip(tBu)のN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物107)を合成した。環化後、減圧下濃縮を行った残渣をジクロロメタンに溶解して試験管に10等分した後、溶媒を再び減圧下留去した。
この10等分した1つの試験管に対し、0.05 M 硫酸水素テトラメチルアンモニウム/HFIP溶液 (2% TIPS) (HFIP: 23.32 mL, TIPS: 0.48 mL, DCE: 0.20 mLを混合した溶液に205.8 mgの硫酸水素テトラメチルアンモニウムを溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、25度にて4時間静置し、LCMS(FA05)にて反応の確認を行った。その結果、側鎖の脱保護(Ser(Trt)のTrt基の脱保護)は完結し、このとき、脱保護された目的のペプチド(化合物137)と、加溶媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマスを示す化合物)とのUVエリア比は53:47であった(図9)。なお、「TM+HFIP」とは、目的物のいずれかのアミド結合の1つがHFIPによって加溶媒分解を受けた化合物を表す。
目的のペプチド(化合物137)
LCMS(ESI)m/z=1492.1(M+H)+
保持時間:0.90分(分析条件SQDFA05)
HFIPによる加溶媒分解体(いずれかのアミド結合がHFIPによって加溶媒分解を受けたもの)
LCMS(ESI)m/z=1660.1(M+H)+
保持時間:0.78分(分析条件SQDFA05)
目的のペプチド(化合物137)
LCMS(ESI)m/z=1492.2(M+H)+
保持時間:0.90分(分析条件SQDFA05)
TFEによる加溶媒分解体(いずれかのアミド結合がTFEによって加溶媒分解を受けたもの)
LCMS(ESI)m/z=1592.0(M+H)+
保持時間:0.75分(分析条件SQDFA05)
0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護、およびその溶液に塩基(DIPEA)を加えての反応停止
Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (化合物50、ローディング:0.342 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にてH-Ala-Trp-Nle-Trp-Ser(Trt)-Gly-MeAla-MePhe(3-Cl)-MeGly-Pro-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物105、Pep5)を合成した。環化後、減圧下濃縮を行った残渣をジクロロメタンに溶解して試験管に10等分した後、溶媒を再び減圧下濃縮を行った。
この10等分した2つの試験管に対し、それぞれ0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに68.5 mgの硫酸水素テトラブチルアンモニウムを溶解させたもの)を0.40 mL加えた。ラバーセプタムにて栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(SQDFA05)にて反応の確認を行った。その結果、側鎖の脱保護(Ser(Trt)のTrt基の脱保護)は完結し、このとき、目的の脱保護されたペプチド(化合物135)以外の加媒分解体(ペプチドのいずれかのアミド結合が溶媒であるHFIPにて加溶媒分解されたもののマスを示す化合物)や、加水分解体(ペプチドのいずれかのアミド結合が水分にて加溶媒分解されたもののマスを示す化合物)のマスを示すピークは検出されなかった(図11)。この反応混合物にそれぞれジイソプロピルエチルアミン(DIPEA、14 μL, 硫酸水素テトラメチルアンモニウムに対して2等量)を加えて1つの試験管は25度にて18時間静置をし、もう1つの試験管は減圧下濃縮を行った。これらのLCMS(SQDFA05)を測定したところ、脱保護された目的のペプチド以外の加溶媒分解体や加水分解体のマスを示すピークは、この時点でも検出されなかった(図11)。
目的のペプチド(化合物135)
LCMS(ESI)m/z=1331.9(M+H)+
保持時間:0.74分(分析条件SQDFA05)
0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を脱保護条件として用いた脱保護、およびその溶液に塩基(DIPEA)を加えての反応停止
Fmoc-Asp(O-Trt(2-Cl)-resin)-pip (化合物50、ローディング:0.316 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にてH-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAspの側鎖カルボン酸とでアミド結合を形成した環状化合物(化合物103、Pep3)を合成した。環化後、減圧下濃縮を行った残渣をジクロロメタンに溶解して試験管に10等分した後、溶媒を再び減圧下濃縮を行った。
この10等分した2つの試験管に対し、それぞれに0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)(HFIP: 11.66 mL, TIPS: 0.24 mL, DCE: 0.10 mLを混合した溶液から4 mLを抜き取り、これに68.5 mgの硫酸水素テトラメチルアンモニウムを溶解させたもの)を0.40 mL加えた。ラバーセプタムにて試験管に栓をし、3分間振とうしたのちに25度にて4時間静置し、LCMS(FA05)にて反応の確認を行った。その結果、側鎖の脱保護(MeSer(DMT)のDMT基の脱保護、およびSer(Trt)のTrt基の脱保護)は完結し、脱保護された目的のペプチド(化合物133)と、目的のペプチドのN→O-アシルシフト体(デプシペプチド)のLCでのUVエリア比は、93:7であった。
この反応混合物にそれぞれジイソプロピルエチルアミン(DIPEA、14 μL, 硫酸水素テトラメチルアンモニウムに対して2等量)を加えて1つの試験管は25度にて18時間静置をし、もう1つの試験管はDIPEAを加えた直後に減圧下濃縮を行った。これらのLCMS(FA05)を測定したところ、18時間静置したものに関しては目的ペプチドとそのN→O-アシルシフト体のUVエリア比は変化せず、減圧下濃縮を行ったものに関しては、目的ペプチドとそのN→O-アシルシフト体のUVエリア比は98:2となった(図12)。
目的のペプチド(化合物133)
LCMS(ESI)m/z=1474.1(M+H)+
保持時間:0.78分(分析条件SQDFA05)
N→O-アシルシフト体
LCMS(ESI)m/z=1474.1(M+H)+
保持時間:0.64分(分析条件SQDFA05)
伸長反応時の低反応性が懸念されるThrとMeSerの側鎖ヒドロキシル基の保護基としてTHP基を用いた場合の反応性について以下の実験を行った。
レジン上にて伸長したペプチドで、N末端にN-メチルアミノ基がある化合物(H-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-2-Cl-Trt-resin)-pipに対するFmoc-Thr(Trt)-OHとFmoc-Thr(THP)-OH(化合物2)の伸長反応性の比較評価
伸長反応性の比較評価は、立体障害によってアミノ基の反応性が低いMePhe(3-Cl)をN末端に有する配列にて行った。
Fmoc-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-Trt(2-Cl)-resin)-pip(化合物108)は既に記載の方法で調製したFmoc-Asp(O-Trt(2-Cl)-resin)-pip (化合物50、ローディング:0.329 mmol/g, 100 mg)をレジンとして用い、既に記載の方法にて合成した。
得られたFmoc-MePhe(3-Cl)-D-Tyr(tBu)-Trp-MePhe-Trp-MePhe-Ile-Asp(O-Trt(2-Cl)-resin)-pip(化合物108)にジクロロメタン(600uL)を加え、30分静置してレジンを膨潤させた。液相を除いた後、続いてレジンをDMF(600uL)にて3度洗浄した。得られたレジンに2% DBU/DMF (v/v, 600uL)を加えて20分間振とうさせ、液相を取り除いた。レジンをDMF(600uL)で3度洗浄した。
このレジンに対し、0.60 M Fmoc-Thr(Trt)-OH/0.375 M oxymaのNMP溶液(300 uL)と10%(v/v) DIC/DMF (300uL)とを混合した溶液、もしくは0.60 M Fmoc-Thr(THP)-OH(化合物2)/0.375 M oxymaのNMP溶液(300 uL)と10%(v/v) DIC/DMF (300uL)とを混合した溶液を加えて振とうした。振とう中、1時間、2時間、4時間の段階で反応中のレジンをそれぞれ~10mgずつ取り出し、取りだしたレジンをDMF(600uL)にて3度洗浄し、さらに2% DBU/DMF (v/v, 600uL)を加えて20分間振とうさせ、液相を取り除いた。レジンをDMF(600uL)で3度、さらにジクロロメタン(600uL)で3度洗浄した。
得られたレジンにTFE/DCM (1/1, v/v, 1 mL)を加えて10分間振とうし、レジンをろ過で取り除いた後に、液相を減圧下濃縮した。残渣をLCMS(分析条件SQDFA05)にて分析した。結果を表4に示す。
H-b-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr(PG)-MePhe-MeAla-MeLeu-MePhe-Asp(O-Trt(2-Cl)-resin)-pipを合成機にて合成した際の、Fmoc-Thr(Trt)-OHもしくはFmoc-Thr(THP)-OH(化合物2)の伸長反応性
立体障害によって反応性が低いMePheをN末端に有する配列、およびThrのアミノ基に対して立体的に嵩高いMeLeuをN末端に有する配列に対してThrを伸長することにより、伸長反応性を検討した。
H-b-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr(PG)-MePhe-MeAla-MeLeu-MePhe-Asp(O-Trt(2-Cl)-resin)-pip(Thr側鎖のPGは保護基を表し、本実験ではTrt保護もしくはTHP保護を表す)は、既に記載の方法で調製したFmoc-Asp(O-Trt(2-Cl)-resin)-pip(化合物50、100 mg)をレジンとして用い、既に実施例に記載のFmoc法によるペプチド合成法に従い、ペプチドの伸長を行った。その際に、Thrの伸長においてはFmoc-Thr(Trt)-OHもしくはFmoc-Thr(THP)-OH(化合物2)を用いた。
ペプチドの伸長後、N末端のFmoc基の除去をペプチド合成機上にて行った後、レジンをDMFおよびDCMにて洗浄した。
レジンをDCMにて再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 2 mL)を加えて室温にて2時間振とうし、ペプチドのレジンからの切り出しを行った。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 1 mL)にて2回洗浄した。
切り出し後、Fmoc-Thr(Trt)-OHを用いた際には、続いて4N HCl/1,4-ジオキサン(19.5 uL)とTIPS (0.25 mL)とDCM (0.73 mL)を混合した溶液を用いて25度にて5分間振とうしてThr(Trt)のTrt基の脱保護をおこない、続いてDIPEA (24 uL)を加えることで酸の中和をし、LCMSにて伸長反応性を検討した。
目的物(化合物112、H-b-MeAla-Ile-MeLeu-MeAla-MeLeu-Thr-MePhe-MeAla-MeLeu-MePhe-Asp-pip)
LCMS(ESI)m/z=1373.6(M+H)+
保持時間:0.69分(分析条件SQDAA50)
LCMS(ESI)m/z=1272.6(M+H)+
保持時間:0.69分(分析条件SQDAA50)
目的物(化合物114)
LCMS(ESI)m/z=1458.1(M+H)+
保持時間:0.73分(分析条件SQDFA05)
H-MeSer(PG)-MeVal-MeHis(Trt)-Tyr(3-F,tBu)-Pro-MeHis(Trt)-Pro-Trp-MePhe(4-Cl)-Asp(O-Trt(2-Cl)-resin)-Pro-OPisを合成機にて合成した際の、Fmoc-MeSer(DMT)-OHもしくはFmoc-MeSer(THP)-OH(化合物6)を用いた場合の、MeSerの伸長反応性の確認
H-MeSer(PG)-MeVal-MeHis(Trt)-Tyr(3-F,tBu)-Pro-MeHis(Trt)-Pro-Trp-MePhe(4-Cl)-Asp(O-Trt(2-Cl)-resin)-Pro-OPis(MeSer側鎖のPGは保護基を表し、本実験ではDMT保護もしくはTHP保護を表す)は、既に記載の方法で調製したFmoc-Asp(O-Trt(2-Cl)-resin)-Pro-OPis(化合物58、ローディング量0.3736 mmol/g、100 mg)をレジンとして用い、既に実施例に記載のFmoc法によるペプチド合成法に従い、ペプチドの伸長を行った。その際に、MeSerの伸長においてはFmoc-MeSer(DMT)-OHもしくはFmoc-MeSer(THP)-OH(化合物6)を用いた。
ペプチドの伸長後、N末端のFmoc基の除去をペプチド合成機上にて行った後、レジンをDMFおよびDCMにて洗浄した。
得られたレジンを減圧下乾燥させた後、それぞれのレジンを30 mgずつ取り出した。
取りだした各々30 mgのレジンをDCMにて再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 2 mL)を加えて室温にて2時間振とうし、ペプチドのレジンからの切り出しを行った。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 1 mL)にて2回洗浄した。得られた全ての切り出し溶液を混合し、減圧下濃縮した。
得られた残渣に、既に記載の方法にて調製した0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を1.3 mL加え、残渣を溶解させた後、室温にて1時間静置し、Tyr(3-F)の側鎖tBu保護以外の側鎖保護基(MeSer側鎖のDMT保護もしくはTHP保護、およびMeHis側鎖のTrt保護)および主鎖C末端のPis保護を脱保護し、LCMSを測定することで、反応の確認をおこなった。
またMS(ネガティブモード)より、MeSerが抜けたペプチド(化合物116、H-MeVal-MeHis-Tyr(3-F,tBu)-Pro-MeHis-Pro-Trp-MePhe(4-Cl)-Asp-Pro-OH)が50%含まれていることが分かった。
目的物(化合物115)
LCMS(ESI)m/z=1559.7(M+H)+
保持時間:0.50分(分析条件SQDFA50)
目的物-MeSer(化合物116)
LCMS(ESI)m/z=1458.8(M+H)+
保持時間:0.50分(分析条件SQDFA50)
目的物(化合物115)
LCMS(ESI)m/z=1559.7(M+H)+
保持時間:0.50分(分析条件SQDFA50)
目的物-MeSer(化合物116)
LCMS(ESI)m/z=1458.7(M+H)+
保持時間:0.50分(分析条件SQDFA50)
H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物101、Pep-1)の側鎖保護基の脱保護(D-Tyr(tBu)のtBu保護の脱保護)(5% TFA/DCE (5% TIPS)を用いた場合)
既に記載の方法にて合成したFmoc-Asp(O-Trt(2-Cl)-resin)-pip(化合物50、レジン担持量0.373 mmol/g、100 mg)を用いて、合成機上でペプチド伸長を行い、H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp(O-Trt(2-Cl)-resin)-pipを得た。
続いてDCMにてレジンを再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 2 mL)を加えて室温にて2時間振とうし、ペプチドのレジンからの切り出しを行った。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 1 mL)にて2回洗浄した。得られた全ての切り出し溶液を混合し、減圧下濃縮した。
得られた残渣をDMF/DCM (1/1, v/v, 8 mL)に溶解し、O-(7-アザ-1Hベンゾトリアゾール-1-イル)-N,N,N,N-テトラメチルウロニウム ヘキサフルオロホスフェート(HATU、21 mg)/DMF溶液(0.5 M)と、DIPEA(12 μL)/DMF(88 μL)溶液を加え、室温にて2時間攪拌した。LCMS測定(分析条件SQDFA05)にて反応の確認をし、H-Ala-Trp-Nle-Trp-D-Tyr(tBu)-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物101、Pep-1)の生成を確認した。
LCMS(ESI)m/z=1480.0(M+H)+
保持時間:0.93分(分析条件SQDFA05)
その後、減圧下溶媒を留去し、得られた残渣に5% TFA/DCE (5% TIPS) (8 mL, 含有水分量は<200 ppmであることをカールフィッシャー測定にて確認)を加えて2時間30分攪拌した。減圧下、溶媒を留去し、残渣のLCMS(FA05)測定を行ったところ、目的物であるH-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物131)と、その加水分解体(いずれかのアミド結合が加水分解されたもの)のMSが確認され、対応するUVエリアの比は13:87であった(図17)。LCの測定結果を図17に示す。なお、本実施例中に記載の「TM+H2O」とは、目的物のいずれかのアミド結合の1つが加水分解を受けた化合物を表す。
目的物(化合物131、H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物)
LCMS(ESI)m/z=1424.0(M+H)+
保持時間:0.79分(分析条件SQDFA05)
加水分解体(H-Ala-Trp-Nle-Trp-D-Tyr-MeGly-MeAla-MePhe(3-Cl)-MeGly-nPrGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物の、いずれかのアミド結合が加水分解されたもの)
LCMS(ESI)m/z=1442.0(M+H)+
保持時間:0.61分(分析条件SQDFA05)
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物103、Pep3)の側鎖保護基(MeSer側鎖のDMT保護およびSer側鎖のTrt保護)の脱保護(5% TFA/DCE (5% TIPS)を用いた場合)
既に記載の方法にて合成したFmoc-Asp(O-Trt(2-Cl)-resin)-pip(化合物50、レジン担持量0.316 mmol/g、100 mg)を用いて、合成機上でペプチド伸長を行い、H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp(O-Trt(2-Cl)-resin)-pipを得た。
続いてDCMにてレジンを再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 2 mL)を加えて室温にて2時間振とうし、ペプチドのレジンからの切り出しを行った。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 1 mL)にて2回洗浄した。
ペプチドのレジンからの切り出し操作を2度繰り返し、得られた全ての切り出し溶液を混合し、減圧下濃縮した。
得られた残渣をDMF/DCM (1/1, v/v, 8 mL)に溶解し、O-(7-アザ-1H-ベンゾトリアゾール-1-イル)-N,N,N,N-テトラメチルウロニウム ヘキサフルオロホスフェート(HATU、18 mg)/DMF溶液(0.5 M)と、DIPEA(9.9 μL)/DMF(39.6 μL)溶液を加え、室温にて2時間攪拌した。LCMS測定(SQDFA05)にて反応の確認をしたところ、H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物103、Pep3)からMeSerの側鎖のDMT保護が外れたものが70%(LCMS(ESI) m/z = 1716.2 (M+H)+、保持時間:1.06分)、MeSerの側鎖のDMT保護およびSerの側鎖のTrt保護の両方が外れたものが30%(LCMS(ESI) m/z = 1474.1 (M+H)+、保持時間:0.78分)確認された。割合はLCのUVエリア比によって算出した。その後、減圧下溶媒を留去し、残渣をジクロロメタンに溶解させ、試験管に10等分した。これらを減圧下濃縮し、ジクロロメタンを取り除いた。なお、上述の実施例において使用された「環化後の残渣」とは、この10等分した後に減圧濃縮して得られた残渣のことを指す。
このうちのひとつの試験管に5% TFA/DCE (5% TIPS) (0.8 mL, 含有水分量は32.5 ppm、カールフィッシャーにて測定)を加えて3分間振とうし、その後25度にて2時間静置した。減圧下、溶媒を留去し、残渣のLCMS(FA05)測定を行ったところ、目的物であるH-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物133)と、目的物のN→O-アシルシフト体と、目的物の1つのヒドロキシル基がTFAエステル化したものと、目的物の2つのヒドロキシル基がTFAエステル化したもののUVエリア比は17:46:32:5であることが確認された。LCの測定結果を図18に示す。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物)
LCMS(ESI)m/z=1473.8(M+H)+
保持時間:0.79分(分析条件SQDFA05)
目的物のN→O-アシルシフト体(目的物の2つのヒドロキシル基のうち、いずれかもしくは両方でN→O-アシルシフトが進行した化合物)
LCMS(ESI)m/z=1473.8(M+H)+
保持時間:0.62分(分析条件SQDFA05)
目的物の1つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1569.8(M+H)+
保持時間:0.89分(分析条件SQDFA05)
目的物の2つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1665.9(M+H)+
保持時間:0.99分(分析条件SQDFA05)
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物103、Pep3)の側鎖保護基(MeSer側鎖のDMT保護およびSer側鎖のTrt保護)の脱保護(5% TFA/DCE (5% TIPS)を用いて0度で行った場合)
上記環化後、10等分したうちのひとつの試験管に、5% TFA/DCE (5% TIPS) (0.8 mL, 含有水分量は36.6 ppm、カールフィッシャーにて測定)を0度にて加えて1分間振とうし、その後0度のまま4時間静置した。反応溶液のLCMS(FA05)測定を行ったところ、目的物であるH-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物133)と、目的物のN→O-アシルシフト体と、目的物の1つのヒドロキシル基がTFAエステル化したものと、目的物のN→O-アシルシフト体の1つのヒドロキシル基がTFAエステル化したもののUVエリア比は56:12:21:11であることが確認された。LCの測定結果を図19に示す。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物)
LCMS(ESI)m/z=1473.7(M+H)+
保持時間:0.78分(分析条件SQDFA05)
目的物のN→O-アシルシフト体(目的物の2つのヒドロキシル基のうち、いずれかもしくは両方でN→O-アシルシフトが進行した化合物)
LCMS(ESI)m/z=1473.7(M+H)+
保持時間:0.65分(分析条件SQDFA05)
目的物の1つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1569.7(M+H)+
保持時間:0.89分(分析条件SQDFA05)
目的物のN→O-アシルシフト体の1つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1569.7(M+H)+
保持時間:0.73分(分析条件SQDFA05)
H-g-EtAbu-MeSer(DMT)-Hyp(Et)-Ile-MePhe(3-Cl)-Ser(Trt)-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物103、Pep3)の側鎖保護基(MeSer側鎖のDMT保護およびSer側鎖のTrt保護)の脱保護(2% TFA/DCE (5% TIPS)を用いて25度で行った場合)
上記環化後、10等分したうちのひとつの試験管に、2% TFA/DCE (5% TIPS) (0.8 mL, 含有水分量は30.1 ppm、カールフィッシャーにて測定)を25度にて加えて1分間振とうし、その後室温にて4時間静置した。反応溶液のLCMS(FA05)測定を行ったところ、目的物であるH-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物(化合物133)と、目的物のN→O-アシルシフト体と、目的物の1つのヒドロキシル基がTFAエステル化したものと、目的物の2つのヒドロキシル基がTFAエステル化したものと、目的物のN→O-アシルシフト体の1つのヒドロキシル基がTFAエステル化したもののUVエリア比は30:34:24:3:9であることが確認された。LCの測定結果を図20に示す。
目的のペプチド(化合物133、H-g-EtAbu-MeSer-Hyp(Et)-Ile-MePhe(3-Cl)-Ser-Trp-Trp-Pro-MeGly-Asp-pipのN末端アミノ基とAsp側鎖カルボン酸とでアミド結合を形成した化合物)
LCMS(ESI)m/z=1473.8(M+H)+
保持時間:0.78分(分析条件SQDFA05)
目的物のN→O-アシルシフト体(目的物の2つのヒドロキシル基のうち、いずれかもしくは両方でN→O-アシルシフトが進行した化合物)
LCMS(ESI)m/z=1473.8(M+H)+
保持時間:0.65分(分析条件SQDFA05)
目的物の1つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1569.8(M+H)+
保持時間:0.89分(分析条件SQDFA05)
目的物の2つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1665.7(M+H)+
保持時間:0.99分(分析条件SQDFA05)
目的物のN→O-アシルシフト体の1つのヒドロキシル基がTFAエステル化した化合物
LCMS(ESI)m/z=1569.8(M+H)+
保持時間:0.73分(分析条件SQDFA05)
N末端のアミノ基とアスパラギン酸の側鎖カルボン酸基とでアミド環化したペプチド群の合成
C末端がアミド化(ピペリジン、4-(tert-ブチル)ピペリジン、N-メチルオクタン-1-アミンのいずれかにてアミド化)されているか、もしくはC末端にプロリンが結合しているアスパラギン酸の側鎖のカルボン酸基と、N末端の主鎖アミノ基とがアミド結合により環化したペプチド群を合成した。
配列中にTyr(3-F,tBu)を含む場合には、既に記載の方法にて調製した0.1 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を2 mL加え、残渣を溶解させた後、室温もしくは30度にて24時間静置した。配列中にTyr(3-F)を含まない場合には、既に記載の方法にて調製した0.05 M 硫酸水素テトラメチルアンモニウム/ HFIP溶液(2% TIPS)を4 mL加え、残渣を溶解させた後、室温にて4時間静置した。一定時間静置した後、ジイソプロピルエチルアミン(DIPEA、70 μL)を加え、減圧下溶媒を留去した。
液相法での伸長反応を含む合成を以下に示す。
液相でのFmoc-Ala-OSu(化合物152)とH-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis(化合物151)とのカップリングを含む、環状ペプチド(化合物154、H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe(3-Cl)-MeHis-MeGly-Pro-Asp-Pro-OHの主鎖N末端のアミノ基とAspの側鎖カルボン酸基との間でアミド結合を形成した環状ペプチド)の合成
液相法での伸長反応を含む図21に記載の合成ルートにて、ペプチドの合成を行った。
H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis(化合物151)の合成
続いてDCMにてレジンを再膨潤させた後、レジンにTFE/DCM (1/1, v/v, 4 mL)とジイソプロピルエチルアミン(24 μL)を加えて室温にて2時間振とうし、ペプチドのレジンからの切り出しを行った。続いてチューブ内の溶液を合成用カラムでろ過することによりレジンを除き、残ったレジンをさらにTFE/DCM (1/1, v/v, 2 mL)にて2回洗浄した。得られた全ての切り出し溶液を混合し、減圧下濃縮して、標題の化合物(化合物151、H-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis、113.8 mg)を得た。精製は行わずに次の工程に用いた。
LCMS(ESI)m/z=1860.9(M+H)+
保持時間:0.72分(分析条件SQDFA05)
2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)プロパン酸 (S)-2,5-ジオキソピロリジン-1-イル(化合物152、Fmoc-Ala-OSu)の合成
LCMS(ESI)m/z=409.3(M+H)+
保持時間:0.80分(分析条件SQDFA05)
2-((((9H-フルオレン-9-イル)メトキシ)カルボニル)アミノ)プロパン酸 (S)-2,5-ジオキソピロリジン-1-イル(化合物152、Fmoc-Ala-OSu)とH-Trp-Nle-Trp-Ser(THP)-nPrGly-MePhe(3-Cl)-MeHis(Trt)-MeGly-Pro-Asp-Pro-OPis(化合物151)とのカップリングと、続く脱Fmoc反応
LCMS(ESI)m/z=1931.8(M+H)+
保持時間:0.73分(分析条件SQDFA05)
H-Ala-Trp-Nle-Trp-Ser-nPrGly-MePhe(3-Cl)-MeHis-MeGly-Pro-Asp-Pro-OHのN末端アミノ基とAsp側鎖のカルボン酸基とがアミド環化した化合物(化合物154)の合成(化合物153の環化反応と、続く脱保護反応)
LCMS(ESI)m/z=1469.7(M+H)+
保持時間:0.61分(分析条件SQDFA05)
Claims (16)
- 以下の工程:
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)工程1)で準備されたFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを固相に担持する工程、
3)固相に担持されたFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
4)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程、及び、
5)工程4)で得られたペプチドを、TFAよりも弱酸となる条件下で固相から切り出す工程、
を含む、少なくとも1つのN-置換アミノ酸又はN-置換アミノ酸類縁体を含むペプチドの製造方法。 - 前記工程4)で得られたペプチドを構成するアミノ酸またはアミノ酸類縁体の少なくとも1つの側鎖が、塩基性条件下では脱保護されず、かつ第1の酸で脱保護される保護基で保護されており、前記工程5)の前又は後で、該第1の酸にて該保護基を脱保護する工程をさらに含み、かつ
前記工程5)において、第2の酸を用いてペプチドを切り出す、請求項1に記載の製造方法であって、
第1の酸および第2の酸がいずれもTFAよりも弱酸であり、かつ第1の酸の酸度が第2の酸の酸度よりも高い、製造方法。 - 以下の工程:
1)以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸(Fmoc保護アミノ酸)、以下のi)及びii)の官能基をそれぞれ少なくとも1つ有するアミノ酸類縁体(Fmoc保護アミノ酸類縁体)、又は、該Fmoc保護アミノ酸及び該Fmoc保護アミノ酸類縁体の両方又はいずれか一方を含むペプチド(Fmoc保護ペプチド)を準備する工程;
i)Fmoc骨格を有する少なくとも1つの保護基により保護されている主鎖のアミノ基、
ii)遊離の又は活性エステル化された少なくとも1つのカルボン酸基、
2)Fmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護し、アミノ基を露出する工程、
3)新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程であって、この工程で得られるペプチドを構成するアミノ酸またはアミノ酸類縁体の少なくとも1つの側鎖が、塩基性条件下では脱保護されずTFAよりも弱酸となる条件下で脱保護される保護基を有する工程、及び、
4)前記側鎖の保護基を、TFAよりも弱酸となる条件下で脱保護する工程、
を含む、少なくとも1つのN-置換アミノ酸又はN-置換アミノ酸類縁体を含むペプチドの製造方法。 - ペプチドの製造が固相法によって行われる、請求項3に記載の製造方法。
- 前記工程3)で得られたペプチドを、前記工程4)の前又は後で前記工程4)で用いられる弱酸条件よりも更に弱酸となる条件下で固相から切り出す工程をさらに含む、請求項4に記載の製造方法。
- ペプチドの製造が液相法によって行われる、請求項3に記載の製造方法。
- 請求項1の工程4)又は請求項3の工程3)が、
新たに添加したFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドのFmoc骨格を有する保護基を塩基で脱保護してアミノ基を露出する工程、および
更に新たなFmoc保護アミノ酸、Fmoc保護アミノ酸類縁体又はFmoc保護ペプチドを添加して、アミド結合を形成する工程をさらに含み、
これらの工程を1回または複数回繰り返す、請求項1から6のいずれかに記載の製造方法。 - 製造されたペプチドが、1つの反応点を有するアミノ酸残基又はアミノ酸類縁体残基をC末端側に含み、かつもう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体をN末端側に含む、請求項1から7のいずれかに記載の製造方法。
- 前記1つの反応点と前記もう一つの反応点とを結合させ、前記ペプチドを環化させる工程をさらに含む、請求項8に記載の製造方法。
- 前記もう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体がN末端にあり、かつ前記結合がアミド結合である、請求項9に記載の製造方法。
- 前記もう1つの反応点を有するアミノ酸残基、アミノ酸類縁体残基又はカルボン酸類縁体がN末端にあり、かつ前記結合が炭素-炭素結合である、請求項9に記載の製造方法。
- TFAよりも弱酸となる条件下で行われる工程が、水中でのpKaの値が0~9である弱酸を、イオン化能YOTs値が正の値で水中でのpKaが5~14である溶媒に含む、弱酸溶液を用いて行われる、請求項1から11のいずれかに記載の製造方法。
- 溶媒がフルオロアルコールである、請求項12に記載の製造方法。
- フルオロアルコールがTFE又はHFIPである、請求項13に記載の製造方法。
- 側鎖の保護基が、pH1からpH7の範囲で脱保護される保護基であるか、又は10%以下のTFAにおいて脱保護される保護基である、請求項2から14のいずれかに記載の製造方法。
- 側鎖の保護基が以下のa)~d)から選択される、請求項2から15のいずれかに記載の製造方法:
a)側鎖の保護基がSer、Thr、Hyp、及び、それらの誘導体の側鎖のヒドロキシル基の保護基である場合、以下の一般式で表わされるMOM骨格基、Bn骨格、Dpm骨格、Trt骨格、シリル骨格及びBoc骨格から選ばれるいずれかの保護基;
b)側鎖の保護基がTyr及びその誘導体の側鎖のヒドロキシル基の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格、Dpm骨格、Trt骨格、シリル骨格、Boc骨格及びtBu骨格から選ばれるいずれかの保護基;
c)前記側鎖の保護基がHis及びその誘導体の側鎖のイミダゾール環の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格及びTrt骨格から選ばれるいずれかの保護基;
d)前記側鎖の保護基がAsp、Glu、及び、それらの誘導体の側鎖のカルボン酸基の保護基である場合、以下の一般式で表わされるMOM骨格、Bn骨格、Dpm骨格、Trt骨格、tBu骨格、フェニル-EDOTn骨格及び保護をするカルボン酸基の炭素原子を3つのアルコキシ基が置換した骨格に変換したオルトエステル骨格から選ばれるいずれかの保護基;
<MOM骨格を有する保護基>
R1はHであり、R2はHであり、かつXはメチル、ベンジル、4-メトキシベンジル、2,4-ジメトキシベンジル、3,4-ジメトキシベンジル、または2-トリメチルシリルエチルであるか、
R1はメチルであり、R2はHであり、かつXはエチルであるか、
R1、R2、R3は、いずれもメチルであるか、または
R1とXは、一緒になって-CH2-CH2-CH2-または-CH2-CH2-CH2-CH2-を形成し、かつR2はHであり
ここで、R1、R2、およびXのいずれかがメチルまたはエチルである場合、これらの基はさらにアルキル、ベンジル、またはアリールで置換されていてもよい。)
<Bn骨格を有する保護基>
R1~R5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR6およびR7はアルキルであるか、
R1、R2、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、R3はメトキシであり、かつR6およびR7はHであるか、
R1およびR3がメトキシであり、R2、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR6およびR7はHであるか、または
R1、R4、およびR5は、それぞれ独立してH、アルキル、アリール、またはハロゲンであり、かつR2とR3は一緒になって-O-CH2-O-を形成する。)
<Dpm骨格を有する保護基>
R1~R10は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、または
R1~R4およびR7~R10は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR5およびR6は一緒になって-O-または-CH2-CH2-を形成する。)
<Trt骨格を有する保護基>
R1~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、
R1、R2、およびR4~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR3は、メチルまたはメトキシであるか、
R1はClであり、かつR2~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであるか、または
R1~R4、およびR7~R15は、それぞれ独立してH、アルキル、アリール、アルコキシ、またはハロゲンであり、かつR5とR6は一緒になって-O-を形成する。)
<シリル骨格を有する保護基>
R1~R3は、それぞれ独立してアルキル、またはアリールである。)
<Boc骨格を有する保護基>
R1~R9は、それぞれ独立してH、アルキル、またはアリールである。)
<tBu骨格を有する保護基>
R1~R9は、それぞれ独立してH、アルキル、またはアリールである。)
<フェニル-EDOTn骨格を有する保護基>
R1~R3は、それぞれ独立して、H、またはメトキシである)。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019523990A JP7229158B2 (ja) | 2017-06-09 | 2018-06-08 | N-置換アミノ酸を含むペプチドの合成方法 |
US16/619,388 US11542299B2 (en) | 2017-06-09 | 2018-06-08 | Method for synthesizing peptide containing N-substituted amino acid |
KR1020237041542A KR20230169447A (ko) | 2017-06-09 | 2018-06-08 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
EP18813662.6A EP3636656A4 (en) | 2017-06-09 | 2018-06-08 | PROCESS FOR SYNTHESIS OF A PEPTIDE CONTAINING AN N-SUBSTITUTED AMINO ACID |
KR1020207000271A KR102610527B1 (ko) | 2017-06-09 | 2018-06-08 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
CN201880036609.0A CN110799520B (zh) | 2017-06-09 | 2018-06-08 | 用于合成含有n-取代氨基酸的肽的方法 |
US17/976,942 US11787836B2 (en) | 2017-06-09 | 2022-10-31 | Method for synthesizing peptide containing N-substituted amino acid |
US18/459,998 US20230406879A1 (en) | 2017-06-09 | 2023-09-01 | Method for synthesizing peptide containing n-substituted amino acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-114073 | 2017-06-09 | ||
JP2017114073 | 2017-06-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/619,388 A-371-Of-International US11542299B2 (en) | 2017-06-09 | 2018-06-08 | Method for synthesizing peptide containing N-substituted amino acid |
US17/976,942 Continuation US11787836B2 (en) | 2017-06-09 | 2022-10-31 | Method for synthesizing peptide containing N-substituted amino acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018225851A1 true WO2018225851A1 (ja) | 2018-12-13 |
Family
ID=64566048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/021998 WO2018225851A1 (ja) | 2017-06-09 | 2018-06-08 | N-置換アミノ酸を含むペプチドの合成方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US11542299B2 (ja) |
EP (1) | EP3636656A4 (ja) |
JP (2) | JP7229158B2 (ja) |
KR (2) | KR102610527B1 (ja) |
CN (1) | CN110799520B (ja) |
WO (1) | WO2018225851A1 (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10815489B2 (en) | 2015-03-13 | 2020-10-27 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-tRNA synthetase and use thereof |
WO2021090855A1 (ja) * | 2019-11-07 | 2021-05-14 | 中外製薬株式会社 | Kras阻害作用を有する環状ペプチド化合物 |
WO2021117848A1 (ja) | 2019-12-12 | 2021-06-17 | 中外製薬株式会社 | 非天然アミノ酸を含むペプチドの製造方法 |
WO2021246471A1 (ja) * | 2020-06-03 | 2021-12-09 | 中外製薬株式会社 | 高難度配列の効率的ペプチド縮合法 |
WO2022097540A1 (ja) | 2020-11-05 | 2022-05-12 | 中外製薬株式会社 | ジケトピペラジン形成による欠損を抑制するペプチド合成方法 |
CN114585916A (zh) * | 2019-10-15 | 2022-06-03 | 中外制药株式会社 | 含有用具有Fmoc骨架的保护基保护的氨基的化合物的定量法 |
WO2022138891A1 (ja) | 2020-12-25 | 2022-06-30 | 中外製薬株式会社 | N-置換-アミノ酸残基を含むペプチド化合物の製造方法 |
WO2022145444A1 (ja) | 2020-12-28 | 2022-07-07 | 中外製薬株式会社 | アミノ酸の固相合成用樹脂への担持方法 |
JP7165289B1 (ja) * | 2021-05-07 | 2022-11-02 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状化合物の製造方法 |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
WO2022234853A1 (ja) | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物 |
WO2022234864A1 (ja) * | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状化合物の製造方法 |
WO2022234852A1 (ja) * | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | 環状ペプチド化合物の医薬用途 |
WO2023063376A1 (ja) * | 2021-10-13 | 2023-04-20 | 中外製薬株式会社 | ペプチド化合物及び界面活性剤を含む組成物 |
US11732002B2 (en) | 2018-11-30 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound |
WO2023214509A1 (ja) * | 2022-05-02 | 2023-11-09 | 中外製薬株式会社 | 界面活性剤と併用するためのペプチド化合物を含む組成物 |
US11891457B2 (en) | 2011-12-28 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Peptide-compound cyclization method |
WO2024080333A1 (ja) * | 2022-10-13 | 2024-04-18 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状ペプチド化合物の製造方法 |
WO2024085235A1 (ja) * | 2022-10-20 | 2024-04-25 | 中外製薬株式会社 | 環状ペプチドの結晶の製造方法 |
US12071396B2 (en) | 2019-03-15 | 2024-08-27 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing aromatic amino acid derivative |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11542299B2 (en) * | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
EP4056580A4 (en) * | 2019-11-07 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR MANUFACTURING A PEPTIDE COMPOUND CONTAINING A HIGHLY STERICALLY HINDERED AMINO ACID |
CN113801215B (zh) * | 2021-09-13 | 2024-01-16 | 苏州携创生物技术有限公司 | 一种环瓜氨酸肽、含该肽的抗原、试剂、试剂盒及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177533A1 (en) * | 2008-10-09 | 2010-04-21 | TU München | Multiple N-methylated cyclic hexapeptides for treatment of neurogenic inflammation |
EP2380596A1 (en) * | 2010-04-20 | 2011-10-26 | Technische Universität München | Cyclopentapeptide derivatives and uses thereof |
WO2013100132A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
WO2015185162A1 (en) * | 2014-06-06 | 2015-12-10 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57159747A (en) | 1981-03-27 | 1982-10-01 | Kenji Okawa | Synthesis of amino acid derivative |
JPS60169451A (ja) | 1984-02-13 | 1985-09-02 | Mitsui Toatsu Chem Inc | L−フエニルアラニンの分離精製法 |
FR2583432B1 (fr) | 1985-06-13 | 1988-11-04 | Inst Francais Du Petrole | Procede de production enzymatique de l-a-aminoacides a partir d'a-cetoacides |
ES8607214A1 (es) | 1985-10-16 | 1986-06-01 | Gema Sa | Procedimiento enzimatico de resolucion de n-fenilacetil-ami-nocompuestos y purificacion de sus isomeros opticamente ac- tivos |
US4670607A (en) | 1985-10-29 | 1987-06-02 | Hamari Chemicals, Ltd. | Method for producing 2-(substituted aryl) propionaldehyde |
JPS6393796A (ja) | 1986-10-09 | 1988-04-25 | Shin Etsu Chem Co Ltd | ペプチド合成の脱保護基用薬剤 |
US4859736A (en) | 1987-03-30 | 1989-08-22 | Ciba-Geigy Corporation | Synthetic polystyrene resin and its use in solid phase peptide synthesis |
DE3733198A1 (de) | 1987-10-01 | 1989-04-13 | Kernforschungsanlage Juelich | Enzymatisches verfahren zur herstellung von dipeptiden |
JPH0681759B2 (ja) | 1988-03-31 | 1994-10-19 | 信越化学工業株式会社 | ポリペプチドの製造方法 |
SK26999A3 (en) | 1996-09-12 | 1999-10-08 | Rhone Poulenc Rorer Pharma | Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2- -substituted ethyl-2-amines |
CN1238366C (zh) | 1997-01-21 | 2006-01-25 | 综合医院公司 | 利用rna-蛋白融合体筛选蛋白 |
IL125314A (en) | 1998-07-12 | 2004-07-25 | Peptor Ltd | Processes for attaching amino acids using a bite - (trichloromethyl) carbonate |
JP4502293B2 (ja) | 1999-06-04 | 2010-07-14 | 長瀬産業株式会社 | 軸不斉を有する光学活性な4級アンモニウム塩、その製法およびα−アミノ酸誘導体の不斉合成への応用 |
DE19942624A1 (de) | 1999-08-28 | 2001-03-08 | Chemotopix Gmbh | Verfahren zur Herstellung von zyklischen Peptidomimetika |
CA2381713A1 (en) | 1999-09-02 | 2001-03-08 | Big Bear Bio, Inc. | Methods and compositions for reducing serum phosphate levels |
MXPA02010375A (es) | 2000-04-19 | 2003-04-25 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2. |
EP1277755A4 (en) | 2000-04-21 | 2006-01-11 | Nagase & Co Ltd | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT BY AXIAL ASYMMETRY, METHOD FOR THE PRODUCTION THEREOF, AND THEIR APPLICATION IN THE ASYMMETRIC SYNTHESIS OF ALPHA-AMINO-ACID DERIVATIVES |
MXPA03009566A (es) | 2001-04-19 | 2004-12-06 | Scripps Research Inst | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
WO2003014354A1 (en) | 2001-08-01 | 2003-02-20 | Japan Science And Technology Agency | Tyrosyl-trna synthase variants |
US7288372B2 (en) | 2002-01-17 | 2007-10-30 | Ambergen, Inc. | Methods for the preparation of chemically misaminoacylated tRNA via protective groups |
EP1504111A4 (en) | 2002-04-19 | 2005-11-23 | California Inst Of Techn | PEPTIDES NUCLEIC ACID PEPTIDE DISPLAY LIBRARS CONTAINING UNNATURELY AMINO-ACID-RESISTANT AND METHOD FOR THE PRODUCTION THEREOF |
JP4490663B2 (ja) | 2003-09-22 | 2010-06-30 | 株式会社東京大学Tlo | イソロイシンtRNA(tRNAIle)のライシジン合成酵素(TilS)としてのmesJ遺伝子産物及びその相同性遺伝子(COG0037) |
EP1701969B1 (en) | 2003-12-31 | 2007-10-24 | F.Hoffmann-La Roche Ag | Process for peptide synthesis using a reduced amount of deprotection agent |
US20080221303A1 (en) | 2004-02-18 | 2008-09-11 | Jehoshua Katzhendler | Method for the Preparation of Peptide-Oligonucleotide Conjugates |
EP1964916B1 (en) | 2005-12-06 | 2012-08-01 | The University of Tokyo | Multi-purpose acylation catalayst and use thereof |
JP5808882B2 (ja) | 2006-03-03 | 2015-11-10 | カリフォルニア インスティテュート オブ テクノロジー | 分子へのアミノ酸の部位特異的な組み込み |
CA2649303C (en) | 2006-04-11 | 2016-09-27 | Sloan-Kettering Institute For Cancer Research | Homogeneous erythropoietin and other peptides and proteins, methods and intermediates for their preparation |
JP2007319064A (ja) | 2006-05-31 | 2007-12-13 | Japan Science & Technology Agency | 修飾化アミノ酸を部位特異的に導入したタンパク質を発現させる方法 |
WO2008040536A1 (en) | 2006-10-05 | 2008-04-10 | Lonza Ag | Method for peptide synthesis |
JP5200241B2 (ja) | 2006-11-17 | 2013-06-05 | 国立大学法人 東京大学 | N末端に非天然骨格をもつポリペプチドの翻訳合成とその応用 |
US9090668B2 (en) | 2007-03-26 | 2015-07-28 | The University Of Tokyo | Process for synthesizing cyclic peptide compound |
JP2009096791A (ja) | 2007-09-26 | 2009-05-07 | Kaneka Corp | アミノ酸の製造方法 |
TWI468375B (zh) | 2008-10-27 | 2015-01-11 | Janssen Pharmaceutica Nv | 製備經保護之l-丙胺酸衍生物之方法 |
WO2010053050A1 (ja) | 2008-11-04 | 2010-05-14 | 株式会社カネカ | O-アルキルセリンおよびn-ベンジル-o-アルキルセリンの製造法 |
CN102239176A (zh) | 2008-12-03 | 2011-11-09 | 弗·哈夫曼-拉罗切有限公司 | 用于制备治疗性肽的方法 |
JP2012525348A (ja) | 2009-05-01 | 2012-10-22 | エフ.ホフマン−ラ ロシュ アーゲー | 固相及び溶液相の組み合わせ技術を用いたインスリン分泌促進ペプチド合成 |
EP2492344B1 (en) | 2009-10-22 | 2016-04-06 | PeptiDream Inc. | Rapid display method in translational synthesis of peptide |
GB0919194D0 (en) | 2009-11-02 | 2009-12-16 | Lytix Biopharma As | Compounds |
US20110118314A1 (en) | 2009-11-16 | 2011-05-19 | Weiya Yun | Piperidine analogs as glycogen synthase activators |
JP2011139667A (ja) | 2010-01-07 | 2011-07-21 | Tottori Univ | プロリンおよびβ−アラニンをN末端に有するジペプチド、及びその環化ジペプチドの酵素合成法 |
JP5725467B2 (ja) | 2010-08-27 | 2015-05-27 | 国立大学法人 東京大学 | 新規人工翻訳合成系 |
JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
JP6206943B2 (ja) | 2010-12-03 | 2017-10-04 | 国立大学法人 東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
ES2586411T3 (es) | 2011-03-04 | 2016-10-14 | New York University | Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras |
US9133245B2 (en) | 2011-06-13 | 2015-09-15 | Trustees Of Boston College | Cyclic lactadherin peptide mimetics and their uses |
WO2012171984A1 (en) | 2011-06-16 | 2012-12-20 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
GB201215538D0 (en) | 2012-08-31 | 2012-10-17 | Stetsenko Dmitry | Method and compositions for removing acid-labile protecting groups |
JP6440055B2 (ja) | 2013-05-10 | 2018-12-19 | 国立大学法人 東京大学 | ペプチドライブラリの製造方法、ペプチドライブラリ、及びスクリーニング方法 |
JP6357154B2 (ja) | 2013-08-05 | 2018-07-11 | 国立大学法人 東京大学 | 荷電性非タンパク質性アミノ酸含有ペプチドの製造方法 |
SG11201600473UA (en) | 2013-08-05 | 2016-02-26 | Medimmune Ltd | Amino acid derivatives |
US20170022254A1 (en) * | 2014-04-08 | 2017-01-26 | Novartis Ag | Novel Aldehyde Acetal Based Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates |
WO2015179434A1 (en) | 2014-05-20 | 2015-11-26 | Ohio State Innovation Foundation | Small molecule ras inhibitors |
US20170369871A1 (en) | 2015-01-12 | 2017-12-28 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
HUE059925T2 (hu) | 2015-03-13 | 2023-01-28 | Chugai Pharmaceutical Co Ltd | Módosított aminoacil-tRNS-szintetáz és alkalmazása |
CN107614689A (zh) | 2015-03-27 | 2018-01-19 | 昆士兰大学 | 用于将非天然氨基酸并入蛋白质中的平台 |
WO2017150732A1 (ja) | 2016-03-03 | 2017-09-08 | 中外製薬株式会社 | チオール基をアミノ基近傍に有するアミノ酸をn末端に持つ非環状ペプチド-核酸複合体、そのライブラリー、およびそれから誘導される環状ペプチド-核酸複合体ライブラリーの製造方法 |
WO2017181061A1 (en) | 2016-04-15 | 2017-10-19 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
IT201600122363A1 (it) | 2016-12-02 | 2018-06-02 | Dolores Fregona | Composti di coordinazione, sintesi, nanoformulazione ed uso degli stessi in oncologia |
JP7187323B2 (ja) | 2017-01-31 | 2022-12-12 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
CN110869544B (zh) | 2017-06-09 | 2024-03-08 | 中外制药株式会社 | 膜透过性高的环状肽化合物及包含其的文库 |
EP3725796A4 (en) | 2017-12-15 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR MANUFACTURING PEPTIDE AND METHOD FOR PROCESSING BASES |
KR20210088619A (ko) | 2018-11-07 | 2021-07-14 | 추가이 세이야쿠 가부시키가이샤 | O-치환 세린 유도체의 제조 방법 |
JPWO2020111238A1 (ja) | 2018-11-30 | 2021-10-21 | 中外製薬株式会社 | ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法 |
WO2020122182A1 (ja) | 2018-12-12 | 2020-06-18 | 中外製薬株式会社 | 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法 |
US20220205009A1 (en) | 2018-12-26 | 2022-06-30 | Chugai Seiyaku Kabushiki Kaisha | MUTATED tRNA FOR CODON EXPANSION |
US12071396B2 (en) | 2019-03-15 | 2024-08-27 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing aromatic amino acid derivative |
EP4083051A4 (en) | 2019-12-27 | 2024-01-17 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR SYNTHESIS OF A PEPTIDE COMPOUND |
-
2018
- 2018-06-08 US US16/619,388 patent/US11542299B2/en active Active
- 2018-06-08 KR KR1020207000271A patent/KR102610527B1/ko active IP Right Grant
- 2018-06-08 CN CN201880036609.0A patent/CN110799520B/zh active Active
- 2018-06-08 EP EP18813662.6A patent/EP3636656A4/en active Pending
- 2018-06-08 KR KR1020237041542A patent/KR20230169447A/ko not_active Application Discontinuation
- 2018-06-08 WO PCT/JP2018/021998 patent/WO2018225851A1/ja active Application Filing
- 2018-06-08 JP JP2019523990A patent/JP7229158B2/ja active Active
-
2022
- 2022-10-31 US US17/976,942 patent/US11787836B2/en active Active
-
2023
- 2023-02-14 JP JP2023020564A patent/JP7550898B2/ja active Active
- 2023-09-01 US US18/459,998 patent/US20230406879A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177533A1 (en) * | 2008-10-09 | 2010-04-21 | TU München | Multiple N-methylated cyclic hexapeptides for treatment of neurogenic inflammation |
EP2380596A1 (en) * | 2010-04-20 | 2011-10-26 | Technische Universität München | Cyclopentapeptide derivatives and uses thereof |
WO2013100132A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
WO2015185162A1 (en) * | 2014-06-06 | 2015-12-10 | Technische Universität München | Modified cyclopentapeptides and uses thereof |
Non-Patent Citations (21)
Title |
---|
"Greene's Protective Groups in Organic Synthesis", 1 May 2002, MERCK CO. |
"Peptide Coupling Reagents, More than a Letter Soup", CHEM. REV., vol. 111, 2011, pages 6557 - 6602 |
ALBERICIO, FERNANDO ET AL.: "Fmoc Methodology: Cleavage from the Resin and Final Deprotection, Amino Acids", PEPTIDES AND PROTEINS IN ORGANIC CHEMISTRY, vol. 3, 2011, pages 349 - 369, XP055554734, ISBN: 978-3-527-32102-5 * |
ALBERT ISIDRO-LLOBET ET AL.: "Amino Acid-Protecting Groups", CHEM. REV., vol. 109, 2009, pages 2455, XP055559012, DOI: 10.1021/cr800323s |
BEHRENDT, RAYMOND ET AL.: "Advances in Fmoc solid- phase peptide synthesis", J. PEPT. SCI., vol. 22, 2016, pages 4 - 27, XP055554732 * |
CHATTERJEE, JAYANTA ET AL.: "N-Methylation of Peptides: A New Perspective in Medicinal Chemistry", ACCOUNTS OF CHEMICAL RESEARCH, vol. 41, no. 10, 2008, pages 1331 - 1342, XP055164292 * |
CHEMICAL REVIEWS, vol. 109, no. 6, 2009, pages 2455 - 2504 |
E. MARCUCCI: "Solid-Phase Synthesis ofNMe-IB-01212, a Highly N-Methylated Cyclic Peptide", ORG. LETT., vol. 14, 2012, pages 612 |
H. EBERHARD ET AL.: "N-O-Acyl shift in Fmoc-based synthesis of phosphopeptides", ORG. BIOMOL. CHEM., vol. 6, 2008, pages 1349, XP055163101, DOI: 10.1039/b718568e |
H. RODRIGUEZ ET AL.: "A convenient microwave-enhanced solid-phase synthesis of short chain N-methyl-rich peptides", J. PEPT. SCI., vol. 16, 2010, pages 136 |
J. CHATTERJEE ET AL.: "N-Methylation of peptides: A new perspective in medicinal chemistry", ACC. CHEM. RES., vol. 41, 2008, pages 1331, XP055164292, DOI: 10.1021/ar8000603 |
J. E. BOCK ET AL.: "Getting in Shape: Controlling Peptide Bioactivity and Bioavailability Using Conformational Constraints", ACS CHEM. BIOL., vol. 8, 2013, pages 488, XP055287068, DOI: 10.1021/cb300515u |
J. URBAN ET AL.: "Lability of N-alkylated peptides towards TFA cleavage", INT. J. PEPT. PROT. RES., vol. 47, 1996, pages 182, XP000581089 |
K. JPSEPHSON ET AL.: "mRNA display: from basic principles to macrocycle drug discovery", DRUG DISCOVERY TODAY |
L. A. CARPINO ET AL.: "Stepwise Automated Solid Phase Synthesis of Naturally Occurring Peptaibols Using FMOC Amino Acid Fluorides", J. ORG. CHEM., vol. 60, 1995, pages 405, XP055093096, DOI: 10.1021/jo00107a020 |
L. A. CARPINO: "Dramatically enhanced N-O acyl migration during the trifluoroacetic acid-based deprotection step in solid phase peptide synthesis", TETRAHEDRON LETT., vol. 46, 2005, pages 1361, XP025384490, DOI: 10.1016/j.tetlet.2004.12.089 |
M. TEIXIDO ET AL.: "Solid-phase synthesis and characterization of N-methyl-rich peptides", J. PEPTIDE RES., vol. 65, 2005, pages 153 |
PROG. PHYS. ORG. CHEM., vol. 17, 1990, pages 121 - 158 |
R. ROODBEEN ET AL.: "Microwave Heating in the Solid-Phase Synthesis of N-Methylated Peptides: When Is Room Temperature Better?", EUR. J. ORG. CHEM., 2012, pages 7106 |
S. R. GRACIA ET AL.: "Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry", FUTURE MED. CHEM., vol. 1, 2009, pages 1289 |
W.-J. FANG ET AL.: "Deletion of Ac-NMePhel From [NMePhel]arodyn Under Acidic Conditions, Part 1: Effects of Cleavage Conditions and N-Terminal Functionality", PEPTIDE SCIENCE, vol. 96, pages 97 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11891457B2 (en) | 2011-12-28 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Peptide-compound cyclization method |
US10815489B2 (en) | 2015-03-13 | 2020-10-27 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-tRNA synthetase and use thereof |
US11492369B2 (en) | 2017-12-15 | 2022-11-08 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide, and method for processing bases |
US11732002B2 (en) | 2018-11-30 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound |
US12071396B2 (en) | 2019-03-15 | 2024-08-27 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing aromatic amino acid derivative |
CN114585916A (zh) * | 2019-10-15 | 2022-06-03 | 中外制药株式会社 | 含有用具有Fmoc骨架的保护基保护的氨基的化合物的定量法 |
EP4043478A4 (en) * | 2019-11-07 | 2024-01-03 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION |
CN114729006A (zh) * | 2019-11-07 | 2022-07-08 | 中外制药株式会社 | 具有Kras抑制作用的环状肽化合物 |
JP6880352B1 (ja) * | 2019-11-07 | 2021-06-02 | 中外製薬株式会社 | Kras阻害作用を有する環状ペプチド化合物 |
WO2021090855A1 (ja) * | 2019-11-07 | 2021-05-14 | 中外製薬株式会社 | Kras阻害作用を有する環状ペプチド化合物 |
TWI788724B (zh) * | 2019-11-07 | 2023-01-01 | 日商中外製藥股份有限公司 | 具有Kras抑制作用的環狀胜肽化合物 |
WO2021117848A1 (ja) | 2019-12-12 | 2021-06-17 | 中外製薬株式会社 | 非天然アミノ酸を含むペプチドの製造方法 |
WO2021246471A1 (ja) * | 2020-06-03 | 2021-12-09 | 中外製薬株式会社 | 高難度配列の効率的ペプチド縮合法 |
KR20230019120A (ko) | 2020-06-03 | 2023-02-07 | 추가이 세이야쿠 가부시키가이샤 | 고난도 서열의 효율적 펩티드 축합법 |
WO2022097540A1 (ja) | 2020-11-05 | 2022-05-12 | 中外製薬株式会社 | ジケトピペラジン形成による欠損を抑制するペプチド合成方法 |
KR20230097018A (ko) | 2020-11-05 | 2023-06-30 | 추가이 세이야쿠 가부시키가이샤 | 다이케토피페라진 형성에 의한 결손을 억제하는 펩타이드 합성 방법 |
WO2022138891A1 (ja) | 2020-12-25 | 2022-06-30 | 中外製薬株式会社 | N-置換-アミノ酸残基を含むペプチド化合物の製造方法 |
KR20230125807A (ko) | 2020-12-28 | 2023-08-29 | 추가이 세이야쿠 가부시키가이샤 | 아미노산의 고상 합성용 수지에의 담지 방법 |
WO2022145444A1 (ja) | 2020-12-28 | 2022-07-07 | 中外製薬株式会社 | アミノ酸の固相合成用樹脂への担持方法 |
JP7179241B1 (ja) * | 2021-05-07 | 2022-11-28 | 中外製薬株式会社 | 環状ペプチド化合物の医薬用途 |
WO2022234852A1 (ja) * | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | 環状ペプチド化合物の医薬用途 |
WO2022234864A1 (ja) * | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状化合物の製造方法 |
WO2022234853A1 (ja) | 2021-05-07 | 2022-11-10 | 中外製薬株式会社 | Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物 |
JP7165289B1 (ja) * | 2021-05-07 | 2022-11-02 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状化合物の製造方法 |
WO2023063376A1 (ja) * | 2021-10-13 | 2023-04-20 | 中外製薬株式会社 | ペプチド化合物及び界面活性剤を含む組成物 |
WO2023214509A1 (ja) * | 2022-05-02 | 2023-11-09 | 中外製薬株式会社 | 界面活性剤と併用するためのペプチド化合物を含む組成物 |
WO2024080333A1 (ja) * | 2022-10-13 | 2024-04-18 | 中外製薬株式会社 | N-置換アミノ酸残基を含む環状ペプチド化合物の製造方法 |
WO2024085235A1 (ja) * | 2022-10-20 | 2024-04-25 | 中外製薬株式会社 | 環状ペプチドの結晶の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20230169447A (ko) | 2023-12-15 |
JPWO2018225851A1 (ja) | 2020-04-09 |
EP3636656A4 (en) | 2021-04-14 |
US20200277327A1 (en) | 2020-09-03 |
CN110799520B (zh) | 2024-07-12 |
US20230406879A1 (en) | 2023-12-21 |
JP2023053290A (ja) | 2023-04-12 |
JP7229158B2 (ja) | 2023-02-27 |
CN110799520A (zh) | 2020-02-14 |
JP7550898B2 (ja) | 2024-09-13 |
US20230138226A1 (en) | 2023-05-04 |
US11542299B2 (en) | 2023-01-03 |
US11787836B2 (en) | 2023-10-17 |
KR102610527B1 (ko) | 2023-12-05 |
EP3636656A1 (en) | 2020-04-15 |
KR20200016941A (ko) | 2020-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018225851A1 (ja) | N-置換アミノ酸を含むペプチドの合成方法 | |
Paradís-Bas et al. | The road to the synthesis of “difficult peptides” | |
ES2957399T3 (es) | Método de síntesis de péptidos | |
EP2873677B1 (en) | Method of producing self-assembling peptide derivative | |
JP7411414B2 (ja) | ペプチドの製造方法、及び塩基の処理方法 | |
RU2515555C2 (ru) | Способ получения дегареликса | |
JP5515738B2 (ja) | ジベンゾフルベン誘導体の淘汰方法 | |
WO2020111238A1 (ja) | ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法 | |
JP2003522198A (ja) | カハラリド化合物 | |
JP2002525376A (ja) | アミド結合形成のための補助基 | |
CN114630835A (zh) | 包含空间位阻大的氨基酸的肽化合物的制备方法 | |
EP4269422A1 (en) | Method for producing peptide compound containing n-substituted-amino acid residue | |
EP4242219A1 (en) | Peptide synthesis method for suppressing defect caused by diketopiperazine formation | |
KR20230019120A (ko) | 고난도 서열의 효율적 펩티드 축합법 | |
CN116615411A (zh) | 包含n-取代氨基酸残基的肽化合物的制造方法 | |
WO2023214577A1 (ja) | ジケトピペラジン形成による欠損を抑制するペプチド合成方法 | |
RU2777327C1 (ru) | Способ синтеза пептидов | |
WO2024110477A2 (en) | Synthesis of a cyclic peptide | |
Blanc | Synthesis on solid phase of a bicyclic octapeptide amatoxin | |
JP2024531394A (ja) | ペグ化アドレノメデュリンを調製する方法、その中間体およびその使用 | |
Chen | Ionic liquids as novel reaction media for the chemical synthesis of peptides | |
JPS6346759B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18813662 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019523990 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207000271 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018813662 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018813662 Country of ref document: EP Effective date: 20200109 |